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Down syndrome (DS) is the most common known cause of intellectual disability (ID), 
affecting 1 in 800-1000 births.  This disorder is caused by triplication of human chromosome 
21(HSA21) due to nondisjunction during meiosis.   In addition to ID, individuals with DS exhibit 
dementia by the third or fourth decade of life, due to the early onset of neuropathological 
changes typical of Alzheimer's disease (AD).  Although there are currently no effective 
treatments for either the ID or dementia seen in this disorder, it is hoped that the recent 
development of murine models of this disease will aid in elucidating the pathogenic mechanisms 
and testing potential therapies. The Ts65Dn mouse model of DS survives to adulthood and 
exhibits key features of this disorder, notably impairments in learning, attention, and memory, as 
well as deficient ontogenetic neurogenesis and degeneration of basal forebrain cholinergic 
neurons (BFCNs) in the medial septum (MS).  The overarching goal of the present thesis was to 
use this mouse model to study the role of cholinergic atrophy in the age-related cognitive decline 
seen in DS (Chapter 3), and to test the effectiveness of one promising therapy for DS (Chapter 1 
and 2): maternal choline supplementation (MCS).  
Our studies revealed that Ts65Dn mice exhibit attentional dysfunction as early as 3 
months of age, which becomes more pronounced with aging.  Moreover, assessment of 
cholinergic neurons in the nucleus basalias of meynert/substantia innominata revealed a reduced 
density of these neurons in both young and old trisomic mice (relative to 2N), but no age-related 
changes in the count, density or size of these neurons was observed with aging as is commonly 
believed. Our subsequent studies using MCS revealed that the Ts65Dn offspring of dams 
supplemented with additional choline during pregnancy and lactation exhibited improvements in 
spatial cognition, relative to Ts65Dn offspring of dams on the control diet. In addition, MCS 
significantly increased adult neurogenesis of the trisomic offspring and offered protection to 
BFCNs in the MS.  These results provide exciting new evidence that MCS may represent a safe 
and effective treatment approach for expectant mothers carrying a DS fetus, as well as a possible 
means of BFCN neuroprotection during aging for the population at large.    
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INTRODUCTION 
Down Syndrome in Humans  
Affecting 1 in every 800-1,000 live births and currently seen in over 5 million globally 
(Roizen and Patterson, 2003), Down syndrome (DS) is the most common known cause leading to 
intellectual disabilities (ID).  The primary predisposing factor for DS is advanced maternal age 
(Abruzzo and Hassold, 1995). DS is caused by a sporadic event known as nondisjunction during 
meiosis that leads to an extra copy of all or part of the long arm of human chromosome 21 
(HSA21; Rachidi and Lopes, 2008). The disease is characterized by numerous somatic abnor-
malities such as heart and gastrointestinal defects (van Trotsenburg et al., 2006), immunological 
(Cruz et al., 2009) and pulmonary diseases (Cooney and Thurlbeck, 1982; Schloo et al., 1991), 
and epilepsy (Roizen and Patterson, 2003; Sorge and Sorge, 2010).  ID is amongst the most se-
vere problems affecting individuals with DS (Noble, 1998; Rachidi and Lopes, 2008; Roizen and 
Patterson, 2003).  During fetal development and at birth, a variety of neuropathological deficien-
cies (e.g., hypocellularity, deficient neurogenesis, apoptosis) are evident in regions such as the 
cerebellum (a structure important in proprioceptive-motor control and motor learning) and the 
hippocampus (a structure important in spatial and dissociative learning and memory; Contesta-
bile et al., 2007; Guidi et al., 2011). Furthermore, individuals with DS develop age-related cog-
nitive decline due to the onset of Alzheimer’s disease (AD) -like neuropathology at the 
third-fourth decade of life (Isacson et al., 2002; Sendera et al., 2000; Whitehouse et al., 1982, 
Wisniewski et al., 1985a).   Researchers believe that this may due to the Amyloid precursor pro-
tein (APP) gene, a culprit in AD, being located on HSA21 (Wilcock and Griffin, 2013). Current-
ly, there are no approved therapies for the ID and cognitive decline during mid-life seen in hu-
mans with DS.   
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Brain pathology in DS without AD 
Numereous reports have found that the brains of DS patients are smaller in size compared 
with normal individuals, suggesting a casual link between ID and brain hypothrophy (i.e., de-
crease volume and degeneration; Aylward et al., 1997; Aylward et al., 1999; de la Monte and 
Hedley-Whyte, 1990; Jernigan et al., 1993; Pinter et al., 2001; Rotmensch et al., 1997; 
Schmidt-Sidor et al., 1990; Sylvester, 1983; Teipel et al., 2003; Winter et al., 2000; Wisniewski, 
1990).   In fetuses and children with DS, post-mortem tissue studies have revealed brain hypo-
trophy that is associated with hypocellularity and cortical dysplasia (Golden and Hyman, 1994; 
Ross et al., 1984; Wisniewski, 1990). Studies measuring neurogenesis (i.e., the production of 
new neurons) in DS post-mortem fetal brain tissue have detected reductions in the number of 
newly born cells that is believe to contribute to the observed brain hypotrophy (Contestabile et 
al., 2007). Specifically, the cerebellum, a structure that is important in the regulation of proprio-
ceptive-motor control and motor learning, demonstrates growth disturbances during the se-
cond-trimester that is solely due to reductions in neurogenesis (Guidi et al., 2008; 2011).  The 
hippocampus, a structure that is important in assocaitve learning and memory as well as spatial 
cognition, also shows reductions in neurogenesis during fetal development (Contestabile et al., 
2007). However, unlike the cerebellum, the hippocampus also shows increased apoptosis and a 
higher number of cells going to a glial phenotype and fewer cells expressing neuronal markers 
were evident (Guidi et al., 2011). This suggests that there are different factors contributing to the 
decreased volume within certain brain structures in DS.   
Data from both post-mortem tissue and neuroimaging studies in DS patients have re-
vealed that changes beginning early in life become more prominent in adolescence and through-
out adulthood (reviewed in Nadel, 2003). Magnetic resonance imaging (MRI) volumetric anal-
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yses have detected reductions in brain volume, including reduced gray and white matter in addi-
tion to regional differences in areas such as the cerebellum, frontal and temporal lobes of chil-
dren (Kates et al., 2002; Pinter et al., 2001) and young adults (Nadel, 2003; Menghini et al., 
2011).   Smigielska-Kuzia and colleagues (2011) found that the volume of both the left and right 
hippocampus is significantly reduced in 8 year-old DS patients. This is further confirmed in 
adults with DS who have not reached the AD dementia.  Weis (1991) applied both stereological 
techniques and MRI to post-mortem tissue samples of DS patients with ages ranging from 30-45 
years and found that the whole brain was significantly smaller.  Specific brain regions were also 
smaller in volume in this study, including the cortex and cerebellum.   Collectively, these find-
ings suggest that the brains of DS patients continue to show deficiencies from childhood 
throughout adulthood that is likely the basis of ID throughout life.    
 
Behavioral deficits in DS  
Assessing learning and memory abilities in infants has proven difficult due to structures 
such as the hippocampus not becoming fully functional until many months after birth; perhaps 
even as long as 16-18 months of age (Nadel and Wilner, 1989; Nadel and Zola-Morgan, 1984).  
One study examining basic learning in 3 month old infants with DS found that they performed 
normally, in terms of initial learning, acquisition, speed and retention, in a task that required 
learning about contingencies between their own movements (e.g. kicking their leg) and rein-
forcement (Ohr and Fagen, 1993).  At 9 months however, this same group found that DS infants 
were impaired in learning about the contingency between arm movements and reinforcement 
(Ohr and Fagen, 1994).  This may be due to controls performing better, thus making the deficit 
appear more profound in DS infants.  These researchers concluded that there is a relative decline 
9 
 
in conditionability in infants with DS after 6 months of age.   These researchers suggested that 
this might coincide with the increasing brain abnormalities after 6 months of age.  
Mangan (1992) was one of the first researchers to examine hippocampal-dependent defi-
cits in toddlers with DS. Mangan (1992) tested toddlers who were 26-30 months of age since it is 
known that place learning does not emerge until around 18 months, which coincides with esti-
mates on when the hippocampus itself becomes functional (Magan and Nadel, 1990).  Mangan 
(1992) found that toddlers with DS do in fact show deficits in place learning, which requires the 
use of cues in the surrounding environments to guide the subject to a hidden object and is de-
pendent on the hippocampus.  DS infants were not impaired in a cued-learning task that requires 
subjects to locate one visible object; this latter finding is hippocampal-independent (Mangan, 
1992).  The deficits in place learning may be related to the hypocellularity and deficient neuro-
genesis seen within the hippocampus of DS fetuses and children (Contestaible et al., 2007; Guidi 
et al., 2008).   
 Language development is another area of dysfunction in DS.  We will only briefly dis-
cuss deficits in language development in infants and children with DS, since it is not a focus of 
this dissertation.   
Most infants with DS are delayed at saying their first words (i.e., show a longer delay 
from babbling to speech), their vocabulary grows more slowly than in ordinary children and alt-
hough they use the same range of two- word phrases as all children, they have difficulty in mas-
tering the many rules for talking in grammatically correct sentences (Chapman, 1997; reviewed 
in Chapman and Hesketh, 2000; Stoel-Gammon. 2001).  As infants with DS progress into child-
hood and early adulthood, they are restricted to short telegraphic utterances (keywords without 
the function words, for example "went swimming Dad" rather than "I went swimming last night 
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with my Dad") and also tend to have difficulty in pronouncing words clearly (Bray and 
Woolnough, 1988). Researchers suggest that language and speech is important for other cogni-
tive abilities.  For example, the storage and recall of information from long term memory is de-
pendent on organizing the information on the basis of meanings conveyed by language.  Thus, 
any serious language delay will inevitably result in increasing cognitive delay (Chapman and 
Hesketh, 2000; Chapman, 1997).  This is further supported by work showing that children with 
DS show deficits in verbal short-term working memory (Chapman and Hesketh, 2000; Con-
stanzo et al., 2013). Collectively, these results show that language development is delayed in DS 
patients and that these delays may lead to deficits in cognitive functioning.  
  Executive functions are a set of high cognitive abilities that control and regulate other 
functions and behaviors (Welsh et al., 1991).  These processes include short term and working 
memory, reasoning, inhibition, behavioral flexibility, planning and problem solving (Costanzo et 
al., 2013; Friedman et al., 2006; Pennington and Ozonoff, 1996).  Studies have shown that pa-
tients with DS are impaired in certain components of executive functions and this impairment 
becomes progressively worse as patients enter early onset AD dementia (Rowe et al., 2006).  
Constanzo and colleagues (2013) more recently investigated executive functions in DS 
patients ranging from ages 8.6 to 21.2 years (who did not show signs of dementia) and found 
impairments in an auditory-sustained attention task (Manly et al., 1999, 2001), which requires 
subjects to count silently tones and announce the total number of these tones at the end of each 
trial.  Visual-selective attention, measured by the Sky search task (Manly et al., 1999, 2001) that 
requires subjects to circle pairs of identical artifacts as quickly as possibly, was also impaired in 
DS patients relative to mental age-matched controls. Further impairments were seen in the for-
ward digit span task (Orsini et al., 1987), a test of verbal short-term memory, which requires 
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subjects to recall a sequence of digits that was read to them.   Verbal working memory, which is 
also measured using the digit span task but requires subjects to recall the digits in the reverse 
order, was also impaired in DS patients. Visual-spatial short-term and working memory were 
also impaired in DS patients as evident by impaired performance in the Corsi block test (Orsini 
et al., 1987), which requires subjects to reproduce a sequence of blocks in either the same order 
(short-term memory) or in the reverse order (working memory).  Lastly, response inhibition, as 
measured by the stroop task was impaired in these DS children.  Collectively, these findings 
suggest that executive functions are impaired in young individuals with DS that may affect adap-
tive behaviors.  
One last areas that is of particular importance to discuss in this introduction, as it is a 
primary component in the chapters ahead, is that of spatial learning and memory, which is medi-
ated in part by the hippocampus and becomes noticeably impaired in DS individuals during ado-
lescence and adulthood (Caltagirone et al., 1990; Devenny et al., 1992; Ellis et al., 1989; Pen-
nington et al., 2003). Pennington and colleagues (2003) examined hippocampal function in DS 
children ranging from 12 – 16 years of age.  They administered a spatial long-term memory task 
(Thomas et al., 2001) that is adapted from the water maze task used in animal models of learning 
and memory and requires animals to use contextual cues in the environment to remember the 
location of a submerged platform. Utilizing a spatial map requires intact spatial memory skills; 
animals with lesions to the hippocampus are generally not able to use spatial cues to create this 
kind of spatial map.  In the human version, subjects use a joystick to move around a comput-
er-generated virtual arena.  During the first four trials, the children had to locate a blue rug on the 
floor of the arena.  After the fourth trials, children were to locate the blue rug by using contextual 
cues, although they were not instructed to use cues.  Whenever the subjects located the area 
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where the blue rug was previously, a sound came on letting them know they were in the right 
location.  After five trials, a probe trial was given where children were not notified that they had 
found the location of the rug.  If the subjects had utilized the contextual cues in the virtual envi-
ronment to develop a spatial map of the arena, he or she should have spent the majority of the 
probe trial searching in the correct quadrant. Results showed that DS children spent less time 
searching in the correct quadrant then controls during the probe trial, suggesting that they were 
unable to form a spatial map of the environment, suggesting hippocampal dysfunction.   Several 
other studies have found that adults with DS show marked deficits in long-term memory 
(Caltagirone et al., 1990; Devenny et al., 1992; Ellis et al., 1989), mediated by the hippocampus.  
An example of these impairments comes from a study that used a book of pictures in which sub-
jects had to both recognize specific items and also remember there location; DS adults were im-
paired in the recall task when long delays were implemented, suggesting long-term memory def-
icits.   
In sum, decades of reports have shown that individuals with DS are impaired in a range 
of cognitive functions starting from infancy up to adulthood.  Researchers suggest that these im-
pairments are likely due the brain pathologies evident in fetuses and children with DS that con-
tinue throughout adulthood (Contestabile et al., 2007; Guidi et al., 2008, 2011; Aylward et al., 
1997; Aylward et al., 1999; de la Monte and Hedley-Whyte, 1990; Jernigan et al., 1993; Pinter et 
al., 2001; Rotmensch et al., 1997; Schmidt-Sidor et al., 1990; Sylvester, 1983; Teipel et al., 2003; 
Winter et al., 2000; Wisniewski, 1990). Further compromising cognitive functions in DS patients 
is the start of AD-like neuropathology that is imminent in all patients with DS (Isacson et al., 
2002; Sendera et al., 2000; Whitehouse et al., 1982, Wisniewski et al., 1985a).  
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Alzheimer’s disease (AD) in DS patients  
Greater than 98% of DS patients develop AD-like neuropathology at around the 
third-fourth decade of life, which is characterized by beta-amyloid (Αβ) plaques, neurofibrillary 
tangles and degeneration of BFCN neurons (Lott and Dierssen, 2010; Ness et al., 2012; Wilcock, 
2012; Zigman and Lott, 2007). This strong increase in AD-like neuropathology during midlife 
has been attributed to the triplication of the amyloid precursor protein APP gene on HSA21, 
which yields higher levels of Αβ, the main constituent of plaques in AD that are toxic to nerve 
cells in the brain (Ness et al., 2012; Wilcock and Griffin, 2013).  This is further supported by 
work showing that an elderly adult with DS who had a microdeletion resulting in APP disomy 
did not develop dementia or classic AD neuropathology (Zigman and Lott, 2007). The location 
and progression of Αβ plaques and neurofibrillary tangles in patients with DS at autopsy mimic 
those found in the general AD population (reviewed in Ness et al., 2012).  Both Αβ plaques and 
neurofibrillary tangles are thought to further contribute to the cognitive deficits in DS patients.  
One of the most prominent neuropathological changes in both DS and AD, which is par-
ticularly important to discuss, as it is the basis of chapter 2 and 3 in this dissertation, is that of 
degenerating BFCN neurons (Bowen et al., 1976; Casanova et al., 1985; Davies and Maloney, 
1976; Whitehouse et al., 1982; Yates et al., 1980). Cholinergic neurons within the basal forebrain 
project to the entire cortical mantle and hippocampus (Mesulam et al., 1983) and are important in 
modulating functions of these target regions.  The basal forebrain is divided into the medial sep-
tum (MS), diagonal band, and nucleus basalis of meynert (NBM) and together form a single cho-
linergic system whose three regions differ principally in their projections (Mesulam et al., 1983; 
Casanova et al., 1985). The NBM sends projections to the neocortex and is important in modu-
lating attention (Gratwicke et al., 2013). The MS sends cholinergic projections to the hippocam-
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pus and is important in modulating functions such as spatial and dissociative memory (reviewed 
in Everitt and Robbins, 1997). Reductions in the size and number of cholinergic neurons within 
the NBM and MS have been observed in postmortem tissue of DS patients ages  >59 years 
(Casanova et al., 1985).  Although the exact cause of BFCN atrophy in humans with DS has not 
been identified, animal models (see mouse model section) have shed light on the possible mech-
anism leading to such pathologies, which will be discussed in a proceeding section.   
Documenting the cognitive deficits after the onset of AD in DS patients has proven 
somewhat difficult because of the preexisting ID.  There is evidence however that the nature of 
these deficits tends to mimic those seen in general AD (Oliver et al., 1998). Deterioration in 
learning, memory and orientation are typically the first signs/symptoms of AD in DS patients 
(Cosgrave et al., 2000).  Further impairments in executive functioning have been shown when 
comparing DS patients with and without AD (Rowe et al., 2006). For example, there are slight 
declines in verbal and long-term memory for those over 50 years of age with DS, and the ability 
to form long-term memories and visual spatial construction may be impaired (see Stanton and 
Coetzee, 2004). Demented DS patients experience cognitive deficits such as forgetfulness of 
recent events, geographically orientation, loss of previously learned skills and confusion.  There 
is also evidence of personality changes, social isolation, increase dependence, and excessive un-
cooperativeness.  Selective attention, which is the ability to focus on a predetermined stimulus 
while ignoring irrelevant or distracting stimuli, is also deficient in DS patients with AD patholo-
gy (Krinsky-Mchale, et al., 2008). Collectivity, these data show that DS patients exhibit further 
deficits in cognitive functions with the onset of AD-like neuropathology during midlife.  
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Experimental treatments utilized in humans with DS and AD  
 There are currently no clinically approved treatments for the ID or dementia observed in 
DS patients. Several therapeutic interventions have been utilized to try and ameliorate the cogni-
tive dysfunctions seen in DS.  This section will focus on therapies aimed at improving the cogni-
tive dysfunction of DS patients with and without AD.  
 The first set of drugs that have been tested in an effort to ameliorate the cognitive deficits 
in DS target specific neurotransmitter systems. Donepezil, which is a cholinesterase inhibitor and 
blocks the breakdown of acetylcholine, only showed improvements in language (Heller et al., 
2003, 2004; Johnson et al., 2003; Kishnani et al., 2009) in children with DS. Other cognitive 
dysfunctions were not ameliorated with this drug in both children and adults with and without 
AD (see de la Torre and Dierssen, 2012).  These findings in DS adults with AD are of particular 
importance since BFCN atrophy is evident in these patients, suggesting that simply increasing 
acetylcholine may not be sufficient to ameliorate the cognitive deficits.  Rivastigmine, an inhibi-
tor of acetylcholineesterase similar to Donepezil, also failed to improve language and cognition 
in both children and adults with DS (Heller et al., 2010; Prasher et al., 2005).  One drug that has 
not yet been tested in DS patients that holds promise is Galantamine.  Galantamine is a reversible 
and competitive cholinesterase inhibitor and is also an allocentric ligand, thus increasing acetyl-
choline binding at nicotinic receptors.  It is used in AD and has had success in improving 
memory deficits.  Researchers suggest that it may be the next drug utilized to treat and amelio-
rate the cognitive deficits that arise with AD pathologies in DS (de la Torre and Dierssen, 2012).  
 Acetyl-carnitine, derived from carnitine, has been reported to display beneficial proper-
ties, such as increasing activity of cholinergic neurons, membrane stabilization, and mitochon-
drial antioxidant activity in AD patients without DS (Palacios et al., 2011).  This compound was 
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administered to 40 individuals with DS for a 6-month period, but failed to show any improve-
ments in cognitive functions (Pueschel, 2006).   Nicotine patches have also been tested in DS 
patients, specifically because of the cholinergic deficits with the onset of AD.  The testing of 
such treatment has been done in a very limited number of DS patients, however. Interestingly, 
results have shown improvements in attention and information processing; researchers suggest a 
more thorough investigation to confirm these benefits (Bernert et al., 2001; Seidl et al., 2000).  
 Memantine is another treatment option that gained attention due to its benefits in the 
Ts65Dn mouse model of DS (Rueda et al., 2010).  Memantine is an uncompetitive NMDA re-
ceptor antagonist that was approved as a treatment option in severe AD (Mohan et al., 2009).  
The rationale for its use in DS is that it should help reduce abnormal activation of excitatory glu-
tamatergic neurotransmission. Abnormal excitatory glutamatergic neurotransmiion leads to sei-
zures and disruptions in memory formation (reviewed in Francis, 2005). In the general AD pop-
ulation, this drug has already showed benefits in cognitive functioning and slowing of the decline 
seen in AD overtime (Mohan et al., 2009).  Currently, there is an ongoing clinical trial in young 
adults with DS that is examining improvements in memory and other cognitive abilities. In sum, 
memantine helps those with pathologies relevant to AD in the general population, making it a 
possible therapeutic intervention for DS patients with AD.     
 The treatments presented above constitute the main clinical trials performed in DS sub-
jects, none of which have shown compelling results (reviewed in de la Torre and Dierssen, 
2012).  Not having the ability to investigate the neural level changes within the brains of DS pa-
tients upon testing these treatments makes it difficult to troubleshoot and understand why they 
may or may not ameliorate cognitive deficits.  The introduction of the Ts65Dn mouse model of 
DS by Davisson (1990) has led to a more complex understanding of DS both at the behavioral 
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and neural level.  This has consecutively led to the development of treatments that one day may 
prove beneficial to those with DS. 
 
The Ts65Dn mouse model of DS 
 In an effort to further understand the disease process seen in DS and consequently devel-
op treatments that may help ameliorate deficits, a mouse model that mimics the human disease 
was developed (Davisson, et al., 1990).  The Ts65Dn mouse was the first segmental trisomy cre-
ated and is in now the best characterized and most-widely used model of DS. The Ts65Dn mouse 
(Davisson, et al., 1990; Holtzman et al., 1996) is trisomic for the distal portion of mouse chro-
mosome 16 (MMU16), which contains approximately 100 genes orthologous to those on HSA21 
(Mural et al., 2002; Patterson and Costa, 2005). This triplicated chromosomal segment also in-
cludes the “Down syndrome critical region,” (DSCR) which is considered necessary, although 
not solely sufficient, for the DS phenotype (Belichenko et al., 2009; Olson et al., 2007, 2004). 
Ts65Dn mice survive to adulthood and exhibit many morphological, biochemical, and transcrip-
tional changes seen in the human disorder (Antonarakis et al., 2001; Capone, 2001; Davisson, et 
al., 1990; Davisson et al., 1993; Holtzman et al., 1996; Reeves et al., 1995). The most important 
feature of this mouse model is that it exhibits central nervous system deficits similar to humans 
with DS.  Notably, this mouse model shows deficiencies in developmental and adult neurogene-
sis (Bartesaghi et al., 2011; Bianchi 2010a, b.; Chakrabarti et al., 2011; Clark et al., 2006; 
Llorens-Martin et al., 2010; Velazquez et al., 2013) and AD-like neuropathology during midlife 
(Cooper et al., 2001; Granholm et al., 2002; Holtzman et al., 1996).  In addition, the mouse mod-
el exhibits impairments in hippocampal-mediated learning and memory (reviewed in Crnic and 
Pennington, 2000; Davison and Costa, 1999; Patterson et al., 2005; Reeves et al., 1995), motor 
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dysfunction (Costa et al., 1999), delays in achieving sensorimotor milestones (Holtzman et al., 
1996), lack of behavioral inhibition (Coussons-Read and Crnic, 1996), attentional dysfunction 
and deficits in emotional regulation (Driscoll et al., 2004; Moon et al., 2010), and deficiencies in 
operant learning (Wenger et al., 2004) when the demands of the task increase.  
Like humans with DS (discussed above; Contestaible et al., 2007, Guidi et al., 2008, 2011; 
Rachidi and Lopes, 2008), Ts65Dn mice exhibit widespread neurogenesis reduction during fetal 
brain development that may lead to the numerous neurological deficits (Bianchi et al., 2010a, 
2014). Neurogenesis reductions during pre- and early post-natal life have been observed in brain 
regions such as the subgranular zone of the dentate gyrus (DG), subvenrticular zone of the lateral 
ventricles, striatum, neocortex and cerebellum (Bartesaghi et al., 2011; Bianchi et al., 2010).  
This is consistent with the post-mortem reports in fetuses with DS that show deficiencies of 
neurogenesis in the hippocampus (Guidi et al., 2008). This suggests that reductions in neurogen-
esis during development may underlie the reductions in brain size (Aylward et al., 1997; Ayl-
ward et al., 1999; de la Monte and Hedley-Whyte, 1990; Jernigan et al., 1993; Pinter et al., 2001; 
Rotmensch et al., 1997; Schmidt-Sidor et al., 1990; Sylvester, 1983; Teipel et al., 2003; Winter 
et al., 2000; Wisniewski, 1990) in humans with DS and furthermore may be associated with the 
cognitive impairment seen in both humans and the Ts65Dn mouse model of DS.    
Evidence for a continued deficiency in adult neurogenesis has also been demonstrated in 
the Ts65Dn mouse model.  The proliferation and survival of new neurons throughout adulthood 
in mammalian species is confined to 2-brain regions.  This includes the hippocampus and sub-
ventricular zone of the lateral ventricles (reviewed in Braun and Jessberger, 2014). Ts65Dn mice 
show deficient adult neurogenesis in both these brain regions, which likely contributes to dys-
functions in spatial or declarative memory (Abrous et al., 2008; Aimone et al., 2006; Leuner et 
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al., 2006; Lledo et al., 2006; Madsen, et al., 2000; Shors et al., 2001, 2002) and olfactory learn-
ing (Bianchi et al., 2014). Interestingly, Mohapel and colleagues (2005) found that adult hippo-
campal neurogenesis is modulated by cholinergic activity from the MS.  Thus one possibility for 
continued deficiencies in adult hippocamal seen in adult Ts65Dn mice may be due to the degen-
eration of MS neurons, which fail to modulate hippocampal function.  
 
AD-like neuropathology in Ts65Dn mice 
At around 4-6 months of age, Ts65Dn mice begin to show a progressive loss of basal 
forebrain cholinergic neurons (BFCN; Granholm et al., 2002; Holtzman et al., 1996).  The basal 
forebrain provides the major cholinergic inputs to the neocortex (e.g., attention; Driscoll et al., 
2004; Moon et al., 2010) and hippocampus (e.g., explicit memory function; Hyde et al., 2001; 
Hyde and Crnic, 2001), thus modulating functions associated with these target regions.  The at-
rophy of BFCNs has been attributed to a malfunction in the trafficking of neurotrophins, specifi-
cally the neurotrophin “nerve growth factor” (NGF).  Cooper and colleagues (2001) found that 
the retrograde transport of NGF was faulty in 6 months old TS65Dn mice that carry a triplication 
of the APP gene.  Importantly, they found that if you infuse NGF directly into the cell body, 
neurons that were beginning to show signs of atrophy would develop a healthier phenotype. This 
suggests that the atrophy of BFCNs in the Ts65Dn mice is due to a malfunction in NGF transport 
from the terminal button to the synapse and not a lack of its availability. In sum, the Ts65Dn 
mouse model of DS shows behavioral and neural deficits that mimic the human disease and fur-
thermore make it a suitable model to test potential therapeutics. 
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Treatments utilized in the Ts65Dn mouse to ameliorate cognitive deficits 
 A series of pharmacotherapies have been tested in the Ts65Dn mouse and have shown 
significant amelioration of cognitive dysfunction.   Most of the pharmacotherapies designed to 
improve cognitive functions have been attempted in the mouse model during the adult stages 
(reviewed in Bartesaghi et al., 2011). There have however been recent studies that have found 
benefits of treatments administered prenatally (Guidi et al., 2014, Incerti et al., 2012; Moon et al., 
2010; Velazquez et al., 2013) and since prenatal testing can identity triplications of chromosomal 
abnormalities in humans, this allows the opportunity of early interventions that may help im-
prove brain development in fetuses with DS. Here we will discuss treatments utilized in the 
Ts65Dn mouse during early development, adulthood and during fetal development.   
Both fluoxetine and lithium have been tested in Ts65Dn mice in an effort to increase 
neurogenesis, serotonin and cognitive functions. Both these drugs affect the serotonergic system 
by increasing the amount of serotonin in the synaptic cleft (Wang et al., 2008). Studies have 
shown that both humans with DS and this mouse model show reduced levels of serotonin 
(Whitaker-Azmitia, 2001). Furthermore, serotonin has been linked to developmental neurogene-
sis (Faber and Haring, 1999; Whitaker-Azmitia, 2001), thus decreases in serotonin may account 
for deficiencies of neurogenesis in the mouse model.   
Bianchi and colleagues (2010a) administered Fluoxetine to neonatal Ts65Dn mice for 13 
days (PND 3-PND15) and measured neurogenesis at both PND 15 and PND 45.  Fluoxetine did 
in fact normalize the number of adult born neurons at both time points in the hippocampus and 
subventricular zone of Ts65Dn neonates.  A subset of fluoxetine treated trisomics were tested on 
a hippocampal-dependent fear conditioning task and were found to perform significantly better 
than those trisomics that did not receive fluoxetine. Guidi and colleagues (2013) took a subset of 
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these same animals and found that the granule cells from the hippocampi of Ts65Dn mice had a 
severely hypotrophic dendritic arbor, fewer spines and a reduced innervation then 2N mice.  
Fluoxetine corrected such deficiencies and furthermore, they found that serotonin levels, which 
were deficient in Ts65Dn mice, were normalized by the fluoxetine. Even more recently, Guidi 
and colleagues (2014) administered fluoxetine to Ts65Dn pregnant dams from embryonic day 10 
until birth.  The brains of these offspring were extracted either 2hrs or 45 days after birth. 
Ts65Dn mice offspring that were not treated with fluoxetine were found to have severe neuro-
genesis reductions and hypocellularity throughout the forebrain, mid brain and hindbrain, in-
cluding the hippocampus at both time points. Ts65Dn mice treated with prenatal fluoxetine 
showed full restoration of neurogenesis in all brain regions at both time points. In addition, 
fluoxetine treated Ts65Dn mice performed significantly better on a hippocampal-dependent 
fear-conditioning task.  Although these findings seem encouraging and researchers have recom-
mended fluoxetine as a treatment option in humans with DS, one study actually found behavioral 
impairments in >7month old T65Dn mice that received fluoxetine for 4 weeks (Heinen et al., 
2012). Even more concerning was an observed increase in seizure activity and mortality in 
fluoxetine treated Ts6Dn mice.  One possibility for such discrepancies may be the age of admin-
istration, as Bianchi (2010a) and Guidi’s (2013, 2014) studies examined fluoxetine early in de-
velopment while Heinen (2012) examined administration later in adulthood. It’s possible that at 
later ages, fluoxetine may do more harm then provide benefits.  Another cautionary note comes 
from studies revealing that human mothers taking fluoxetine while pregnant can have newborns 
with malformations, cardiovascular abnormalities (for review see Morrison et al., 2005), and 
even spontaneous abortions (Nakhai-Pour et al., 2010). In sum, it appears that fluoxetine admin-
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istration requires further examination in the mouse model before being suggested as a potential 
therapy for humans with DS.   
Bianchi and colleagues (2010b) found that 1-month of lithium administration, in diet, was 
sufficient to correct deficient neurogenesis in the subventricular zone of 12-month Ts65Dn mice.  
A more recent study by this same group found that adding lithium to the diet of 5-6 month old 
Ts65Dn mice for 1-month was sufficient to increase the proliferation of neuronal precursors and 
restore adult-hippocampal neurogenesis in the DG (Contestaible et al., 2013). These animals also 
performed significantly better in several behavioral tasks, including fear conditioning, object 
location, and novel object recognition task.  The findings from these two studies suggest that 
lithium may be a suitable treatment option for correcting deficiencies in adult neurogenesis and 
ameliorating cognitive deficits in DS.  
Melatonin is another compound that was administered to middle aged (5-6 month old) 
Ts65Dn mice for 5 months in an effort to ameliorate cognitive deficits as well as protect from 
degeneration of BFCNs (Corrales et al., 2013).  Melatonin plays key roles in circadian rhythms, 
sleep homeostasis, behavioral modulation, and aging (Hardeland et al., 2011) and decreases with 
age, which is thought to contribute to age-related neurodegeneration (Corrales et al., 2013; Reiter 
et al., 1998).  Treatment in AD patients has been shown to reduce Aβ neurotoxicity, apoptosis, 
neuroinflammation, oxidative stress, and degeneration in BFCNs (Dragicevic et al., 2011; Feng 
et al., 2004; Matsubara et al., 2003; Olcese et al., 2009).  Administration for 5 months in Ts65Dn 
mice improved spatial learning and memory and increased the number of ChAT-positive cells 
within the MS. These results suggest that melatonin may be a suitable treatment option for the 
protection of BFCNs and spatial learning and memory.  
The use of treatments during fetal development provides a unique opportunity to attempt 
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to correct early deficiencies in neurogenesis that are thought to cause widespread hypocellularity 
in DS (Guidi et al., 2010).  Only a few studies have attempted such treatments in the TS65Dn 
mouse model of DS.  As previously discussed, fluoxetine from embryonic day 10 to birth led to 
benefits in neurogenesis and hippocampal dependent tasks (Guidi et al., 2014).  Although it 
could be suggested that fluoxetine corrected the deficits in neurogenesis, it is hard to say whether 
these benefits would have held up through adulthood.  Without examining the offspring at later 
ages, it is hard to say whether such benefits are long lasting.   
A few studies have examined the lasting benefits of treatments administered during fetal 
development.  Incerti and colleagues (2012) administered daily 20µg injections of vasoactive 
intestinal peptide, NAPVSIPQ (NAP) and SALLRSIPA (SAL), to pregnant Ts65Dn mice from 
embryonic day 8 to 12.  These two peptides have revealed therapeutic effects for developmental 
delay and learning deficits in various diseases.  Furthermore, theses peptides have been shown to 
increase the survival of DS cortical neurons (Busciglio et al., 2007).  Ts65Dn offsrping were 
tested at 8-10 months of age on a hippocampal-dependent Morris water maze task.  The findings 
revealed that Ts65Dn offspring of dams treated with the NAP + SAL compound learned the lo-
cation of the hidden platform significantly faster.  These researchers suggest that this early inter-
vention may have corrected the deficient neurogenesis and hippocampal hypocellularity, but no 
neural data were presented in this paper.  Although this treatment seems as a possibility for DS, 
further work is required to confirm whether this early intervention corrected neuropathologies.   
 Our laboratory previously reported that supplementing the maternal diet of Ts65Dn dams 
with addtitional choline (CH) provides lasting benefits for the trisomic offspring in a task of fo-
cused and sustained attention (Moon et al., 2010).   This has led to further questions of whether 
MCS may be a suitable treatment option for other cognitive abilities and whether neuropatholo-
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gies may be reduced in the mouse model.  A detailed description of maternal CH as a potential 
treatment option for DS is presented next.  
 
Maternal choline supplementation as a potential treatment for DS 
Growing evidence suggests that the current recommended daily intake of choline for 
pregnant women may not be optimal for fetal development and lifelong health of the offspring.  
Two decades of research with normal rodents has shown that increasing maternal intake of cho-
line (4.5X the amount in normal chow) produces lasting improvements in offspring cognitive 
functioning (Cheng et al., 2008; Glenn et al., 2007, McCann et al., 2006, Meck et al., 1988; 
Meck et al., 1999; Meck and Williams, 2003; Mohler et al., 2001; Moon et al., 2010; Powers et 
al., 2011; Wong-Goodrich et al., 2008; Zeisel, 2000). More recent rodent studies have shown that 
increasing maternal choline intake also increases offspring  neurogenesis (Glenn et al., 2007), 
cholinergic activity (Meck et al., 1989, 2007), and brain neurotrophin levels (Glenn et al., 2007; 
Sandstrom et al., 2002).  Furthermore, a study in our laboratory found that supplementing the 
maternal diet with additional choline significantly improved attentional functioning in the 
Ts65Dn mouse model of Down syndrome (Moon et al., 2010).  Collectively, these studies sug-
gest that current estimates of adequate choline intake may not be sufficient during pregnancy to 
allow optimal fetal development and offspring cognitive functioning. Below, I provide back-
ground on choline and possible mechanisms for these beneficial effects, which is central to the 
studies in this dissertation.    
 
What is choline? 
Choline is an essential nutrient, grouped with the vitamin B complex, which plays key 
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roles in fetal development. During development, CH is a source of major dietary source of me-
thyl groups for the production of S-adenosylmethionine (SAM), which is a substrate for epige-
netic mechanisms, such as DNA methylation, that can alter gene expression throughout life 
(Niculescu et al., 2002).  Choline is also a precursor of the neurotransmitter acetylcholine 
(Blusztajn and Wurtman, 1983), which is essential for proper organization and function of the 
developing brain through its effects on neurogenesis and synaptic formation (reviewed in Jiang 
et al., 2014; Meck and Williams, 2003). Furthermore, CH is important in the metabolism of fats 
(Vance, 1990), and is a precursor of phosphatidylcholine, which is used in the synthesis of the 
constructional components in the bodies’ cell membranes (Hanada et al., 1991). The important 
role of CH during fetal development may explain why insufficient amounts (insufficient relative 
to needs) may result in suboptimal fetal development.  
CH can be found in a variety of foods. Foods highest in total CH concentrations per 100g 
include: beef liver (418 mg), chicken liver (290 mg), eggs (251 mg), wheat germ (152 mg), bacon 
(125 mg), dried soybeans (116 mg), and pork (103 mg). Researchers suggest that CH-rich foods 
are an important component of the diet and that especially during pregnancy it would be prudent 
to include them as part of a healthy diet in order to ensure adequate fetal development.   
  
CH during pregnancy and lactation 
 As evident by the major roles that CH plays during fetal development (see section above), 
CH is in high demand during pregnancy and lactation.  Studies have shown that there is a pro-
nounced depletion of CH-derived methyl groups in pregnant vs non-pregnant women (Jiang et al., 
2014; McMahon and Farrell, 1985; Sweiry et al., 1986; Sweiry and Yudilevich, 1985). Moreover, 
the plasma and serum CH concentrations are 6 or 7-fold higher in the fetus and neonate than they 
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are in the mother (Zeisel et al., 1980; Zeisel and Wurtman, 1981), suggesting a transfer from the 
mother to the fetus. In pregnant rats, total liver CH stores are diminished compared to nonpreg-
nant controls (Zeisel et al., 1995), suggesting that endogenous pools of CH are also utilized due 
to the demands imposed by the developing fetus. Furthermore, because milk contains a great deal 
of CH, lactation further increases the demand maternal CH, resulting in further depletion of tis-
sue stores (McMahon and Farrell, 1985; Holmes-McNary et al., 1996). These observations sug-
gest that the demand for choline rises dramatically during pregnancy and that choline intake must 
be increased to promote optimal fetal development.  
 Studies measuring CH levels in pregnant women have found that CH is positively associ-
ated with cognitive measures in the offspring both early after birth and later on in childhood.  For 
example, Wu and colleagues (2012) found that maternal plasma concentrations of choline and 
betaine, the metabolite of choline, at 12 weeks of gestation were positively associated with 
measures of early cognitive development in the offspring, indicating a possible benefit of CH 
supply on cognitive function in humans. Similarity, Boeke and colleagues (2013) reported that 
children born to mothers in the highest quartile of choline intake performed significantly better 
on a measure of visual memory at 7 years of age.  In sum, these findings suggest that CH is very 
important during the gestation and lactation and is associated with cognitive functions after birth.  
 
Supplementing the maternal diet with CH during pregnancy 
 Although these epidemiological data are provocative, it is possible that they reflect con-
founding with other nutrients.  For that reason, stronger evidence is provided by studies that have 
experimentally increased choline intake during pregnancy and/or lactation. Numerous studies 
have demonstrated that the offspring of dams supplemented with additional choline during preg-
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nancy and/or lactation (about 4.5 X the amount in control chow) performed significantly better 
on tests of spatial memory than the offspring of dams on a control diet meeting the RDI for cho-
line (Meck et al., 1988; Meck et al., 1989; Meck and Williams, 1997a; Meck and Williams, 1999; 
Williams et al., 1998). Similar performance increases have been reported for prenatal CH sup-
plemented rats on temporal processing tasks that require divided attention or increments in atten-
tion following a change in the predictiveness of a stimulus (Lamoureux et al., 2008; Meck and 
Williams, 1997a). In sum, these studies suggest that offspring of CH supplemented dams are 
characterized in adulthood by improved performance relative to control rats in tasks measuring 
spatial memory, temporal processing, and attention (Brandner, 2002; Meck et al., 1988, 1989; 
Meck and Williams, 1997a; Ricceri and Berger-Sweeney, 1998; Zeisel et al., 1991). Supple-
menting the maternal diet with additional CH has also been shown to have lasting facilitative 
effects on offspring cholinergic activity (Meck et al., 1989, 2007), adult neurogenesis (Glenn et 
al., 2007), and brain levels of neurotrophins (NGF and BDNF) in rodents (Glenn et al., 2007; 
Sandstrom et al., 2002).  Although much remains to be learned concerning the mechanisms by 
which these lifelong effects are produced, it has been hypothesized that they reflect lasting 
changes in gene expression, secondary to epigenetic mechanisms, due to choline’s role as the 
major dietary source of methyl groups (Zeisel, 2004).  
These studies have shown that there are two critical periods when MCS produces most 
pronounced affects on health outcomes, memory function and longevity (McCann et al., 2006; 
Meck and Williams, 2003). Meck and colleagues (2007) reported that these two critical periods 
include gestational days 12–17 and postnatal days 16–30 in rodents. In light of these findings, 
recent studies suggest supplementing with CH during the entire gestation and lactation (i.e. peri-
natal) due to the high need in the developing fetus (Holmes-McNary et al., 1996; McMahon and 
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Farrell, 1985; Zeisel et al., 1980; Zeisel and Wurtman, 1981).  
Although the majority of research on optimal maternal CH has been conducted in rodent 
models, the effects of additional maternal CH supplementation has been recently examined in 
humans. In a randomized placebo-controlled study, Ross and colleagues (2013) evaluated the 
effect of supplementing pregnant women with 900mg CH/day, which is twice the current RDI by 
IOM, from the second trimester through birth. Newborns were then supplemented with an addi-
tional 100mg CH/day (vs placebo) up to the third month after birth.   The results showed that CH 
supplementation (vs placebo) yielded more infants within the normal cerebral inhibition range at 
the 5th postnatal week, indicating that the additional CH facilitates appropriate sensory gating 
development (Ross et al., 2013).  Although much more remains to ascertain the exact benefits of 
additional CH during fetal development, the current findings in both rodents and humans suggest 
that the current RDI may not be optimal for proper development and the RDI may need recon-
sideration.  
These observed lasting facilitative effects of maternal choline supplementation seen in 
normal rats and humans have triggered numerous studies looking at the potential neuroprotective 
effects in various types of disease processes.  Recently, it has been shown that perinatal (gesta-
tion and lactation) CH supplementation improves cognitive functioning in a mouse model of 
Down syndrome (Ts65Dn) when tested as adults (Moon et al., 2010).  Perinatal CH supplemen-
tation also exerts lasting neuroprotective effects, as evidenced by a reduction in MK-801-induced 
neurotoxicity (Guo-Ross et al., 2002) as well as attenuation of memory impairment associated 
with senescence  (Blusztajn, 1998; Meck and Williams, 1997b; Meck and Williams, 2003), epi-
leptic-seizures (Yang et al., 2000) and prenatal alcohol exposure (Thomas et al., 2000). Collec-
tively, these studies indicate that availability of CH during early development has significant 
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neuronal organizational effects and may increase the restorative and/or neuroprotective capacity 
of the adult brain. 
A possible concern is the potential dangers, if any, of consuming too much CH during 
pregnancy.  Researchers have shown that in order to experience side effects from high doses of 
CH (e.g. low blood pressure, fishy odor smell, and diarrhea), an 8-9 fold increase of the DRI 
needs to be consumed (about 3.5 - 4 grams; WebMD, 2009).  This in unlikely due to the current 
suboptimal consumption in humans (Fischer et al., 2007) and furthermore, studies on the benefits 
of addition maternal CH in rodents has suggest an increase of no more then ~4.5 X the RDI to 
see benefits (e.g. Albright et al. 1999a, Albright et al., 199b; Meck and Williams, 1988; Moon et 
al., 2010); one study found benefits in humans with only 2 X the RDI amount (Ross et al., 2013), 
which is nowhere near the 8-9 fold increase that shows adverse effects. Overall, these results 
suggest that supplementing with additional CH during pregnancy and lactation is safe and should 
pose no side effects when given 2 – 4.5 X the RDI amount.    
 
The current recommended daily intake amount and the need for reconsideration 
The findings in both normal rodents and humans, as well as various models of 
neurological disorders suggest that the current recommended intake amount for preganant 
mothers may not be optimal for fetal develoopment and lifelong cognitive functioning of the 
offspring. The current established recommedations for CH intake for pregnant mothers were 
established in 1998 by the IOM based on the estimated level of CH intake required to prevent 
liver damage (Institute of Medicine, 1998).   The current established adequate intake level for 
CH is 550 mg/day for men aged 19 years and older, 425 mg/day for women aged 19 and older, 
450mg/day for pregnant women, 550mg/day for lactating women, and 18 mg/kg /day for infants 
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(Institute of Medicine, 1998). A study examining daily human CH intake on an ad libitum diet 
found averages to be lower then the RDI, especially in women (Fischer et al., 2007).  In the same 
study, 6 out of 26 men developed CH deficiency symptoms while consuming the adequate intake, 
suggesting that the current DRI may not be sufficient. Furthermore, Shaw et al. (2004) found that 
25% of pregnant women from a California study showed intakes of less than half the DRI. These 
findings suggest that 1) the current RDI amounts may not be optimal and 2) that pregnant may 
not even be consuming the current RDI, perhaps leading to deficiencies and further compromis-
ing fetal development.   
 To date, the available data suggest that pregnant and lactating women are the most sensi-
tive to availability of dietary CH because of the greatly increased need for CH to form the fetus 
and produce milk (Zeisel et al., 1980; Zeisel et al., 1981; Zeisel et al., 1995). Researchers believe 
that adjusting for additional CH intake during gestation and lactation will allow for proper fetal 
development, which includes adequate building of cell membranes, proper precursor to build 
acetylcholine, which leads to proper neurogenesis and building of synapses, adequate availability 
of methyl groups for regulation of gene expressions (Zeisel, 2006).  
 
The following chapters 
This dissertation encompasses three chapters, each describing a single study.  The first 
two chapters describe studies designed to determine whether supplementing the maternal diet 
with additional CH improves spatial cognition in the Ts65D mouse model of DS and assess two 
possible underlying neural mechanisms for the improved cognitive functioning seen in this mod-
el following MCS: (1) increased adult hippocampal neurogenesis and (2) protection of choliner-
gic neurons within the basal forebrain, which normally atrophy starting at 6 months of age, due 
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to the onset of AD. The third chapter was designed to characterize NBM/SI cholinergic neurons 
in young and aged Ts65Dn mice, describing the changes that occur with aging and investigate 
whether these changes correspond to progressive attentional dysfunction in these animals as they 
age. 
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CHAPTER 1 
Maternal choline supplementation improves spatial learning and adult hippocampal neu-
rogenesis in the Ts65Dn mouse model of Down syndrome 
 
ABSTRACT 
In addition to intellectual disability, individuals with Down syndrome (DS) exhibit dementia by 
the third or fourth decade of life, due to the early onset of neuropathological changes typical of 
Alzheimer's disease (AD). Deficient ontogenetic neurogenesis contributes to the brain hypoplasia 
and hypocellularity evident in fetuses and children with DS. A murine model of DS and AD (the 
Ts65Dn mouse) exhibits key features of these disorders, notably deficient ontogenetic neurogen-
esis, degeneration of basal forebrain cholinergic neurons (BFCNs), and cognitive deficits.  Adult 
hippocampal (HP) neurogenesis is also deficient in Ts65Dn mice and may contribute to the ob-
served cognitive dysfunction.  Herein, we demonstrate that supplementing the maternal diet with 
additional choline (approximately 4.5 times the amount in normal rodent chow) dramatically 
improved the performance of the adult trisomic offspring in a radial arm water maze task. 
Ts65Dn offspring of choline-supplemented dams performed significantly better than unsupple-
mented Ts65Dn mice.  Furthermore, adult hippocampal neurogenesis was partially normalized in 
the maternal choline supplemented (MCS) trisomic offspring relative to their unsupplemented 
counterparts.  A significant correlation was observed between adult hippocampal neurogenesis 
and performance in the water maze, suggesting that the increased neurogenesis seen in the sup-
plemented trisomic mice contributed functionally to their improved spatial cognition. These 
findings suggest that supplementing the maternal diet with additional choline has significant 
translational potential for DS.  
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INTRODUCTION                    
Down syndrome (DS) is the most common known cause of intellectual disability, affect-
ing 1 in 800-1000 births.  This disorder is caused by triplication of human chromosome 
21(HSA21) due to nondisjunction during meiosis.   In addition to intellectual disability, individ-
uals with DS generally develop dementia by the third decade of life (Lai and Williams, 1989; 
Mann, 1988; Visser et al., 1997; Wisniewski et al., 1985a; Wisniewski et al., 1985b) due to the 
onset of Alzheimer’s disease (AD)-like neuropathology, including atrophy of basal forebrain 
cholinergic neurons (BFCNs) (Isacson et al., 2002; Sendera et al., 2000; Whitehouse et al., 1982), 
and formation of neuritic plaques and neurofibrillary tangles (Wisniewski et al., 1985a).  
Currently there are no clinically approved treatments for either intellectual disability or 
dementia in DS. The development of a mouse model of DS provides a tool to investigate the 
pathogenic process(es) underlying this disorder and consequently provide effective therapies. A 
segmental trisomy mouse model of DS, the Ts65Dn mouse (Davisson, et al., 1990 Holtzman et 
al., 1996), is trisomic for the distal portion of mouse chromosome 16 (MMU16), which contains 
100 highly conserved genes that are orthologous to those on HSA21 (Mural et al., 2002; Patter-
son and Costa, 2005; Sturgeon and Gardiner, 2011).  This triplicated chromosomal segment also 
includes the “Down syndrome critical region,” (DSCR) which is considered necessary, although 
not solely sufficient, for the DS phenotype (Belichenko et al., 2009; Olson et al., 2007, 2004).  
Ts65Dn mice survive to adulthood and exhibit many morphological, biochemical, and 
transcriptional changes seen in the human disorder (Antonarakis et al., 2001; Capone, 2001; Da-
visson, et al., 1990; Davisson et al., 1993; Holtzman et al., 1996; Reeves et al., 1995).  Notably, 
similar to humans with DS, these mice exhibit pronounced impairments in functions modulated 
by BFCN projections to the neocortex (e.g., attention; Driscoll et al., 2004; Moon et al., 2010) 
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and hippocampus (e.g., explicit memory function; Hyde et al., 2001; Hyde and Crnic, 2001).  
These cognitive deficits are seen early in life (Bianchi et al., 2010a; Guidi et al. 2011), and be-
come more pronounced in adulthood, coincident with degeneration of BFCNs (Granholm et al., 
2000; Holtzman et al., 1992; Holtzman et al., 1996; Hyde and Crnic, 2001) and increased activa-
tion of microglia (Hunter et al., 2003).  
 A factor that likely contributes to the aberrant brain development and cognitive dysfunc-
tion in DS is impaired ontogenetic neurogenesis, demonstrated in humans with DS (Rachidi and 
Lopes, 2008) and Ts65Dn mice (Bianchi et al., 2010a).  Deficient adult neurogenesis has also 
been demonstrated in the hippocampus (Chakrabarti et al., 2011; Clark et al., 2006; 
Llorens-Martin et al., 2010) and subventricular zone (Bianchi et al., 2010a,b; Chakrabarti et al., 
2011) in Ts65Dn mice, likely contributing to dysfunction in spatial or declarative memory 
(Abrous et al., 2008; Aimone et al., 2006; Leuner et al., 2006; Lledo et al., 2006; Madsen, et al., 
2000; Shors et al., 2001, 2002). These findings suggest that treatments which restore neurogene-
sis will also improve brain development and cognitive function in DS.   
 A putative treatment for restoring neurogenesis and cognitive function in DS is to sup-
plement the maternal diet with additional choline.  Maternal choline supplementation (MCS) has 
been shown to improve learning, attention, and affect regulation in adult Ts65Dn offspring 
(Moon et al, 2010; Powers et al., 2011).  Similar effects have been reported in normal rodents 
born to choline-supplemented dams (Cheng et al., 2008; Glenn et al., 2007, McCann et al., 2006, 
Meck et al., 1988; Meck et al., 1999; Meck and Williams, 2003; Mohler et al., 2001; Moon et al., 
2010; Powers et al., 2011; Wong-Goodrich et al., 2008; Zeisel, 2000). Furthermore, MCS en-
hances adult hippocampal neurogenesis in normal rats (Glenn et al., 2007), suggesting that this 
same intervention would improve neurogenesis in the Ts65Dn mouse (Bianchi et al., 2010a,b; 
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Chakrabarti et al., 2011; Clark et al., 2006; Llorens-Martin et al., 2010). Therefore, the present 
study tested the hypothesis that supplementing the maternal diet with additional choline during 
pregnancy and lactation increases hippocampal neurogenesis and improves spatial learning of the 
adult trisomic offspring.  
 
METHODS 
Subjects   
 Breeder pairs of mice (Ts65Dn female and C57Bl/6J Eicher × C3H/HeSnJ F1 male) were 
purchased from Jackson Laboratories (Bar Harbor, ME) and mated at Cornell University, Ithaca, 
N.Y. Breeder pairs were randomly assigned to receive one of two concentrations of choline chlo-
ride in the diet (1.1 and 5.0 g/kg, respectively; Dyets; Bethlehem, PA), similar to previous stud-
ies reporting lasting beneficial cognitive effects of maternal choline supplementation (Meck and 
Williams, 1999, 2003; Meck et al., 2007). These two diets (normal choline and choline supple-
mented) were provided to the dams at the time that the males and females were paired. The lower 
concentration of choline chloride (1.1 g/kg) is the standard concentration of choline chloride 
found in rodent diets, and is currently considered to provide “adequate” choline intake (Meck et 
al., 2007).  The choline intake of the choline-supplemented dams (those in the group assigned to 
the diet containing 5.0 g choline/kg diet) is approximately 4.5 times the amount of choline con-
sumed by the dams in the “control-choline” group), within the range of dietary variation ob-
served in the human population (Detopoulou et al., 2008). These two levels of maternal choline 
intake continued until the pups were weaned at postnatal day (PND) PND21.  Food intake of 
pregnant dams maintained on these two diets has not revealed an influence of the choline content 
(e.g., Wong-Goodrich et al., 2008).  
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 At weaning (PND 21), tissue was obtained from ear punches and genotyped, at Jackson 
laboratories (Bar Harbor, ME), for the presence of the extra chromosome (HSA21) by quantita-
tive polymerase chain reaction (qPCR) and for amplification of the viral insert in the Pdeb6b 
gene that leads to retinal degeneration and eventual blindness. Mice homozygous for the Pdeb6b 
mutation were excluded from the study. Whenever possible, one trisomic and one normal diso-
mic (2N) male pup were selected from each litter to participate in the behavioral testing.   
 After weaning, all pups were maintained on a diet containing standard choline levels (1.1 
g choline chloride/kg diet; Dyets # 110098; Bethlehem, PA).  The daily ration was calculated to 
yield body weights that were approximately 90% of their free-feeding weights to prevent obesity. 
Pilot studies in our lab indicate that mice weighing more than 40 g had a greater tendency to float 
when placed in the water maze.  At this time, the pups were group-housed (2-4 mice/cage) in 
cages equipped with various objects (plastic igloos, t-tubes, and plastic-gel bones) to lessen the 
environmental impoverishment of the laboratory setting.   Two weeks prior to testing, the ani-
mals were moved to a room with a 12:12 reversed light cycle (lights on at 8pm) and singly 
housed, based on prior evidence that male mice of this strain often fight when reunited after daily 
behavioral testing.  Since mice are nocturnal animals, we tested them during the dark portion of 
the day-night cycle. 
 All protocols were approved by the Institutional Animal Care and Use Committee of 
Cornell University and conform to the National Institutes of Health Guide for the Care and Use 
of Laboratory Animals.   
There were a total of 13 litters for the dams maintained on the normal choline diet (with 8 
providing littermate pairs) and 13 litters for the choline-supplemented dams, with 9 providing 
littermate pairs. The sample sizes for the four groups were: 10 wild-type mice born to dams fed 
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normal choline diet (2N), 11 Ts65Dn mice born to dams fed normal choline diet (Ts65Dn), 11 
2N mice born to dams fed choline-supplemented diet (2N Ch+), and 11 Ts65Dn mice born to 
dams fed choline supplemented diet (Ts65Dn Ch +).  
 
Assessment of spatial learning in the radial arm water maze (RAWM) 
 Assessing hippocampal function is challenging because Ts65Dn mice follow odor trails 
in the radial arm maze (Crnic, 1999) and exhibit thigmotactic behavior in the Morris water maze 
(Costa et al., 1999; Escorihuela et al., 1995).  However, the radial arm water maze (RAWM) 
circumvents these problems and has been used successfully in prior studies using the Ts65Dn 
mouse (Bimonte-Nelson et al., 2003; Howell and Gottschall, 2012; Hunter et al., 2003; Lockrow 
et al., 2011) and other AD mouse models (Arendash et al., 2004).    
The RAWM was configured in a pool (100 cm diameter) and contained six arms (25.5 
cm high, 35 cm long, 20 cm wide) radiating from the center. This configuration created a central 
area of 40 cm diameter. The escape platform was a cylinder (surface 10 cm diameter, 7.5 cm tall) 
made of clear plastic, which was maintained 1 cm below the water surface. Water temperature 
was maintained at 20-22°C to prevent hypothermia but still ensure adequate motivation to find 
the platform.  Both the inside of the pool and the escape platform were black, making the escape 
platform invisible. Extra-maze cues included checkered wall stripes, room furniture, beach balls, 
a metronome and the tester who maintained a position at the same point at the periphery of the 
pool throughout each session. There were a total of two testers during the course of the experi-
ment, each testing an equal number of mice per treatment group. All behavioral testing was con-
ducted by individuals unaware of the animals’ treatment group assignment.  
RAWM testing comprised three phases: (1) training, (2) hidden platform task and (3) 
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visible platform task as described below.   
 
Training  
The training phase acclimated the mice to the maze, to swimming, and to finding the 
hidden platform.  During this phase (termed Day 0, the day prior to the start of testing), all arms 
were blocked except for the start arm and the goal arm that contained the hidden platform, 
providing a direct escape route. This same procedure was used on the first trial of Day 1 but on 
all subsequent trials all arms were accessible. 
 
Hidden platform task   
 The hidden platform task consisted of 5 trials per day for a total of 15 days. The hidden 
escape platform remained in the same location throughout testing for each animal, with the ani-
mals starting from a different arm on each of the 5 daily trials, pseudo-randomly determined. 
Each animal was assigned a different hidden platform location for the entirety of this task, with 
the goal location balanced across treatment groups. On each trial, the mice were given 60 se-
conds to locate the hidden platform; if the platform was not located within that period, the mouse 
was guided to the platform.  Each animal was then given a 15 second resting period on the plat-
form and then returned to its home cage between trials.  All mice in a testing squad were given 
trial 1 before any mouse received trial 2, with the result that each animal had a 10-20 minute rest 
period between consecutive trials.  This procedure prevents hypothermia, a particular concern for 
the trisomic mice (Iivonen et al., 2003; Stasko et al., 2006; Stasko and Costa, 2004).  The mice 
were fed immediately following the last trial of each day.   
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Visible platform task  
 One day after completing the hidden platform task, the mice were tested on a visible 
platform task in the same water maze apparatus for a total of six days with five trials each day. 
The purpose of this task was to determine whether the groups differed in a task which does not 
require spatial mapping but which shares other requirements of the hidden platform task, such as 
swimming ability, motivation to escape from the water, ability to climb onto the platform, and 
visual acuity.  In the visible platform task, a black curtain was placed around the water maze to 
obscure all extramaze cues.  In this task, the location of the platform was indicated by an in-
tramaze cue: a tall white PVC pipe affixed to the platform (3.8 cm diameter X 30.5 cm high).  
The platform changed location on every trial.  The time to locate the visible platform, the resting 
period on the platform, and ITI were identical to that of the hidden platform task.  
 
Age at testing 
 Behavioral testing was started when the animals were, on average, 15.4 months of age, in 
accordance with the hypothesis that the benefits of MCS for the Ts65Dn mice, relative to their 
unsupplemented counterparts, would be most evident in older animals due to effects of the inter-
vention on both brain development and age-related neurodegeneration which begins in these 
mice between 4-6 months of age, and becomes more pronounced over time (Granholm et al., 
2000; Holtzman et al., 1992; Holtzman et al., 1996; Hyde and Crnic, 2001). Due to logistical 
constraints, it was necessary to test the animals in two consecutive cohorts, balanced for the 4 
treatment groups.  As a result, the age at the start of testing ranged from 13 to 17 months (mean = 
15.4 months), balanced for the four treatment groups.  
40 
 
Tissue Preparation                       
 Upon completion of behavioral testing, the mice were deeply anesthetized with ketamine 
(85 mg/kg)/xylazine (13 mg/kg) via intraperitoneal injection and perfused transcardially with 0.9% 
saline (50 ml), followed by 4% paraformaldehyde fixative (50 ml) in phosphate buffer (PB; 0.1M; 
pH = 7.4).  Brains were extracted from the calvaria, postfixed for 24 h in the same fixative, and 
cryoprotected in 30% sucrose in PB solution for 24 h at 4°C.  Each brain was sectioned in the 
coronal plane at 40 μm thickness, on a sliding freezing microtome into six series and stored at 
0 °C in a cryoprotectant solution (30 % ethylene glycol, 30 % glycerol, in 0.1 M PB) prior to 
immunohistochemical staining. 
 
Immunohistochemistry 
 To assess hippocampal neurogenesis, tissue was immunolabeled for doublecortin (DCX), 
a microtubule-associated phosphoprotein that serves as a marker for immature neurons. Briefly, 
one series of free-floating sections were rinsed in PB, washed in Tris-buffered saline (TBS; pH = 
7.4), incubated in TBS containing sodium meta-periodate (0.1 M; 20 min), rinsed for 30 minutes 
in a solution containing TBS and Triton X-100 (0.25 %; TBST) and then blocked in TBST with 
3 % horse serum for 1 h. Sections were incubated with a goat anti-DCX antibody (1:1000; Santa 
Cruz Biotechnology, Santa Cruz, CA) in TBST containing 1% horse serum over-night at room 
temperature. After several washes in TBS containing 1% horse serum, sections were incubated 
with secondary antibody (1:200; horse anti-goat IgG) in TBS with 1% horse serum at room tem-
perature for 1 h. Sections were washed with TBS and incubated with avidin-biotin complex 
(1:500; “Elite Kit,” Vector Labs). Tissue was then washed in sodium acetate trihydrate (0.2 M) 
and imidazole (1.0 M) solution (pH 7.4 with acetic acid). Reaction product was visualized using 
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an acetate-imidazole buffer containing 0.05 % 3/3′-diaminobenzidine tetrahydrochloride (DAB; 
Sigma, MO) and 1.0 % freshly prepared H2O2. Sections were washed in acetate-imidazole buffer 
to terminate the immunochemical reaction, mounted onto alum-submersed slides, air dried for 24 
h, dehydrated through a series of graded alcohols (70 %, 95 %, and 100 %), cleared in xylene, 
and cover-slipped with DPX.  
 
Quantification of DCX-positive cells    
DCX-positive cells in the dentate gyrus of the hippocampus were counted using the opti-
cal fractionator method (Mouton, 2002; Overk et al., 2009; West et al., 1991, West, 1993, 1999). 
Specifically, we sampled every sixth section throughout the rostrocaudal extent of the dentate 
gyrus, including the subgranular zone and granular cell layer. Sampling included both the dorsal 
and ventral blades of the dentate gyrus. Stereoinvestigator 8.21.1 software (Micro-BrightField, 
Cochester, VT) was used to systematically sample throughout the designated region of interest. 
Counts were performed at predetermined intervals (x = 230, y = 230), and a counting frame (130 
x 90 μm = 117002 μm) and superimposed on the live image of the tissue sections.  The sections 
were analyzed using a 60 x 1.4 PlanApo oil-immersion objective. The thickness of each section 
was determined by focusing on the top of the section, zeroing the z-axis followed by focusing on 
the bottom of the section. The average tissue thickness was 8.3 μm with a range of 7.6 μm - 12.1 
μm. The dissector height was set at 6 μm, allowing for a 2-μm top guard zone and at least a 2-μm 
bottom guard zone. A total of 10-12 sections were evaluated per animal. Bright field photomi-
crographs were taken with the aid of a Nikon microscope.  
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Determination of DCX antibody tissue penetration 
          DCX antibody penetration throughout the depth of tissue sections was determined during 
the optical fractionator by visual analysis of immunolabeling throughout the z-axis and 
post-probe run examination of depth histograms which demonstrate marker placement in the 
z-axis (Kelley, et al., 2011, Overk, et al., 2009). DCX antibody penetrated the full depth of the 
section, thus allowing for the equal probability of counting all objects, a prerequisite for unbiased 
stereology. 
 
Data Analysis 
 Statistical analyses were conducted using the Statistical Analysis System (Version 9.1; 
SAS Institute, Cary, NC).  The primary dependent measure for both the hidden and visible plat-
form task was the mean number of errors committed. These data were analyzed using PROC 
GLIMMIX, a generalized linear mixed models procedure for conducting repeated measures 
analyses for various probability distributions including normal data (Wolfinger and O’ Connell, 
1993).  The models used for these analyses included the between-group fixed effects:  cohort (1 
or 2), genotype (Ts65Dn or 2N) and maternal diet [unsupplemented (normal choline content) or 
supplemented], and session-block (3 sessions/session-block) or testing session (as appropriate), 
as well as all relevant higher-order interactions.  Random effects for mouse and block were also 
included. 
 The neurogenesis data (DCX-positive cells) were analyzed using a non-parametric Krus-
kal-Wallis one-way analysis of variance, due to unequal variances between groups [determined 
by the Levene test of homogeneity (Levene, 1960)]. The primary dependent measure was the 
mean number of DCX-positive cells within the dentate gyrus of the hippocampus.  Lastly, 
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Spearman's rank correlation coefficient was used to assess the correlation between mean number 
of errors in the hidden platform task and number of DCX-positive cells.  
 The significance level was 5% for primary analyses of both behavioral and neurogenesis 
endpoints.  To control for multiple comparisons following a significant overall F-test or Krus-
kal-Wallis test, the subsequent pair-wise comparisons were conducted using a Bonferroni pro-
cedure.  Three comparisons were of interest [(1) 2N vs. Ts56Dn (2) Ts65Dn vs. Ts65Dn Ch+, 
and (3) 2N vs. 2N Ch+]; thus, the criteria for significance for these tests was (.05/3) = 0.0167.    
 
RESULTS 
Body Weight 
 Analysis of body weight at the start of testing revealed a main effect of Genotype (F (1, 
40) = 13.59, P < 0.001) but no effect of Diet (F (1, 40) = 0.00, P = 0.95), and no interaction of Diet 
and Genotype (F (1, 40) = 1.05, P = 0.32). The mean body weight of the 2N mice (mean = 35.19 g; 
S.E.M. = 0.53) was significantly greater than that of the trisomic mice (mean = 31.82 g; S.E.M. = 
0.405) (P < 0.001). This effect of the trisomy on body weight is consistent with prior reports 
(Bianchi et al., 2010a; Fuchs et al., 2012; Roper et al, 2012).   
 
Hidden platform  
 Analysis of mean errors per session, across the 5 session-blocks (3 sessions/block) of 
testing in the hidden platform task, revealed a main effect of Genotype (F (1, 50.2) = 9.05, P < 0.01).  
Although the main effect of Diet was not significant (F (1, 50.2) = 0.89, P = 0.35), a significant in-
teraction of Diet and Genotype was found (F (1, 50.2) = 6.76, P = 0.01).  Pair-wise comparisons   
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Figure 1. Mean (+/- SE) errors in the Hidden Platform task. (A) Plotted as a function of session block (3 
sessions per block) and (B) averaged across the 15 sessions: MCS improved performance of the adult 
Ts65Dn offspring in the Hidden Platform task of the radial arm water maze, a hippocampal-dependent task. 
* p ≤ 0.01.  
  
A 
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Figure 2. Mean (+/- SE) errors in the Visible Platform task across the 6 sessions of testing. The 
groups did not differ in their performance in the Visible Platform task. 
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show that the unsupplemented trisomic mice committed a significantly higher number of errors  
than the unsupplemented 2N mice (P = 0.0003). MCS significantly improved performance of  
Ts65Dn offspring relative to their unsupplemented counterparts (P = 0.014).  No effect of MCS 
was detected for the 2N mice (P = 0.25).   
 
Visible platform  
 Analysis of mean errors per session across the six days of testing did not reveal a signifi-
cant main effect of Genotype (F (1, 51.89) = 0.06, P = 0.81) or Diet (F (1, 52.03) = 0.54, P = 0.47) nor a 
significant Genotype × Diet interaction (F (1, 51.89) = 3.51, P = 0.07, see Fig. 2).   These results 
indicate that the observed group differences in performance in the hidden platform task were not 
due to group differences in visuomotor ability, swimming ability, or motivation to find the plat-
form.  
 
Neurogenesis  
 Using unbiased stereology, the total number of DCX-positive cells was estimated within 
the dentate gyrus (see Fig. 3).  A significant effect of treatment group (H (3) = 29.04, P < 0.0001) 
was found for the number of DCX-positive cells.  Unsupplemented Ts65Dn mice had signifi-
cantly fewer DCX- positive cells than unsupplemented 2N mice (P = 0.0001; Fig. 4). Important-
ly, the Ts65Dn Ch+ mice had significantly more DCX-positive cells than unsupplemented 
Ts65Dn mice (P = 0.0002).  No effect of MCS was detected for 2N mice (P = 0.40).   
 
Correlation between water maze errors and adult neurogenesis   
 The Spearman’s rank order analysis revealed a modest but significant negative correla 
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Figure 3. DCX-positive cells in the subgranular zone and granular cell layer of the hippocampus 
across different treatment groups. Adult hippocampal neurogenesis is deficient in Ts65Dn mice (C, D) 
compared to 2N littermates (A, B). Choline supplementation partially normalized adult neurogenesis in 
Ts65Dn mice (G, H). No effect of maternal choline supplementation was observed in 2N mice (E, F). h = 
hilus. 
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Figure 4.  Mean (+/- SE) number of DCX-positive cells in the dentate gyrus of the hippocampus. 
Unsupplemented Ts65Dn mice expressed significantly fewer DCX- positive cells than the 2N mice (P < 
0.0001). Maternal choline supplementation significantly increased the number of DCX positive cells for the 
Ts65Dn mice (P < 0.001). * p ˂ 0.001. 
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Figure 5. Correlation between mean errors in the water maze and DCX-positive cell number, 
showing the line of best fit.  A negative correlation was seen between mean errors in the water maze 
and DCX-positive cell number in the dentate gyrus (rs(41) = -.470, P < 0.001); i.e. as hippocampal neuro-
genesis increased , the number of errors decreased .  
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tion between water maze errors and DCX-positive cell number (rs (41) = -0.470, P < 0.001, see Fig  
5).  Thus, greater neurogenesis in the DG was associated with fewer errors in the water maze.   
Removal of the one animal with an extreme error score did not significantly affect this relation-
ship (rs(40) = -.440, P = 0.0036).   
 
DISCUSSION 
Maternal choline supplementation and impaired spatial learning/memory in the Ts65Dn mice 
Unsupplemented Ts65Dn mice were significantly impaired in their ability to learn and 
perform the hidden platform RAWM task, a hippocampal-dependent task (Mizumori et al., 1999; 
Muller et al., 1996; O’Keefe, 1976; O’Mara, 1995; Wiener, 1996).  In contrast, the trisomic mice 
did not differ from controls in the visible platform task, which places similar demands on motor 
function, visual acuity, and arousal regulation, but does not require spatial mapping.  Thus, the 
pattern of effects in these two tasks implicates impaired spatial cognition in the Ts65Dn mice, 
consistent with prior reports (Belichenko et al., 2007; Bimonte-Nelson et al., 2003; Chang and 
Gold, 2008; Escorihuela et al., 1995; Holtzman et al., 1996; Hunter et al., 2003; Reeves et al., 
1995; Sago et al., 1998). Supplementing the maternal diet with additional choline during preg-
nancy and lactation substantially improved the performance of the adult trisomic offspring in the 
hidden platform task relative to their unsupplemented counterparts, demonstrating that this early 
dietary intervention improves spatial cognition.   
 These findings represent the first demonstration that MCS improves spatial learn-
ing/memory during adulthood in a mouse model of DS and AD. MCS improves spatial learn-
ing/memory in rodent models of various conditions that produce cognitive impairment in humans, 
including normal age-related cognitive decline (Glenn et al., 2008; Meck et al., 2003, Meck et al., 
51 
 
2007), prenatal alcohol exposure (Thomas et al; 2009; Thomas et al., 2010) and seizure disorders 
(Holmes et al., 2002; Wong-Goodrich et al., 2011; Yang et al., 2000), indicative of a neuropro-
tective effect that merits further consideration for translation to human populations including DS.  
 The absence of a beneficial effect of MCS on spatial learning of the 2N mice contrasts 
with several reports that pre- and/or early postnatal choline supplementation of normal rats im-
proves spatial cognition (Cheng et al., 2008; Glenn et al., 2007, 2008; McCann et al., 2006; 
Meck et al., 1988; reviewed in Meck and Williams, 2003; Wong-Goodrich et al., 2008; Zeisel, 
2000) and functioning of the septo-hippocampal system (Jones et al., 1999; Li et al., 2004; 
Pyapali et al., 1998; Steingart et al. 1998).  In the present study, the lack of benefit for the 2N 
mice likely is due to the task not being sufficiently demanding for them. In this regard, prior re-
ports indicate that the spatial cognition benefits of MCS for normal rodents exist for demanding 
tasks, particularly those which place the greatest requirements on hippocampal function 
(McCann et al., 2006; Meck and Williams, 1999).  For example, in one prior water maze study, a 
benefit of MCS was seen for normal rats when the location of the escape platform changed daily 
but not when it remained in the same location across sessions (Tees, 1999; Tees and Mohammadi, 
1999) as in the present study.  The less demanding reference memory version of this task was 
selected only after extensive pilot testing demonstrated that the Ts65Dn mice could not solve the 
former, more demanding version of the test.  
One final interpretive issue pertains to the order of administering the visible and hidden 
platform tasks.  Because the visible platform task was administered after the hidden platform 
task, it cannot provide a pure test of associative learning because the change in task rules also 
placed demands on cognitive flexibility.  Nonetheless, the absence of group differences in this 
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task provides evidence that group differences in performance in the hidden platform task are un-
likely to be due to sensory, motor, or motivational differences.     
 
Lasting effects of early choline supplementation on adult hippocampal neurogenesis 
 Unsupplemented Ts65Dn mice exhibited a reduced number of DCX-positive cells in the 
hippocampus relative to the 2N mice, indicating reduced hippocampal neurogenesis in Ts65Dn 
mice, consistent with prior studies (Bianchi et al., 2010a; Chakrabarti et al., 2011; Clark et al., 
2006; Llorens-Martin et al., 2010).  However, in several of these earlier studies, BrdU was used 
to detect new cells but their specificity was not verified by neuronal specific markers (Bianchi et 
al., 2010b; Clark et al., 2006), contrary to the present study.   
   Importantly, the present study also demonstrated that supplementing the maternal diet 
with additional choline substantially increased hippocampal neurogenesis in the adult trisomic 
offspring.  In addition to the implications of this finding for functions dependent on adult hippo-
campal neurogenesis (discussed below), this finding also suggests that MCS may improve de-
velopmental neurogenesis in the trisomic mice, based on evidence that adult neurogenesis is an 
extension of early ontogenetic neurogenesis, relying on similar molecular machinery (reviewed 
in Kuhn and Blomgren, 2011).  Impaired ontogenetic neurogenesis in Ts65Dn mice and DS in-
dividuals likely contributes to the hypoplasia and hypocellularity observed in various brain re-
gions (Guidi et al., 2011; Rachidi and Lopes, 2008) and the consequent developmental delay and 
cognitive impairments. MCS may also reduce hypocellularity, developmental delay, and cogni-
tive impairments in humans with DS.   
 Although prior work has shown that MCS increases adult hippocampal neurogenesis in 
normal rats (Glenn et al., 2007), this effect was not seen in the 2N mice in the present study.  
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Several factors may account for these differences including species differences and the age of the 
animals.  In this prior study, the rats were 8 months of age at the time of the assessment, whereas 
the mice in the present study were much older, averaging 15. 4 months of age. It is possible that 
the benefit of MCS on this function in normal rodents declines with aging.  
 
Mechanisms underlying improved neurogenesis and spatial learning/memory in Ts65Dn mice  
 In the present study, MCS both increased hippocampal neurogenesis and improved spa-
tial cognition in Ts65Dn mice, effects which may be causally linked.  Indeed, a significant nega-
tive correlation was observed between neurogenesis in the DG and errors in the water maze, 
consistent with prior studies showing that treatments which impair adult hippocampal neurogen-
esis also disrupt spatial cognition (Deng et al., 2009; Dupret et al., 2008; Farioli-Vecchioli et al., 
2008; Garthe et al., 2009; Imayoshi et al., 2008; Jessberger et al., 2009; Snyder et al., 2005; 
Zhang et al., 2008).  These data collectively support a functional relationship between the in-
creased hippocampal neurogenesis in the supplemented trisomic mice and their improved spatial 
cognition.    
 It is possible that the beneficial effects of MCS on spatial cognition and neurogenesis in 
the Ts65Dn mice reflect the effects of this early dietary manipulation on neurotrophic factors.  
Notably, MCS in normal rats has been shown to increase levels of brain-derived neurotrophic 
factor (BDNF) (Glenn et al., 2007) and nerve growth factor (NGF) (Sandstrom et al., 2002) in 
the brains of the adult offspring. BDNF increases survival of newly proliferated neurons (Lee et 
al., 2001; Linnarsson et al., 2000; Mattson et al., 2004) and plays an important role in spatial 
learning and memory (Mizuno et al., 2000).  Another possibility, suggested by the effects of 
MCS on NGF expression in normal rats, is that MCS provided target-derived neuroprotection of 
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Ts65Dn BFCNs, which begin to atrophy in Ts65Dn mice by 6 months of age due to impaired 
retrograde transport of NGF (Cooper et al., 2001; Granholm et al., 2000; Holtzman et al., 1992, 
1996; Salehi et al., 2006). Notably, BFCNs projecting from the medial septum to the hippocam-
pus modulate spatial mapping (Ikonen et al., 2002; Leutgeb et al., 1999; Okada and Okaichi , 
2010) and septohippocampal cholinergic activity has been shown to facilitate neurogenesis 
(Mohapel at al., 2005). Parallel studies in our lab provide evidence for a reduction in neuro-
degeneration of BFCNs in Ts65Dn mice supplemented with choline early in life (Ash et al., 
2011).   
 Although much remains to be learned regarding the specific mechanism(s) by which 
MCS exerts lasting effects on cognitive functioning and neurogenesis, both effects (as well as the 
previously documented effects on neurotrophins and cholinergic system structure and function), 
likely reflect either: (i) organizational brain changes secondary to acetylcholine’s role as an on-
togenetic signal (Cermak et al., 1999; Meck et al., 1989; Zeisel and Niculescu, 2006); and/or (ii) 
epigenetic modifications with lasting effects on gene expression, secondary to choline’s role as a 
methyl donor (Niculescu  et al., 2004, 2006; Waterland and Jirtle, 2003; Zeisel, 2009a). 
 
Other manipulations shown to increase neurogenesis in Ts65Dn mice  
 Other treatments have been shown to improve neurogenesis in Ts65Dn mice, but the 
translational potential is much lower for these interventions than for MCS.  First, the combina-
tion of environmental enrichment plus exercise has been shown to increase neurogenesis in both 
trisomic and 2N mice (Chakrabart et al., 2011), but these findings do not imply a therapeutic 
effect of this intervention because the group differences are more accurately interpreted as 
showing the adverse effect of environmental isolation on neurogenesis than the therapeutic ef-
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fects of enrichment (discussed in Strupp and Beaudin, 2006).  Another treatment that has been 
found to increase neurogenesis in both Ts65Dn and 2N mice is neonatal or adult administration 
of fluoxetine (Bianchi et al., 2010a; Clark et al., 2006).  However, it is unlikely that this treat-
ment would be advocated clinically in light of evidence that this drug increases risk of malfor-
mations and cardiovascular abnormalities when given to humans during fetal development (for 
review see Morrison et al., 2005), and exacerbates the behavioral deficits of Ts65Dn mice when 
given during adulthood (Heinen et al., 2012).  A final treatment that has been shown to increase 
neurogenesis in Ts65Dn mice is lithium, although in this case only adult treatment has been 
evaluated (Bianchi et al., 2010b).  Again, translational potential is limited by reports of hypothy-
roidism (discussed in McKnight et al., 2012) and renal toxicity (Grunfeld and Rossier, 2009) 
with chronic administration of the drug. Hypothyroidism would be of particular concern in the 
case of early developmental therapy, due to the lasting adverse effects of this condition on brain 
development (Auso et al., 2004; Williams and Hume, 2008). 
 
Conclusions and Clinical Implications  
Growing evidence indicates that not only is increased maternal intake of choline safe for 
both mother and developing fetus, but that it may be necessary for optimal brain development 
and lifelong cognitive and affective functioning of the offspring. As noted above, lasting benefi-
cial effects of this maternal intervention have been reported for offspring spatial cognition 
(Cheng et al., 2008; Glenn et al., 2007; Meck et al., 1988; Meck and Williams, 1999; 
Wong-Goodrich et al., 2008; Zeisel, 2000), attentional function (Mohler et al., 2001; Moon et al., 
2010; Powers et al., 2011), and emotion regulation (Cheng et al., 2008; Moon et al., 2010), as 
well as protection against age-related cognitive decline (McCann et al., 2006; Meck et al., 1988; 
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2007).   These beneficial effects of increased maternal choline intake likely reflect the intensified 
demand for choline during fetal development (Jiang et al., 2012; Yan et al., 2012), coupled with 
the apparent inadequacy of standard rodent chow to provide sufficient choline to meet these 
needs.  This latter inference is based on the evidence that pregnancy causes a pronounced deple-
tion of choline pools in rats consuming standard laboratory chow (Holmes-McNary et al., 1996; 
McMahon and Farrell, 1985).  The increased demand for choline during fetal development likely 
reflects the numerous ontogenetic roles of this nutrient, including serving as a precursor for 
membrane phospholipids and the neurotransmitter, acetylcholine, as well as serving as the pri-
mary source of methyl groups for methylation reactions, including DNA and histone methylation, 
which play important roles in regulating gene expression (discussed in Zeisel 2009a, b).   
Although the heightened demand for choline during pregnancy is reflected in a slight in-
crease in choline intake recommendations for pregnant women relative to non-pregnant women, 
the increment is small (425 vs. 450 mg/choline/day) (IOM, 1998), and viewed by many as inad-
equate to meet the demands of pregnancy and lactation (Craciunescu et al., 2003; Zeisel, 1995; 
Zeisel, 2000, 2009b; Zeisel and da Costa, 2009).  The current recommended intake level for 
adults (including pregnant women), determined only recently in 1998, was based on the quantity 
of choline required to prevent liver dysfunction; brain function did not factor into this recom-
mendation.   Indeed, in light of the growing evidence from maternal choline supplementation 
studies (reviewed in Meck and Williams, 2003) as well as data demonstrating the increased cho-
line demands of pregnancy (e.g., Holmes-McNary et al., 1996; Jiang et al., 2012; McMahon and 
Farrell, 1985; Yan et al., 2012), many researchers have called for a re-evaluation of choline in-
take recommendations for pregnant women (e.g., Jiang et al., 2012; Meck and Williams, 1999, 
2003; Yan et al., 2012; Zeisel, 1995, 2009b).  
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In sum, the present study demonstrated that supplementing the maternal diet with addi-
tional choline during pregnancy and lactation improves spatial cognition and hippocampal neu-
rogenesis in adult Ts65Dn offspring.  If these findings generalize to humans, MCS could provide 
a therapy to normalize brain development and cognitive function in DS as well as possibly slow 
the neurodegeneration associated with both DS and AD (Ash et al., 2011).  Moreover, because 
the animal literature indicates beneficial effects for both normal offspring as well as those with 
DS, this type of nutritional advice could be given to all women and thereby circumvent the prob-
lem that such treatments need to be implemented during the earliest stages of development to 
have the greatest impact, and yet prenatal testing is not performed in the majority of pregnancies 
yielding DS offspring (discussed in Newberger, 2000).  Future studies are needed to ascertain 
whether the beneficial effects of MCS are seen in humans.    
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CHAPTER 2 
 
Maternal choline supplementation improves spatial mapping and increases basal forebrain 
cholinergic neuron number and size in aged Ts65Dn mice 
 
ABSTRACT 
Down syndrome (DS) is marked by intellectual disability (ID) and early-onset of Alzheimer’s 
disease (AD) neuropathology, including basal forebrain cholinergic neuron (BFCN) degeneration.  
The present study tested the hypothesis that maternal choline supplementation (MCS) lessens 
hippocampal dysfunction and protects against BFCN degeneration in the Ts65Dn mouse model 
of DS and AD.  During pregnancy and lactation, dams were assigned to either a choline suffi-
cient (1.1 g/kg choline chloride) or choline supplemented (5.1 g/kg choline chloride) diet.  Between 
13 and 17 months of age, offspring were tested in the radial arm water maze (RAWM) to exam-
ine spatial learning and memory followed by unbiased quantitative morphometry of BFCNs.  
Spatial mapping was significantly impaired in unsupplemented Ts65Dn mice relative to normal 
disomic (2N) littermates.  Additionally, a significantly lower number and density of medial sep-
tum (MS) hippocampal projection BFCNs was also found in unsupplemented Ts65Dn mice.  
Notably, MCS significantly improved spatial mapping and increased number, density, and size 
of MS BFCNs in Ts65Dn offspring.  Moreover, the density and number of MS BFCNs correlat-
ed significantly with spatial memory proficiency, providing powerful support for a functional 
relationship between these behavioral and morphometric effects of MCS for the trisomic off-
spring. Thus, increasing maternal choline intake during pregnancy may represent a safe and ef-
fective treatment approach for expectant mothers carrying a DS fetus, as well as a possible 
means of BFCN neuroprotection during aging for the population at large. 
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INTRODUCTION 
Down syndrome (DS), caused by triplication of human chromosome 21 (HSA21), is the 
most common genetic disorder resulting in intellectual disability (ID).  By the third or fourth 
decade of life, DS individuals develop dementia and the histopathological characteristics of Alz-
heimer’s disease (AD) (Casanova et al., 1985; Fodale et al., 2006; Mann, 1988; Mann et al., 
1986, 1984; Mann and Esiri, 1989; Wisniewski et al., 1985a, 1985b), including neurofibrillary 
tangles, neuritic plaques, and cholinergic basal forebrain pathology (Mufson et al., 2003; Isacson 
et al., 2002; Sendera et al., 2000; Whitehouse et al., 1982). Currently, there are no therapeutic 
interventions that prevent or reverse ID, age-related cognitive impairment, or brain pathology in 
DS.   
Several mouse models have been developed to study the relationship between the tripli-
cation of specific genes in DS and distinct phenotypic features (see Das and Reeves, 2011; 
Rueda et al., 2011; Salehi et al., 2006 for reviews). The most well-characterized animal model is 
the Ts65Dn mouse, which is segmentally trisomic for the distal region of mouse chromosome 16 
(MMU16) which contains more than 100 highly conserved genes that are orthologous to those on 
HSA21 (Sturgeon and Gardiner, 2011).  This triplicated chromosomal segment also includes the 
“Down syndrome critical region,” (DSCR) which is considered necessary, although not solely 
sufficient, for the DS phenotype (Belichenko et al., 2009; Olson et al., 2007, 2004).   
Similar to humans with DS, Ts65Dn mice are born with an intact basal forebrain cholin-
ergic neuron (BFCN) system, which undergoes progressive atrophy starting between four and six 
months of age (Granholm et al., 2000; Holtzman et al., 1996; Hunter et al., 2003; Seo and Isac-
son, 2005). BFCN atrophy coincides with a decline in hippocampal-dependent memory function 
in Ts65Dn mice likely due to impairment of the cholinergic hippocampal projection system aris-
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ing from the medial septum (MS) and vertical limb of the diagonal band (VDB) (Bimon-
te-Nelson et al., 2003; Crnic and Pennington, 2000; Fernandez and Garner, 2008; Granholm et 
al., 2000; Holtzman et al., 1996; Hunter et al., 2003; Hyde and Crnic, 2001; Hyde et al., 2001; 
Rye et al., 1984; Stasko and Costa, 2004). Cholinergic neurons within the nucleus basalis of Me-
ynert (NBM) also atrophy, which correlates with cognitive decline in both DS and AD (Bierer et 
al., 1995; Davis et al., 1999; DeKosky et al., 2002; Mufson et al., 2003).  
Based on these findings, interventions that maintain BFCN viability are likely to improve 
cognition in DS.  A therapy which may hold promise in this regard is supplementation of the 
maternal diet with additional choline, a hypothesis based on two converging lines of evidence: (a) 
the pattern of cognitive impairment in DS (and the Ts65Dn mouse) is indicative of dysfunction 
of BFCNs and their projections to the hippocampus and frontal cortex (spatial memory and at-
tention, respectively); and (b) in normal rodents, supplementing the maternal diet with additional 
choline (~ 4.5X the amount in normal chow) enhances these two cognitive domains in the off-
spring, and exerts structural and functional changes in the septo-hippocampal cholinergic system 
(reviewed in Meck and Williams, 2003; McCann et al., 2006; Zeisel and Niculescu, 2006). Prior 
findings from our lab have provided support for this hypothesis, demonstrating that maternal 
choline supplementation (MCS) produces lifelong improvements in performance of Ts65Dn 
offspring in behavioral tasks dependent on BFCN projections to the frontal cortex (Moon et al., 
2010), and normalizes hippocampal neurogenesis in these animals (Velazquez et al., 2013).   
The current study was designed to extend this prior work by testing the hypothesis that 
MCS improves performance of aged Ts65Dn offspring on tests of spatial learning and memory, 
and that the mechanism(s) underlying these cognitive benefits are related to protection of the 
BFCN hippocampal and cortical projection systems.  To examine these hypotheses, we assessed 
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the effects of supplementing the maternal diet with additional choline (versus a control diet with 
standard choline content) in Ts65Dn offspring and their normal disomic (2N) littermates, with 
respect to (1) radial arm water maze (RAWM) performance, and (2) morphometric indices of 
MS, VDB, and nucleus basalis of Meynert/ substantia innominata (NBM/SI) cholinergic neurons.  
The morphology of cholinergic neurons was characterized by using 3 cholinergic markers, (1) 
choline acetyltransferase (ChAT), the enzyme which synthesis choline, (2) the pan-neurotrophin 
receptor p75NTR, which is a low affinity neurotrophin receptor and  (3) the nerve growth factor 
(NGF) receptor tyrosine receptor kinase A (TrkA), which is a high affinity neurotrophin receptor.  
Staining for ChAT allows for the characterization of all cholinergic neurons whereas labeling for 
p75 NTR and TrkA is thought to provide for a better index of functioning cholinergic neurons as 
these receptors are lost during the degenerative process seen with the onset of AD.  
 
METHODS 
Subjects  
Breeder pairs (Ts65Dn female and C57Bl/6J Eicher × C3H/HeSnJ F1 male mice) were 
purchased from Jackson Laboratories (Bar Harbor, ME), mated at Cornell University, (Ithaca, 
NY), and randomly assigned to either a choline-controlled, standard rodent chow diet (AIN-76A 
with 1.1 g/kg choline chloride; Dyets Inc., Bethlehem, PA) or a rodent chow diet with choline 
supplementation (AIN-76A with 5.0 g/kg choline chloride; Dyets Inc) as reported previously 
(Kelley et al., 2014a, 2014b; Velazquez et al., 2013).  The two levels of maternal choline intake 
selected for these studies with the Ts65Dn model were based on numerous prior studies demon-
strating lasting cognitive benefits of increased maternal choline intake in normal rodents (Meck 
and Williams, 1999; 2003; Meck et al., 2007).  The choline content of the control diet is consid-
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ered to provide adequate choline intake during pregnancy (Meck et al., 2007).  The cho-
line-supplemented diet provided approximately 4.5 times the concentration of choline in the 
normal diet, within the range of dietary variation observed in the human population (Detopoulou 
et al., 2008). The breeder pairs were provided ad libitum access to their assigned diet.  Pups were 
weaned on postnatal day 21 (PND 21) and given ad libitum access to the control diet. 
 Breeder pairs yield litters with segmentally trisomic (Ts65Dn) mice and disomic (2N) 
littermates. At weaning, tail snips were sent to Jackson laboratories (Bar Harbor, ME) for geno-
typing by quantitative polymerase chain reaction (qPCR) for the detection of the extra chromo-
somal segment of MMU16, and determination of Pde6brd1 homozygosity. Pde6brd1 is a recessive 
mutation that leads to retinal degeneration (Keeler, 1966); mice homozygous for the Pde6brd1 
mutation were excluded from the study.   
 After weaning, the pups were group-housed with same-sex littermates.  Only male mice 
were used for these experiments. To prevent obesity (which can interfere with water maze per-
formance), a daily ration was calculated to yield body weights that were approximately 90% of 
their free-feeding weights. Two weeks prior to behavioral testing, mice were singly housed to 
prevent fighting between cage-mates, which often occurs when group-housed male mice of this 
strain are returned to the home-cage following daily behavioral testing. A combination of daily 
handling, testing and providing objects in the home-cage (i.e., plastic igloos, tubes, and plas-
tic-gel bones, Nestlets) countered the environmental impoverishment of single animal housing. 
Mice were housed in a room with a 12:12-hour reversed light-dark cycle (lights off at 8:00 a.m.) 
and tested during the dark cycle. The behavioral testing room directly adjoined the housing room, 
preventing any light exposure during the transport of the animals between rooms. 
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 All protocols were approved by the Institutional Animal Care and Use Committee of 
Cornell University and conform to the National Institutes of Health Guide for the Care and Use 
of Laboratory Animals.  
  
 
 
Behavioral Testing: Radial arm water maze (RAWM) 
The RAWM was used to assess spatial learning and memory.  Variations of this task have 
been used successfully in prior studies with Ts65Dn mice (Bimonte-Nelson et al., 2003; Howell 
and Gottschall, 2012; Hunter et al., 2003; Lockrow et al., 2011; Velazquez et al., 2013) and other 
AD mouse models (Arendash et al., 2004).  Because this task requires mice to navigate the arms 
of the maze to find the escape platform, it prevents the thigmotactic behavior exhibited by 
Ts65Dn mice in the Morris water maze. 
The RAWM was configured in a pool (100 cm diameter) containing six arms (25.5 cm 
high, 35 cm long, 20 cm wide) radiating from the center. This configuration created a central 
area of 40 cm diameter. Water temperature was maintained at 20–22 ˚C, cool enough to ensure 
adequate motivation to perform the task, but sufficiently warm to avoid hypothermia.  The es-
cape platform was a cylinder (surface 10 cm diameter, 7.5 cm tall) made of clear plastic, tinted 
black, situated 1 cm below the water surface.   Because the inside of the pool was also black, the 
escape platform was not visible to the animals. Numerous distinctive extra-maze cues were 
available to allow the mice to navigate using spatial mapping.  Two individuals conducted the 
behavioral testing, each testing an equal number of mice per treatment group.  Animals were 
tested in two consecutive cohorts, in a stratified randomized balanced design across 4 groups, 
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resulting in an age range of 12.8 to 16.7 months (Mean = 15.5, SD = 1.75; see Table 1) at the 
start of testing.   Behavioral testing followed a 20-day protocol after which the animals were 
immediately sacrificed at ages 13.7 – 17.8 months.  Whenever possible, one Ts65Dn and one 2N 
male pup were selected from each litter for behavioral testing.  Experimenters conducting the 
behavioral testing were blind to the subject’s genotype and maternal diet.  
RAWM testing comprised three phases: (1) training, (2) hidden platform (HP) task, and 
(3) visible platform (VP) task, as described below.  
 
Training 
For one session prior to maze testing, the mice were acclimated to the maze and the basic 
procedures of the task (e.g., swimming, finding the hidden platform).  During this phase, all arms 
were blocked except for the start arm and the goal arm that contained the hidden platform, 
providing a direct escape route. This same procedure was used on the first trial of the first day of 
the hidden platform task (see below) but on all subsequent trials, all arms were accessible. 
 
Hidden platform (HP) task 
The HP task began on the day following training. In this task, mice were tested for five 
trials per session for a total of 15 sessions. The escape platform remained in the same location 
throughout testing for each animal, with the animals starting from a different arm on each of the 
five daily trials, pseudo-randomly determined.  Each animal was assigned a different hidden 
platform location for the entirety of this task, with the goal location balanced across treatment 
groups. On each trial, the mice were given 60 seconds to locate the platform; if the platform was 
not located within that period, the mouse was guided to the platform. If at least half of the ani-
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mal’s body entered a non-goal arm an error was tallied.  After each trial, each animal was given a 
15 second rest period on the platform and then returned to its home cage during the inter-trial 
interval (ITI) in order to prevent hypothermia, a particular concern for Ts65Dn mice (Iivonen et 
al., 2003; Stasko and Costa, 2004; Stasko et al., 2006).  All mice were tested on trial 1 before any 
mouse was tested on trial 2, etc., with the result that each animal had a 10–20 minute rest period 
between consecutive trials. The animals were weighed every other day and fed immediately fol-
lowing the last trial of each day.   
 
Visible platform (VP) task 
 On the day following completion of the HP task, the mice were tested on the VP task for 
five sessions, using the same water maze apparatus.  Successful performance in the VP task does 
not require spatial mapping but depends on other abilities needed for success in the HP task, in-
cluding the ability to swim, and climb onto the platform, motivation to escape from the water, 
arousal regulation, and visual acuity.  In the VP task, a black curtain was placed around the water 
maze to obscure extramaze cues.  The location of the platform was indicated by a prominent in-
tramaze cue: a tall, white PVC pipe affixed to the platform (3.8 cm diameter X 30.5 cm high).  
The location of the platform was changed on every trial.  All other testing characteristics were 
the same as in the HP task, including the amount of time allotted per trial to search for the plat-
form, the resting period on the platform, and the ITI.  
 
Tissue preparation 
  Upon completion of behavioral testing, mice were deeply anesthetized with ketamine (85 
mg/kg)/xylazine (13 mg/kg) via intraperitoneal injection, perfused transcardially with 0.9% sa-
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line (50 ml), followed by 4% paraformaldehyde (50 ml) in phosphate buffer (PB; 0.1M; pH = 
7.4). Ages at sacrifice are shown in Table 1.  Brains were extracted from the calvaria, postfixed 
for 24 h in the same fixative, and placed in a 30% sucrose PB solution at 4 °C until sectioning.  
Each brain was cut in the coronal plane at 40 µm thickness, on a sliding freezing microtome into 
six adjacent series and stored at 4 °C in a cryoprotectant solution (30 % ethylene glycol, 30 % 
glycerol, in 0.1 M PB) prior to immunohistochemical staining (Kelley et al., 2014a, 2014b; Ve-
lazquez et al., 2013).  
 
Immunohistochemistry 
 Immunohistochemistry was performed as previously described (Kelley et al., 2014a, 
2014b). Tissue was immunostained using the following primary antibodies: a goat polyclonal 
antibody against choline acetyltransferase ChAT, 1:1000; Millipore, Billerica, MA), a rabbit 
polyclonal antibody against the pan-neurotrophin receptor p75NTR (1:2000; Millipore), and a 
rabbit polyclonal antibody against the cognate nerve growth factor (NGF) receptor tyrosine re-
ceptor kinase A (TrkA, 1:10,000, gift from Dr. L. Reichardt, UCLA). A 1/6 series of sections 
was singly immunolabeled for each marker, group sizes are as listed in Table 1. Briefly, sections 
were washed in 0.1 M phosphate buffer (PB; pH 7.4) to remove cryoprotectant, rinsed in 
Tris-buffered saline (TBS), and incubated in sodium (meta)periodate (2.139 g per 100 ml TBS) 
to inhibit endogenous peroxidase activity. To improve primary antibody penetrance throughout 
the full depth of the tissue, sections was washed in TBS with 0.25 % Triton X-100, followed by 
rinses in a blocking solution to prevent nonspecific binding consisting of 3 % serum (raised 
against host organism of secondary antibody: ChAT, horse serum; p75NTR and TrkA, goat serum) 
in TBS/Triton X-100. Tissue was then incubated overnight at room temperature with the primary 
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antibody in TBS/Triton X-100 with 1 % serum and then washed in TBS and incubated for 1 h 
with a biotinylated IgG secondary antibody raised against the host of the primary antibody: 
ChAT, anti-goat; p75NTR, anti-rabbit; TrkA, anti-rabbit (Vector Laboratories, Burlingame, CA). 
Tissue was washed in TBS and incubated with an avidin-biotin complex  (ABC) solution (Elite 
Kit, Vector Laboratories) for 1 h to amplify the immunochemical reaction. Immunolabeling was 
visualized using an acetate-imidazole buffer containing 0.05 % 3,3′-diaminobenzidine tetrahy-
drochloride (DAB; Sigma-Aldrich, St. Louis, MO) and 0.0015 % freshly prepared H2O2. Sec-
tions were washed in acetate-imidazole buffer to terminate the immunochemical reaction, 
mounted onto chrome-alum-subbed slides, air dried for 24 h, dehydrated through a series of 
graded alcohols (70%, 95%, and 100 %), cleared in xylenes, and cover-slipped with disty-
rene/dibutylphthalate (plasticizer)/xylene (DPX) mounting medium (Kelley et al., 2014a, 2014b; 
Velazquez et al., 2013).  
 
BFCN nomenclature  
The BFCN subregions examined included the medial septum (MS), vertical limb of the 
diagonal band (VDB), and nucleus basalis of Meynert/substantia innominata (NBM/SI).  
 
Stereology 
 ChAT-, p75NTR-, and TrkA-positive neuron counts were determined in the MS, VDB, 
and NBM/SI using the optical fractionator, a stereological model that pairs the optical disector 
probe (a three-dimensional counting space) with a two-dimensional grid that provides an unbi-
ased random-start and systematic interval sampling of the region of interest. All analyses were 
conducted using Stereo Investigator software (version 9.14.5 32-bit, MicroBrightField, Inc., Wil-
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liston, VT, USA) coupled to a Nikon Optiphot-2 microscope. Values are presented as estimate 
per brain derived from a sampling of the region of interest bilaterally across a 1/6 series for each 
marker (X60, n.a. 1.40, 50 x 50 µm counting frame, 151 x 151 µm grid size, 10 µm disector 
height).  Tissue thickness was measured at every site that contained cells and the reciprocal for 
(disector height) / (mean measured thickness) was used for reported numbers and statistical 
analyses. The large sampling fraction allowed for a CEm = 1 of ≤ 0.10 (Gundersen, 1999).  Cell 
density is presented as cells per 1,000,000 µm3 (Kelley et al., 2014a). Calculation was performed 
for each animal, prior to group averages. Photomicrographs were taken on a Nikon Optiphot-2 
microscope (Tokyo, Japan) connected to Stereo Investigator software (MicroBrightField, Inc.) 
Background correction was used at the time of image capture to establish evenness of illumina-
tion across the field, and scale bars were added within the Stereo Investigator software. Panels 
were compiled in PowerPoint (version 14.0.6129.5000, 32-bit, Microsoft, Redmond, WA, USA) 
and each micrograph was equally corrected for brightness and contrast. No retouching or further 
manipulations were performed. 
 
Regional area analysis 
Regional basal forebrain areas (µm2) were derived by planimetry.  Previous comparison 
between Cavalieri estimator and planimetry values showed no difference between methods (Kel-
ley et al., 2014a: slope m = 1.001, correlation r2 = 0.998, r = 0.999).  Values represent summa-
tion from tracings outlining each basal forebrain subfield across a 1/6 series: an average of four 
MS sections, four VDB sections, and seven NBM/SI sections.   An area estimate for each basal 
forebrain subregion was calculated by averaging measures for ChAT- and 
p75NTR-immunolabeled tissue prior to deriving group averages.  
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Neuron size 
BFCN size was measured using a 5-ray nucleator probe for an average of 60 cells per 
stain, per region, per animal (X60 oil-immersion lens n.a. 1.40) using random sampling across 
rostrocaudal and dorsoventral axes derived with the optical fractionator. The nucleator involves 
taking five measurements from an approximate center of the cell to the perimeter of the cell in 
one plane (< 1.0 µm z-axis) of section (Gundersen, 1988). The probe derives an average radius 
for each cell and volume was calculated from this value using a weighted geometric formulae 
(shape assumption spheroid).  
 
Antibody tissue penetration 
A major criterion for the use of the optical disector is antibody penetration through the 
full depth of the stained section. The depth of ChAT, p75NTR, and TrkA antibody penetration 
through a tissue section in the z-axis was determined using the same optical disector system and 
software used to count labeled neurons in this study (see above). ChAT, p75NTR, and TrkA anti-
bodies penetrated the full depth of the section allowing for the equal probability of counting all 
objects, a prerequisite for stereology (Mufson et al., 2000; Kelley et al., 2014a, 2014b; Ve-
lazquez et al., 2013).  
 
Statistical Analyses  
Statistical and correlation analyses were performed using the Statistical Analysis System 
(version 9.3; SAS Institute, Cary, NC).  The statistical procedure used for each outcome measure 
is presented below.   
70 
 
HP and VP tasks 
For both the HP and VP tasks, the dependent measure for each mouse was the mean 
number of errors committed per trial, averaged for each block of sessions. For the HP task, the 
15 sessions were divided into five 3-day blocks for analysis; for the VP task, the 6 sessions were 
divided into three 2-day blocks.  The data were analyzed using a generalized linear mixed model 
(PROC GLIMMIX), an established method for conducting repeated measures analyses with var-
ious probability distributions including Gaussian (Wolfinger and O’ Connell, 1993).  Fixed fac-
tors for the models included Genotype (Ts65Dn and 2N), Maternal Diet (diet containing normal 
levels of choline or choline-supplemented), and Cohort (cohorts 1 and 2), as well as appropriate 
interaction terms.  The random factors in the model included Session-Block (defined above) and 
individual mouse performance.  If the interaction between Genotype and Maternal Diet was sig-
nificant, three post-hoc contrasts of interest were examined: (1) Comparison of unsupplemented 
Ts65Dn and 2N mice to determine the effect of genotype for mice born to dams maintained on a 
diet with normal choline levels; (2) Comparison of Ts65Dn mice born to unsupplemented dams 
versus supplemented dams to determine the effect of MCS for Ts65Dn mice; and (3) Compari-
son of supplemented 2N mice to unsupplemented 2N mice to determine the effects of MCS for 
the 2N mice. A Bonferroni correction was applied to these three comparisons, yielding an alpha 
level of 0.05/3 or 0.0167 as the threshold for significance. If the interaction was not significant, 
only the main effects of Maternal Diet and/or Genotype are reported. 
  
Morphometric analyses 
Analyses of variance (ANOVA) assessed group differences in mean number, density, and 
size of neurons reactive for ChAT, p75NTR, and TrkA within each BFCN region (MS, VDB, 
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NBM/SI) as described previously (Kelley et al., 2014a).  Significant interactions between Ma-
ternal Diet and Genotype (p = 0.05) were followed up with the three comparisons of interest 
listed above using a Bonferroni correction.  
Group differences in regional area of the various BFCN regions were assessed using the 
non-parametric Wilcoxon rank sum because normality assumptions of ANOVA were not met.  
 
Correlations between behavioral and morphometric data 
A non-parametric Spearman rank correlation was used to assess the relationship between 
each of the morphometric indices for the MS [count, density, and neuron size for each marker 
(ChAT, p75NTR, TrkA)], and the mean number of errors committed in block 3 of the HP task, the 
block of testing sessions in which the largest group differences were observed. The use of a 
non-parametric test mitigated the influence of a few outliers.  
 
RESULTS 
Sample size  
 The final sample size for all behavioral and morphometric measures is presented in Table 
1.  The four treatment groups were: 1) disomic mice born to dams maintained on a choline nor-
mal diet (2N Ch); (2) Ts65Dn mice born to dams maintained on a choline normal diet (Ts Ch); (3) 
disomic mice born to dams maintained on a choline supplemented diet (2N Ch+); and (4) 
Ts65Dn mice born to dams maintained on a choline supplemented diet (Ts Ch+).  Note that the 
final sample size for the TrkA endpoints was smaller than for the other analyses due to tissue 
labeling variability.  
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Body Weight 
 Analysis of body weight at the start of testing revealed a main effect of Genotype (F 
(1,69) = 16.61, p < 0.0001) but no effect of Maternal Diet (F (1,69) = 0.35, p = 0.556), and no inter-
action of Genotype and Maternal Diet (F (1,69) = 0.09, p = 0.769). The average body weight of 
trisomic mice was 9% lower than the 2N mice (means ± S.E.M: 2N mice: 35.2 ± 0.50; Ts65Dn 
mice: 32.18 ± 0.55), consistent with prior reports (Bianchi et al., 2010; Fuchs et al., 2012; Roper 
et al., 2006; Velazquez et al., 2013). 
BFCN Subregions 
The nomenclature and topography of the mouse BFCN subfields are in accordance with 
earlier studies by our collaborative group (Kelley et al., 2014a; 2014b). BFCNs of the MS, VDB 
and NBM/SI appear as small, spherical and ovoid ChAT-immunoreactive neurons concentrated 
along the midline with extensions ventrolaterally between the subcallosal region, rostrally, and 
hemispheric crossing of the anterior commissure, caudally. More caudally, a diffuse group of 
large multipolar cholinergic neurons are located along the ventromedial aspect of the globus pal-
lidus, which correspond to the NBM/SI (see Supplementary Fig. A.1 – A.3). 
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Table 1: Age and treatment groups 
 
 
  Final sample size (Mean age in months) 
Groupa 
Age range & 
mean age  
at sacrifice  RAWM ChAT b p75NTR b TrkA b 
2N      
Ch 13.7–17.8 (15.6) 19 (15.6) 18 (15.6) 15-20 (15.6) 7-12 (15.5) 
Ch+ 13.7–17.6 (15.5) 20 (15.5) 19 (15.4) 15-18 (15.5) 9-13 (15.0) 
Ts65Dn      
Ch 13.7–17.4 (15.3) 13 (15.3) 15 (15.4) 14-16 (15.3) 4-8 (15.3) 
Ch+ 13.8–17.6 (15.7) 21 (15.7) 21-22 (15.8) 20-23 (15.7) 9-14 (15.7) 
 
a 2N: disomic wildtype mice whose dams were provided either a choline normal 
(Ch) or choline supplemented (Ch+) diet; Ts65Dn mice whose dams were 
provided either a choline normal (Ch) or choline supplemented (Ch+) diet. 
Tissue immunolabeled for antibodies: ChAT: choline acetyltransferase, 
p75NTR: pan-neurotrophin receptor protein 75 KDa, TrkA: tyrosine kinase re-
ceptor A. 
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Effects of genotype and MCS on HP and VP task performance  
Analysis of mean errors in the HP task revealed a main effect of Genotype (F (1, 101.5) = 
20.77, p < 0.0001).   Although the main effect of Maternal Diet was not significant (F (1, 101.5) = 
2.43, p = 0.122), there was a significant interaction of Genotype and Maternal Diet (F (1, 101.5) = 
5.11, p = 0.026). Specifically, Ts65Dn mice born to dams on the unsupplemented diet committed 
a significantly higher number of errors than their 2N counterparts (p < 0.0001, Fig. 1A). Sup-
plementing the maternal diet with additional choline significantly improved performance of the 
Ts65Dn offspring relative to Ts65Dn offspring born to dams on the unsupplemented diet (p = 
0.012, Fig. 1A).  The relationship between the groups did not vary by session-block (Fig. 1B).  
MCS did not significantly affect performance of the 2N mice on this task.  
 In the VP task, neither the main effect of Genotype (p > 0.20), the main effect of Mater-
nal Diet (p > 0.20) nor the interaction of Genotype and Maternal Diet (p > 0.20) was significant. 
Although a significant interaction was detected between Genotype and Session-block (F(2, 68.72)  = 
4.61; p = 0.013), the two genotypes did not differ significantly in any session-block (Fig 1C). 
 
Effects of genotype and MCS on BFCN density  
In the MS, there was a significant interaction between Genotype and Maternal Diet for 
ChAT-positive neuron density (F(1,70) = 2.70, p = 0.017). MS ChAT-positive neuron density was 
significantly reduced by 18% for unsupplemented Ts65Dn offspring relative to their 2N coun-
terparts (p = 0.008, Fig. 2A).  MCS significantly increased the density of MS ChAT-positive 
neurons by 17% for Ts65Dn mice (p = 0.036, Fig. 2A), achieving a level comparable to unsup-
plemented 2N mice.  Maternal diet did not affect this measure for the 2N mice.   
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Figure 1. RAWM performance:  (A) Average errors per trial (collapsed across sessions) in the HP Task 
was significantly higher for the unsupplemented Ts65Dn mice than their 2N counterparts. MCS signifi-
cantly improved performance for Ts65Dn (p = 0.011) but not 2N mice; (B) Mean errors per trial across the 
15 sessions of the HP task; (C) Mean errors in the VP task across the 6 sessions on this task; no signifi-
cant groups differences were seen. Abbreviations: 2N Ch: disomic mice born to dams maintained on a 
choline normal diet (n = 19); Ts Ch: Ts65Dn mice born to dams maintained on a choline normal diet (n = 
13); 2N Ch+: disomic mice born to dams maintained on a choline supplemented diet (n = 20); Ts Ch+: 
Ts65Dn mice born to dams maintained on a choline supplemented diet (n = 21); HP: Hidden platform task 
of the radial arm watermaze; VP: Visible platform task of the radial arm watermaze; MCS: maternal choline 
supplementation; * p ≤ 0.05, ** p ≤ 0.001. 
A 
B 
C 
76 
 
 The density of MS p75NTR- positive neurons was also significantly lower (13%) for 
Ts65Dn mice relative 2N counterparts  (Main effect of Genotype: F(1,73) = 16.16, p = 0.0001, Fig. 
2A). This same genotype effect was found for the density of MS TrkA-positive neurons (Main 
effect of Genotype: F(1,43) = 10.97, p = 0.002, Fig. 2A).  MCS significantly increased the density 
of p75NTR-positive MS neurons by 7% for both genotypes (Main effect of Maternal Diet: F(1,73) = 
4.31, p = 0.041, Fig. 2A), but did not affect TrkA-positive neuron density in this region, indicat-
ing a dissociation between NGF receptor phenotypes. 
The NBM/SI of Ts65Dn mice showed a significant 22% reduction in the density of 
p75NTR-positive neurons relative to 2N mice (Main effect of Genotype: F(1,64) = 44.78, p < 
0.0001, Fig. 2C) similar to that seen in the MS. MCS had no effect on this measure in the 
NBM/SI.  In contrast to observations within the MS, neither ChAT- nor TrkA-positive neurons 
were significantly altered by Genotype, Maternal Diet or their interaction, in the NBM/SI. 
For the VDB, there was no significant effect of Genotype, Maternal Diet or their interac-
tion for BFCN density, regardless of the markers examined (Fig. 2B).  
 
Effects of genotype and MCS on BFCN cell counts  
 Genotype did not significantly alter ChAT-positive neuron count in any of the three re-
gions examined.  MCS did alter the number of ChAT-positive BFCN neurons, but the effect var-
ied by subregion and genotype.  In the MS, an interaction between Genotype and Maternal Diet 
was seen (F(1, 70) = 4.63, p = 0.035).   MCS produced a significant 30% increase in the number of 
MS ChAT-positive neurons in Ts65Dn mice (Ts65Dn Ch vs. Ts65Dn Ch+; p = 0.009, Fig. 3A), 
but not 2N mice (p > 0.20).  In the VDB, MCS produced a significant 20% increase in the num-  
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Figure 2. Density of ChAT-, p75NTR-, and TrkA-positive cells in the basal forebrain: (A) In the MS, Ts 
Ch mice showed a significantly lower ChAT-positive density relative to 2N Ch mice (p = 0.008), whereas 
both groups of Ts65Dn mice showed reduced density of p75NTR-positive and TrkA-positive BFCNs relative 
to 2N mice (p75NTR: p = 0.0001; TrkA: p = 0.002). MCS significantly increased the density of ChAT-positive 
BFCNs in Ts65Dn mice (p = 0.036); (B) No significant differences were seen in the VDB; (C) In the 
NBM/SI, both groups of Ts65Dn mice showed reduced p75NTR-positive BFCN density relative to 2N mice 
(p < 0.0001).  Abbreviations: 2N Ch: disomic mice born to dams maintained on a choline normal diet; Ts 
Ch: Ts65Dn mice born to dams maintained on a choline normal diet; 2N Ch+: disomic mice born to dams 
maintained on a choline supplemented diet; Ts Ch+: Ts65Dn mice born to dams maintained on a choline 
supplemented diet; Geno: Main effect of Genotype; MS: Medial Septum; VDB: Ventral Diagonal Band; 
NBM/SI: Nucleus Basalis of Meynert/Substantia Innominata; BFCNs: basal forebrain cholinergic neurons; 
ChAT: Choline Acetyltransferase; p75NTR: pan neurotrophin receptor; TrkA: tyrosine kinase A receptor; 
MCS: maternal choline supplementation;*p ≤ 0.05, **p ≤ 0.001. 
A 
B 
C 
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-ber of ChAT-positive neurons, with a comparable effect seen for the two genotypes (Main effect 
of Maternal Diet: F(1, 70) = 5.58, p = 0.021, Fig. 3B).  A similar but non-significant 9% increase 
in ChAT-positive neurons was seen in the NBM/SI for both genotypes (Main effect of Maternal 
Diet: F(1, 68) = 2.30, p = 0.134, Fig. 3C). 
 The number of p75NTR immunoreactive neurons was significantly reduced (23%) in tri-
somic mice relative to their 2N counterparts in the NBM/SI (Main effect of Genotype: F(1,64) = 
17.61, p < 0.0001; Fig. 3C), with no Genotype effect for the MS (Fig. 3A) or VDB (Fig. 3B).  
MCS did not significantly affect the number of p75NTR- labeled neurons for either genotype in 
any BFCN subregion examined (Fig. 3A-C).  
 The number of TrkA-positive neurons was significantly higher in Ts65Dn mice than their 
2N counterparts in the VDB (Main effect of Genotype: F(1, 37) = 4.72, p = 0.036; Fig 3B). In con-
trast, the genotypes did not differ significantly for TrkA-positive neuron count in the MS (p = 
0.103, Fig. 3A) or NBM/SI (p = 0.150, Fig. 3C).  MCS did not significantly alter TrkA-positive 
neuron counts for either genotype in any region examined. 
 
Effects of genotype and MCS on BFCN size 
ChAT-, p75NTR-, or TrkA-positive neuron size did not differ between the two genotypes 
in any region examined.  MCS altered BFCN size only in the MS, producing a significant 15% 
increase in TrkA-positive neuron size in this region, with a comparable effect seen in both geno-
types (Main effect of Maternal Diet: F(1, 42) = 3.89, p = 0.050, Fig. 4A).  MCS did not alter the 
size of TrkA- positive neurons in the VDB (Fig. 4B) or NBM/SI (Fig. 4C), nor ChAT- or 
p75NTR-positive neurons in any of the three subregions examined (Fig. 4A-C).  
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Figure 3. Number of ChAT-, p75NTR-, and TrkA-positive BFCNs in the basal forebrain: (A) In the MS, 
MCS significantly increased the number of ChAT-positive BFCNs in Ts65Dn mice (p = 0.009); (B) In the 
VDB, both groups of Ts65Dn mice showed a significantly higher number of TrkA-positive BFCNs (p = 
0.036).  MCS increased the number of ChAT-positive BFCNs for both genotypes (p = 0.021); (C) In the 
NBM/SI, Ts65Dn mice exhibited a significantly higher number of p75NTR-positive BFCNs than the 2N mice 
(p < 0.0001).  Abbreviations: 2N Ch: disomic mice born to dams maintained on a choline normal diet; Ts 
Ch: Ts65Dn mice born to dams maintained on a choline normal diet; 2N Ch+: disomic mice born to dams 
maintained on a choline supplemented diet; Ts Ch+: Ts65Dn mice born to dams maintained on a choline 
supplemented diet; Geno: Main effect of Genotype; MS: Medial Septum; VDB: Ventral Diagonal Band; 
NBM/SI: Nucleus Basalis of Meynert/Substantia Innominata; BFCNs: basal forebrain cholinergic neurons; 
ChAT: Choline Acetyltransferase; p75NTR: pan neurotrophin receptor; TrkA: tyrosine kinase A receptor; 
MCS: maternal choline supplementation; * p ≤ 0.05, ** p ≤ 0.001. 
A 
B 
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Figure 4. Size of ChAT-, p75NTR-, and TrkA-positive cells in the basal forebrain: (A) In the MS, MCS 
increased TrkA-positive BFCNs for both genotypes (p = 0.050); There was no effect of genotype, maternal 
diet, nor their interaction in (B) the VDB, or (C) the NBM/SI. Abbreviations: 2N Ch: disomic mice born to 
dams maintained on a choline normal diet; Ts Ch: Ts65Dn mice born to dams maintained on a choline 
normal diet; 2N Ch+: disomic mice born to dams maintained on a choline supplemented diet; Ts Ch+: 
Ts65Dn mice born to dams maintained on a choline supplemented diet; MS: Medial Septum; VDB: Ventral 
Diagonal Band; NBM/SI: Nucleus Basalis of Meynert/Substantia Innominata; BFCNs: basal forebrain 
cholinergic neurons; ChAT: Choline Acetyltransferase; p75NTR: pan neurotrophin receptor; TrkA: tyrosine 
kinase A receptor; MCS: maternal choline supplementation; * p ≤ 0.05, ** p ≤ 0.001. 
A 
B 
C 
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Effects of genotype and MCS on region area 
Region area of the VDB and NBM/SI was significantly larger in the unsupplemented 
Ts65Dn mice relative to their 2N counterparts (Wilcoxon Rank Sum Test, VDB: p = 0.016, Fig. 
5B; NBM/SI: p = 0.033; Fig. 5C). In contrast, MS region area did not vary by genotype (Fig. 
5A).   The effect of MCS on region area varied by genotype and the specific subregion evaluated.  
MCS led to a significant 8% average decrease in MS area for 2N mice (Wilcoxon Rank Test, p = 
0.046, Fig. 5A), with no effect for the VDB or NBM/SI.  There was no effect of MCS on region 
area for Ts65Dn mice for any subfield examined (Fig. 5A-C).  
 
Correlations between maze performance and BFCN indices 
Correlational analyses revealed a significant negative association between the mean 
number of errors in block 3 of the HP task and density of ChAT-positive MS neurons (rs= -0.31, 
p = 0.014; Fig. 6A).  A similar trend was seen for the density of TrkA-positive MS neurons (rs = 
-0.27, p = 0.095; Fig. 6B). There were no significant relationships between maze performance 
and size of ChAT- or TrkA-positive neurons. 
A significant negative correlation was also observed between the mean number of block 
3 errors and size of p75NTR-positive neurons in the MS (rs = -0.26; p = 0.036; Fig. 6C), with a 
similar trend seen for MS p75NTR-positive neuron numbers (rs = -0.23, p = 0.062; Fig. 6D).  
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Figure 5. Regional basal forebrain areas: (A) MCS decreased MS area for 2N mice (p = 0.046), but had 
no effect for Ts65Dn mice; (B) Unsupplemented Ts65Dn mice showed significantly larger VDB area than 
unsupplemented 2N mice (p = 0.016), a pattern also seen for the (C) NBM/SI (p = 0.033). MCS had no 
effect on VDB or NBM/SI for either genotype. Abbreviations: 2N Ch: disomic mice born to dams main-
tained on a choline normal diet; Ts Ch: Ts65Dn mice born to dams maintained on a choline normal diet; 2N 
Ch+: disomic mice born to dams maintained on a choline supplemented diet; Ts Ch+: Ts65Dn mice born to 
dams maintained on a choline supplemented diet; MS: Medial Septum; VDB: Ventral Diagonal Band; 
NBM/SI: Nucleus Basalis of Meynert/Substantia Innominata; BFCNs: basal forebrain cholinergic neurons; 
ChAT: Choline Acetyltransferase; p75NTR: pan neurotrophin receptor; TrkA: tyrosine kinase A receptor; 
MCS: maternal choline supplementation; * p ≤ 0.05, ** p ≤ 0.001. 
B 
C 
A 
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Figure 6. Correlations between HP performance and BFCN indices in the MS: Mean errors in block 3 
of the HP task was negatively correlated with (A) Density of ChAT-positive BFCNs (p = 0.014), (B) Density 
of TrkA-positive BFCNs (p = 0.095); (C) Cell size of p75NTR-positive BFCNs (p = 0.036), and (D) Number of 
p75NTR- positive BFCNs (p = 0.062). Abbreviations: 2N Ch: disomic mice born to dams maintained on a 
choline normal diet; Ts Ch: Ts65Dn mice born to dams maintained on a choline normal diet; 2N Ch+: 
disomic mice born to dams maintained on a choline supplemented diet; Ts Ch+: Ts65Dn mice born to 
dams maintained on a choline supplemented diet; HP: Hidden platform task of the radial arm watermaze; 
BFCNs: basal forebrain cholinergic neurons; C  hAT: Choline Acetyltransferase; p75NTR: pan neurotrophin 
receptor; TrkA: tyrosine kinase A receptor.   
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DISCUSSION 
The present study demonstrated that supplementing the maternal diet with additional cho-
line during pregnancy and lactation significantly improved spatial cognition of Ts656Dn off-
spring and provided BFCN neuroprotection in a phenotypic- and subregion-specific manner. 
Moreover, several of these BFCN indices, notably those in the MS, correlated significantly with 
maze performance, providing powerful support for a functional relationship between these be-
havioral and morphometric effects of MCS.  These data have significant translational potential 
for minimizing BFCN dysfunction in DS, and add to the growing evidence that maternal choline 
intake should be increased during pregnancy.    
 
MCS improves spatial cognition of Ts65Dn offspring   
Unsupplemented Ts65Dn mice performed significantly less well in the HP task than their 
2N littermates. In contrast, these groups did not differ in the VP task, indicating that the impaired 
performance of the unsupplemented trisomic mice in the HP task cannot be attributed to impair-
ments in visuomotor skills, swimming ability, or motivation to escape from the water. Rather, 
these data collectively indicate that the poor performance of Ts65Dn mice in the HP task is due 
to impaired spatial mapping, subserved by the hippocampus, consistent with prior findings with 
spatial mazes (Belichenko et al., 2007; Bimonte-Nelson et al., 2003; Chang and Gold, 2008; Es-
corihuela et al., 1995; Holtzman et al., 1996; Hunter et al., 2003; Reeves et al., 1995; Sago et al., 
1998, Velazquez et al., 2013), as well as other hippocampal-dependent tasks (Bianchi et al., 2010; 
Hyde and Crnic, 2001; Hyde et al., 2001; Lockrow et al., 2011).   
            Importantly, supplementing the maternal diet with additional choline significantly im-
proved performance of the trisomic offspring in the HP task. These results extend our prior find-
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ings that MCS improves attention and emotion regulation in Ts65Dn offspring (Moon et al., 
2010), functions subserved by BFCN projections to the cortex.   A prior study from our lab also 
demonstrated that MCS normalized hippocampal neurogenesis in Ts65Dn offspring, which cor-
related with their improved spatial mapping ability (Velazquez et al., 2013). Together, these 
findings suggest that increased maternal choline intake during pregnancy and lactation results in 
lasting improvement in cognitive and affective functions in Ts65Dn offspring, perhaps due to the 
normalization of BFCN projection systems. 
             MCS did not significantly affect performance of the 2N mice on the spatial learning task.  
This lack of effect in the 2N mice is likely due to the task not being sufficiently demanding. This 
inference is based on prior water maze studies, which have shown benefits of MCS for normal 
rats when the location of the hidden escape platform was changed daily, but not when it re-
mained in the same location across sessions (Tees, 1999; Tees and Mohammadi, 1999), as was 
the case in the version of the HP task used in the present study.  The less demanding reference 
memory version of the HP task was selected for the present study only after extensive pilot test-
ing demonstrated that the Ts65Dn mice could not solve the more demanding explicit memory 
version of this task. 
 
MCS protects MS BFCNs in Ts65Dn offspring  
We observed differences in BFCN number and density between unsupplemented trisomic 
and unsupplemented 2N mice, which varied by BFCN subregion and phenotypic marker.  In the 
MS, the density of ChAT- and p75NTR-immunoreactive neurons was significantly reduced in the 
unsupplemented trisomic mice relative to their 2N counterparts. A similar, albeit non-significant, 
pattern was seen for neuron number in this region consistent with previous reports using Ts65Dn 
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mice in the age-range examined here (Contestible et al., 2006; Cooper et al., 2001; Hunter et al., 
2001; Salehi et al., 2006; Seo and Isacson, 2005). The Ts65Dn mice also show a significant re-
duction in TrkA-positive BFCNs in the MS relative to their 2N littermates; no prior studies have 
reported on this measure in mid-life.   
In the NBM/SI, the trisomic mice exhibited significantly reduced number and density of 
p75NTR-immunoreactive neurons relative to 2N mice, but no differences for ChAT- or 
TrkA-immunoreactive neurons.  In the VDB, there were no genotype differences in the number 
of ChAT- or p75NTR-immunoreactive neurons, commensurate with earlier studies using 18-19 
month old mice (Contestible et al., 2006; Hunter et al., 2004). However, Ts65Dn mice exhibited 
a significantly higher number of VDB TrkA-immunoreactive neurons than 2N mice. These find-
ings are in contrast to reports of reduced numbers of TrkA-positive BFCNs in the MS and VDB 
of younger (6-10 mos) and older (19-22 mos) Ts65Dn mice relative to 2N mice (Granholm et al., 
2000; Lockrow et al., 2011, 2009; Salehi et al., 2006).  
MCS normalized select BFCN phenotypes, with the greatest effect on MS neurons.  
Ts65Dn mice born to supplemented dams had a significantly higher number and density of 
ChAT-positive neurons within the MS than their unsupplemented counterparts.  Moreover, MCS 
increased the density of p75NTR-containing neurons in the MS, and the number of ChAT-positive 
neurons in the VDB for both genotypes.  Although, neither count nor density of these neurons 
was significantly affected by MCS in the NBM/SI, the patterns across groups were similar.  
Taken together, these data collectively suggest that MCS has beneficial effects on cholinotrophic 
BFCN subtypes.  The regional variability of MCS effects may be related to differences in BFCN 
target-derived support related to its survival neurotrophin, NGF, and/or the differences in the 
specific projection sites of each BFCN subregion. In this regard, the MS and VDB project to the 
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hippocampus, whereas the NBM/SI projects to the neocortex (Rye et al., 1984, Mesulam et al., 
1983). 
In contrast to the lower number and density of ChAT- and p75NTR-positive BFCNs for 
unsupplemented Ts65Dn mice, the size of these neurons did not vary by genotype within any 
basal forebrain subregion examined.  Previous findings indicate atrophy for both ChAT- and 
p75NTR-immunolabeled BFCNs in the MS and VDB for Ts65Dn mice at younger (6-10 mos) and 
older (18-22 mos) ages (Lockrow et al., 2011; Salehi et al., 2006; Cooper et al., 2001; Granholm 
et al., 2000; Holtzman et al., 1996). However, similar to the current findings, no differences be-
tween genotypes were reported for BFCN cell size in mice 11 to 14 months of age (Granholm et 
al., 2002; Seo and Isacson, 2005). These findings suggest an overall age-dependent atrophy of 
BFCNs in unsupplemented trisomic mice during early development and advanced age, but nor-
mal cell size during mid-life. These results imply either an increase in cell-size for trisomic mice 
from development to mid-adult life, possibly as a neuroplastic compensation for a frank loss in 
number and density of cholinergic neurons, or alternatively degenerative, neuronal atrophy in 2N 
mice from development to mid-life.  
Supplementing the maternal diet with additional choline significantly increased the size 
of TrkA-positive MS neurons in both Ts65Dn and 2N offspring.  Similar patterns, albeit 
non-significant, were seen for the size of ChAT- and p75NTR-positive neurons in this region. A 
prior study reported that MCS significantly increased p75NTR-positive cell size in the MS/VDB at 
6 to 7 months of age in normal rats, relative to rats born to dams on a standard choline diet (Wil-
liams et al., 1998), but no studies to date have examined the effects of this maternal choline die-
tary intervention on the size of TrkA-positive neurons. The increase in TrkA-immunoreactive 
cell size in the MS suggests upregulation of the NGF cognate cell survival receptor (Bothwell, 
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1995; Hempstead, 2006). These findings lend further support to the concept that MCS has a 
complex, heterogeneous effect on intracellular mechanisms and signaling pathways associated 
with cholinotrophic neuronal activity, which our morphometric data suggests may be region- and 
age-dependent. 
 
Possible Mechanisms 
The current investigation demonstrated that supplementing the maternal diet with addi-
tional choline improved spatial cognition in the Ts65Dn offspring and offered some protection to 
BFCNs, with the greatest effect on those within the MS, which provide the primary cholinergic 
innervation to the hippocampus (Mesulam et al., 1983).  Importantly, errors in the maze task 
were significantly (inversely) correlated with the density of ChAT- and TrkA-positive neurons in 
the MS as well as the number and size of p75NTR- positive neurons in the MS.  The data reported 
herein suggest that the normalization of MS cholinergic hippocampal projection neurons in 
Ts65Dn mice due to MCS contributes to their improved spatial cognition. Our group has also 
shown that MCS partially normalized adult hippocampal neurogenesis in trisomic offspring rela-
tive to their unsupplemented counterparts, and that the degree of neurogenesis was a significant 
predictor of water maze performance (Velazquez et al., 2013).  These findings suggest that both 
of these effects of MCS (increased hippocampal neurogenesis and BFCN neuroprotection) con-
tribute to improved spatial cognition in supplemented Ts65Dn mice. 
The protection of BFCNs in Ts65Dn mice may reflect the effects of increased maternal 
choline intake on neurotrophic factors. For example, normal adult rat offspring of cho-
line-supplemented dams exhibit increased brain levels of NGF and brain-derived neurotrophic 
factor (BDNF) relative to those born to unsupplemented dams (Glenn et al., 2007; Sandstrom et 
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al., 2002).  Based on these data, it is reasonable to posit that MCS enhances target-derived neu-
roprotection of Ts65Dn BFCNs, which typically begin to atrophy at six months of age due to 
impaired retrograde transport of NGF (Cooper et al., 2001; Granholm et al., 2000; Holtzman et 
al., 1996, 1992; Salehi et al., 2006).  The resulting increased functionality of these neurons 
would then contribute to improvement in various cognitive tasks, especially related to BFCN 
projection systems, notably the hippocampus and frontal cortex.  
Although much remains to be learned regarding the specific mechanism(s) by which sup-
plementing the maternal diet with additional choline exerts life-long effects on offspring cogni-
tive functioning, BFCN projection neurons, hippocampal neurogenesis and neurotrophins, all of 
these effects likely reflect one or both of two broad categories of effects:  First, these effects may 
be due to organizational brain changes, secondary to choline’s role as the precursor to phospha-
tidyl choline, a major constituent of cellular membranes, and its role as the precursor of acetyl-
choline, an important ontogenetic signal (Cermak et al., 1999; Meck et al., 1989; Zeisel and 
Niculescu, 2006).  Second, these effects may be related to epigenetic modifications with lasting 
effects on gene expression, secondary to choline’s role as a methyl donor (Niculescu et al., 2004, 
2006; Waterland and Jirtle, 2003; Zeisel, 2009).  Choline has a primary role as a methyl donor, 
through the betaine-methionine pathway, and alterations in dietary levels of choline during early 
development can produce life-long effects on gene expression through DNA methylation and 
histone modifications (Blusztajn and Mellot, 2012; Davison et al., 2009).  
 
Increased need for choline during early development  
The lifelong beneficial effects of MCS seen in the Ts65Dn offspring in the current study 
should be interpreted within the context of current choline intake recommendations. Dietary 
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recommendations for choline, first established in 1998 by the Institute of Medicine, were based 
on the level of choline needed to prevent liver dysfunction.  However, several converging lines 
of evidence suggest that these recommendations are insufficient during pregnancy to optimize 
brain development, cognitive functioning, and lifelong health of the offspring.  First, data from 
both animal models and humans indicate that pregnancy causes a pronounced depletion of ma-
ternal choline pools indicating that choline requirements during pregnancy are increased and that 
the need for this nutrient by the fetus may commonly exceed the amount consumed by the moth-
er (Gwee and Sim, 1979; 1978; Yan et al., 2012; Zeisel et al., 1995).  Indeed, a doubling of cho-
line intake by pregnant women does not increase the urinary excretion of choline, a wa-
ter-soluble biomolecule, indicating that the higher intake level does not exceed metabolic re-
quirements (Yan et al., 2012). Second, and perhaps most importantly, numerous rodent studies 
indicate that supplementing the maternal diet with additional choline produces lifelong beneficial 
cognitive effects for the offspring and reduces age-related cognitive decline (e.g., McCann et al., 
2006; Meck and Williams, 2003; Meck et al., 2008).  Finally, consistent with the present findings, 
MCS not only improves cognitive functioning in normal offspring but also offers protection 
against a variety of neural insults including those associated with fetal alcohol syndrome 
(Thomas et al., 2009), Rett syndrome (Nag and Berger-Sweeney, 2007), epilepsy (Holmes et al., 
2002; Wong-Goodrich et al., 2008), and schizophrenia (Stevens et al., 2008), providing addition-
al support for increasing maternal choline intake during pregnancy.    
 
Conclusions 
The present behavioral and morphometric findings indicate that increasing maternal cho-
line intake normalizes BFCNs in the Ts65Dn mouse model of DS in a complex, phenotype- and 
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subregion-specific manner.  Support for the functional effects of these changes is provided by 
powerful correlative analyses, which link select BFCN changes to improved performance in a 
task subserved by the septo-hippocampal system.  These data suggest that increasing maternal 
choline intake during pregnancy may represent a safe and effective therapy for expectant moth-
ers carrying a DS fetus, as well as possibly provide BFCN neuroprotection during aging for the 
population at large. 
 
 
 
92 
 
APPENDIX 
 
 
Figure. A.1 Photomicrographs of ChAT-, p75NTR-, and TrkA-positive cells in the MS: Photomicro-
graphs show the distribution of ChAT- (A – D), p75NTR- (E – H), and TrkA- (I – L) immunoreactivity within 
the MS for the four groups of mice. Abbreviations: 2N Ch: disomic mice born to dams maintained on a 
choline normal diet; Ts Ch: Ts65Dn mice born to dams maintained on a choline normal diet; 2N Ch+: 
disomic mice born to dams maintained on a choline supplemented diet; Ts Ch+: Ts65Dn mice born to 
dams maintained on a choline supplemented diet; MS: Medial Septum. 
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Figure. A.2 Photomicrographs of ChAT-, p75NTR-, and TrkA-positive cells in the VDB: Photomicro-
graphs show the distribution of ChAT- (A – D), p75NTR- (E – H), and TrkA- (I – L) immunoreactivity within 
the VDB. Abbreviations: 2N Ch: disomic mice born to dams maintained on a choline normal diet; Ts Ch: 
Ts65Dn mice born to dams maintained on a choline normal diet; 2N Ch+: disomic mice born to dams 
maintained on a choline supplemented diet; Ts Ch+: Ts65Dn mice born to dams maintained on a choline 
supplemented diet; VDB: Ventral Diagonal Band. 
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Figure. A.3 Photomicrographs of ChAT-, p75NTR-, and TrkA-positive cells in the NBM/SI: Photomi-
crographs show the distribution of ChAT- (A – D), p75NTR- (E – H), and TrkA- (I – L) immunoreactivity 
within the VDB. Abbreviations: 2N Ch: disomic mice born to dams maintained on a choline normal diet; 
Ts Ch: Ts65Dn mice born to dams maintained on a choline normal diet; 2N Ch+: disomic mice born to 
dams maintained on a choline supplemented diet; Ts Ch+: Ts65Dn mice born to dams maintained on a 
choline supplemented diet; NBM/SI: Nucleus Basalis of Meynert/Substantia Innominata. 
 
 
 
 
 
 
 
 
 
!2N!Ch!
!
!2N!Ch!
!
!2N!Ch!
!
!Ts!Ch!
!
!Ts!Ch!
!
!Ts!Ch!
!
2N!Ch+!
!
2N!Ch+!
!
2N!Ch+!
!
Ts!Ch+!
!
Ts!Ch+!
!
Ts!Ch+!
!
95 
 
CHAPTER 3 
 
Assessment of age-related attention dysfunction in the Ts65Dn mouse model of Down syn-
drome and Alzheimer’s disease  
 
ABSTRACT 
In addition to intellectual disability (ID), individuals with Down syndrome (DS) also develop 
Alzheimer’s disease (AD)-like neuropathology during the third to fourth decade of life.  The 
Ts65Dn mouse model of DS exhibits key features of these disorders, notably, impairments in 
learning, attention, and memory, as well as deficits in development neurogenesis and loss of ba-
sal forebrain cholinergic neurons (BFCNs) in the medial septum (MS).  The present study was 
designed to characterize cholinergic neurons in the nucleus basalis of meynert/ substantia 
innominate (NBM/SI) in young (3 month old) and aged (12 month old) Ts65Dn mice [relative to 
normal disomic (2N) mice], to describe the changes that occur with aging, and investigate 
whether these changes correspond to the attentional deficits in these mice, at either or both ages.  
The mice were tested on a series of automated attention tasks, followed by unbiased quantitative 
morphometry of BFCNs in the NBM/SI.  Ts65Dn mice exhibited attentional dysfunction at both 
ages (relative to age-matched 2N), with greater dysfunction seen in the older animals.  Morpho-
logical analysis of ChAT-immunoreactive neurons in the NBM/SI revealed that the density of 
these neurons in this region was significantly reduced in the trisomic mice relative to the 2N, but 
that aging did not result in a decrease in density, number or size of these neurons, as commonly 
believed.   In addition the morphological analyses revealed a reduction in cell size and number 
for 2N mice as a function of age.  As a result, the number and size of these neurons in this region 
tended to be greater for the aged trisomic mice relative to aged matched 2N mice.  Finally, cor-
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relational analyses revealed that (i) for 2N mice (both ages combined), increasing number of 
ChAT-immunoreactive neurons in the NBM/SI was associated with improved performance in 
Attention Task 2, and (ii) for older animals (genotypes combined), increased size of 
ChAT-immunoreactive neurons in the NBM/SI was associated with poorer performance in At-
tention Task 2.  In sum, these findings revealed that Ts65Dn mice exhibit attentional dysfunction 
as early as 3 months of age, which becomes more pronounced with aging.  The present study 
also found evidence of significantly reduced density of ChAT-immunoreactive neurons in the 
NBM/SI in the trisomic mice, but no age-related changes in the morphology of these neurons 
with aging as is commonly believed.   Thus, although reduced density of these neurons may con-
tribute to the attentional dysfunction seen in Ts65Dn mice, other neural changes likely underlie 
the progressive decline in attentional function with aging in these mice.  
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INTRODUCTION 
Down syndrome (DS) is the most common known cause of intellectual disability (ID), 
affecting 1 in 800-1000 births.  This disorder is caused by triplication of human chromosome 
21(HSA21) due to nondisjunction during meiosis.   In addition to ID, individuals with DS gener-
ally develop dementia by the third decade of life (Lai and Williams, 1989; Mann, 1988; Visser et 
al., 1997; Wisniewski et al., 1985a; Wisniewski et al., 1985b) due to the onset of Alzheimer’s 
disease (AD)-like neuropathology, including atrophy of basal forebrain cholinergic neurons 
(BFCNs) (Isacson et al., 2002; Sendera et al., 2000; Whitehouse et al., 1982), and formation of 
neuritic plaques and neurofibrillary tangles (Wisniewski et al., 1985a).  
Attentional deficits are one of the hallmarks of DS.  Researchers have found shorter and 
fewer periods of sustained attention in toddlers with DS (Brown et al., 2003).  Furthermore, 
chronological studies have found attentional problems in childhood that become progressively 
worse into adolescence and adulthood (Brown et al., 2003; Clark and Wilson, 2003; Cornish et 
al., 2007; Tomporowski et al., 1990; Wilding et al., 2002).  These deficits are in both selective 
and sustained attention.  Researchers believe that the development of AD-like neuropathology 
during the third to fourth of decade of life in DS further contributes to attentional dysfunction 
(Della Sala et al., 1992; Foster, 2001; Krinsky-McHale et al., 2008; Levinoff et al., 2004; Pignat-
ti et al., 2005).   For example, DS patients who have been diagnosed with AD show impairments 
in selective and sustained attention (Krinsky-McHale et al., 2008) in a multi-trial cancellation 
task that requires subjects to selectively attend to certain objects.  It has been hypothesized that 
the attentional dyfunction seen after the onset of AD-like neuropathology may be due, at least in 
part, to the atrophy and loss of BFCNs in the nucleus basalis of meyner/ substantia innominata 
(NBM/SI) that modulate attentional functions (Krinsky-McHale et al., 2008; Sarter and Bruno, 
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1997), but there is no direct evidence for this link.    
 Several mouse models have been developed to study the relationship between the tripli-
cation of specific genes in DS and distinct phenotypic features (Das et al., 2011; Rueda et al., 
2012; Salehi et al., 2006). The most well characterized model of DS is the Ts65Dn mouse (Da-
visson, et al., 1990 Holtzman et al., 1996), which contains over 100 highly conserved genes that 
are orthologous to those on HSA21 (Mural et al., 2002; Patterson and Costa, 2005; Sturgeon and 
Gardiner, 2011). Ts65Dn mice survive to adulthood and exhibit many morphological, biochemi-
cal, and transcriptional changes seen in the human disorder (Antonarakis et al., 2001; Capone, 
2001; Davisson, et al., 1990; Davisson et al., 1993; Holtzman et al., 1996; Reeves et al., 1995).  
Notably, these mice show deficiencies in developmental neurogenesis and hypocellularity 
(Bianchi et al., 2010a; Guidi et al. 2011), which may play a role in their observed cognitive defi-
cits (Abrous et al., 2008; Aimone et al., 2006; Leuner et al., 2006; Lledo et al., 2006; Madsen, et 
al., 2000; Shors et al., 2001, 2002). Furthermore, Ts65Dn mice are born with intact BFCNs, 
which progressively atrophy beginning at approximately 4-6 months of age specifically within 
the MS (Cooper et al., 2001; Granholm et al., 2000; Holtzman et al., 1996). Similar to humans 
with DS, Ts65Dn mice show impairments in explicit memory and spatial mapping, subserved by 
BFCN projections from the medial septal nucleus (MS) to the hippocampus (Granholm et al., 
2000; Hyde and Crnic, 2001; Hyde et al., 2001), as well as impaired attention and emotion regu-
lation (Driscoll et al., 2004; Moon et al., 2010), modulated by BFCN projections from the nucle-
us NBM/SI to the neocortex. 
 Our group has previously reported attentional dysfunction in aged Ts65Dn mice (Driscoll 
et al., 2004; Moon et al., 2010). Similar to humans with DS who show impairments in sustained 
attention in adulthood (Krinsky-McHale et al., 2008), aged Ts65Dn mice tested on a series of 
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visual attention tasks (after the onset of AD-like neuropathology) show deficiencies in their abil-
ity to focus attention and were often “off-task” compared to age-matched wild-type [disomic 
(2N)] mice (Driscoll et al., 2004; Moon et al., 2010). These impairments may reflect dysfunction 
or atrophy of cholinergic neurons in the NBM/SI and their projections to neocortex, based on the 
evidence for loss of these neurons in DS (Casanova et al., 1985) and AD (Casanova et al., 1985; 
Mann et al., 1085; Mufson et al., 2000).  However, there are no reports describing the morphol-
ogy of NBM/SI cholinergic neurons in aged Ts65Dn animals, and importantly none that have 
attempted to relate changes in this system to the attentional dysfunction seen in these animals.   
  The current study was designed to characterize NBM/SI cholinergic neurons in young 
and aged Ts65Dn mice, to describe the changes that occur with aging and investigate whether 
these changes correspond to progressive attentional dysfunction in these animals as they age. 
This study is the first to examine attentional function in young Ts65Dn mice and ascertain 
whether changes in NBM/SI neurons at either age underlies the attentional dysfunction seen in 
these animals. We employed a 2 X 2 design, with two genotypes ([Ts65Dn mice and 2N (diso-
mic) mice]) and two ages (3 months vs. 12 months at start of testing).  We administered the same 
series of visual attention tasks used in two prior studies from our laboratory which demonstrated 
attentional dysfunction in aged Ts65Dn mice (Driscoll, et al., 2004; Moon et al., 2010).  Follow-
ing the completion of behavioral testing, the animals were euthanized, and the brains were im-
munolabeled for ChAT, followed by unbiased stereological assessments of BFCNs to test the 
hypothesis that aging alters BFCN morphology in the NBM/SI. Finally, correlational analyses 
were conducted to assess the relationship between task performance and BFCN characteristics. 
 
METHODS  
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Subjects 
Ts65Dn and age-matched disomic (2N) male mice were purchased from Jackson Labor-
atories (Bar Harbor, ME) and delivered to Weill Hall at Cornell University in Ithaca NY. Before 
the mice were shipped to Cornell University for behavioral testing, they were typed via quantita-
tive polymerase chain reaction (qPCR) for the detection of the extra chromosomal segment and 
determination of Pde6Brd1 homozygosity, a recessive mutation leading to retinal degeneration 
(Bowes et al., 1993). Pde6Brd1 homozygous mice were excluded from the study. The young mice 
were received at an average age of 2 months whereas the older mice arrived at an average 11 
months. 
Upon arrival, the mice were housed individually in polycarbonate cages with food and 
water ad libitum.  Within a week of arrival, the mice were put on a food-restriction regimen to 
ensure motivation for food rewards during testing. Target weights were calculated at approxi-
mately 85% of their ad libitum weight. Mice were singly housed to prevent fighting between 
cage-mates, which often occurs when group-housed male mice of this strain are returned to the 
home-cage following daily behavioral testing. A combination of daily handling, testing and the 
provision of items in the home-cage (i.e., plastic igloos, tubes, and plastic-gel bones, Nestlets) 
countered the environmental impoverishment of single animal housing. The mice were main-
tained on a 12:12 reversed light dark cycle under temperature-controlled conditions. All proto-
cols were approved by the Institutional Animal Care and Use Committee of Cornell University 
and conform to the National Institutes of Health Guide for the Care and Use of Laboratory Ani-
mals.   
 
Food restriction scheduling during behavioral testing 
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The daily food allowance was gradually reduced and then maintained when the mouse 
reached this target weight.   For the young mice, it was necessary to implement a food restriction 
protocol that allowed growth, since the animals were still growing at the age (2 months of age).  
These animals were fed  ~2g/day and changes were made as needed to keep the mice sufficiently 
motivated enough to complete 60-70 trials per day, while allowing them to continue gaining 
weight.  When the young mice reached the age at which mice normally attain their full adult 
weight (~3 months of age), a constant target weight was maintained for the duration of testing.   
 All animals were fed immediately after each daily test session.  This consisted of sub-
tracting the number of calories obtained as a reward in the testing chamber (Liquefied AIN-76A 
purified chow; Bio-Serv, Frenchtown, NJ) from the daily allowance of lab chow (Dyets; Bethle-
hem, PA). 
 
Testing Apparatus 
 The testing apparatus and procedures were similar to that described in our prior study 
(Moon et al., 2010).  Briefly, all subjects were tested individually in one of eight automated 
Plexiglas chambers, each of which was controlled by a PC and enclosed in an insulated, sound 
attenuating chamber.  These testing chambers were originally adapted from the nine hole operant 
chambers developed to asses attention in mice (Humby et al., 1999, Marston et al., 2001). The 
slightly curved rear wall contained five circular response ports, 1 cm in diameter, located 2cm 
above the floor and 5mm apart.  A nose-poke into any of these 5 ports constituted a response (i.e., 
choice).  Infrared photodiodes, positioned inside each port 0.5cm from the opening, monitored 
the responses to each port. Green 4MA LEDs, one embedded on the back surface of each port, 
provided the discriminative visual cues. One the chamber wall opposite the response port was an 
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alcove (15 mm wide, 2 cm above the floor) containing the dipper (ENV0302M, MED Associates, 
East Fairfield, VT), which dispensed the liquid reward. Access to the dipper alcove was con-
trolled by a thin metal door activated by a motor located outside of the testing chamber.  
Nosepokes into the alcove were monitored by infrared photodiodes. Each of the automated 
events in the chamber (e.g. door opening, dipper movement, responses) were timed, controlled, 
and recorded by custom programs written in QBASIC.  Each chamber was equipped with an 
exhaust system that transported air at a rate of four complete air changes per minute. 
 
Behavioral Testing  
At the onset of behavioral testing, the young animals were approximately 3 months of 
age and the older animals were approximately 12 months of age.  Each animal was randomly 
assigned to one of eight chambers, with the stipulation that each chamber was balanced for each 
of the four treatment conditions defined by genotype and age. The animals were tested six days a 
week, for approximately 4-5 months.  Each daily session lasted for 30 minutes or 70 trials, 
whichever came first. All testing was conducted by experimenters who were unaware of the gen-
otype and age of the animals. Testing equipment was thoroughly cleaned and dried following the 
testing of each mouse, using Odormute (R.C. Steele Co, Brockport, NY), a detergent containing 
an enzyme that removes olfactory cues (e.g. pheromones).  
  
Training 
 Training consisted of a series of four stages designed to familiarize the animals with the 
testing chambers and the sequence of responses necessary to complete a trial for the visual atten-
tion tasks.  During these four stages the mice learned that the door to the dipper alcove would be 
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raised at the start of each trial and that a nosepoke into the dipper port, followed by a nosepoke 
into one of five response ports, would produce the delivery of 0.01ml of the liquid diet (i.e., re-
ward) in the dipper alcove.  During the final training stage, each animal was required to respond 
for a fixed number of trials at each of the five response ports, to eliminate preferences or aver-
sions to any of the ports. For a more detailed description of these stages, see Driscoll et al., 2004 
and Moon et al., 2010.   
  
Five-choice visual discrimination task  
In this task, one of the five port LEDs was illuminated on each trial.  The port remained 
illuminated until the mouse made a nosepoke into one of the ports, or until 32 seconds elapsed. 
The mouse was rewarded for making a nose-poke intro the illuminated (i.e., correct) port. The 
location of the visual cue was pseudorandomized across trials; the number of cue presentations in 
each port was balanced for each daily session. A 2-s delay separated trial initiation and cue onset. 
This delay, termed the “turn-around time”, allowed time for the mouse to turn around and orient 
toward the ports before cue illumination. Four types of errors were distinguished: (1) a 
nose-poke into any response port prior to cue onset was termed a premature response; (2) a 
nosepoke made following cue onset but to one of the non-illuminated ports was termed an in-
nacurate response; and (3) failing to respond to any response port within 5sec after the cue 
(omission error). A 5-second intertrial interval (ITI) separated adjacent trials. All trials in which 
the mouse made an initiation poke into the dipper alcove (regradless of the outcome of the trial) 
were defined as response trials. Failures to initiate a trial within 60 seconds were scored as 
“nontrials; no cues were presented on these trials. A 5-second time-out period was imposed fol-
lowing a nontrial or an error. This time-out period was signaled by the illumination of a 3-W 
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houselight on the ceiling of the chamber.  Each mouse remained on this task until it reached a 
criterion of 80% correct for 2 out of 3 consecutive sessions.  
  
Attention Tasks 1 and 2   
The mice were subsequently tested on two variants of the initial visual discrimination 
task that were identical except for the duration of the cue illumination, which was shortened to 2 
seconds and 1 second, respectively, for the two tasks. These tasks tested attentional function and 
prepared the mice for the subsequent two attentional tasks, which were more attentional-
ly-demanding.  Attention tasks 1 and 2 were administered for 8 and 15 sessions, respectively.  
  
Attention Task 3 (learning to wait for the cue)  
 This task was identical to the prior task except that the duration between trial initiation 
and cue onset varied pseudo-randomly across trials. The pre-cue delay varied between 0, 2, 4 
seconds, all added to the 2-second “turn around time” (described above). Cue illumination dura-
tion was constant at 1 second. If a response was made prior to cue onset (i.e., premature re-
sponse), the trial was terminated and no cue was presented.  As noted above, premature respons-
es (as well as all types of errors) were followed by a 5-second time-out period, signaled by the 
illumination of a 3-W houselight on the ceiling of the chamber. The three pre-cue delays were 
presented pseudo-randomly, such that the number of presentations of each combination of 
pre-cue delay and response port (1-5) was balanced across each session. The mice were tested for 
18 sessions on this task.  The early sessions on this task tap the ability of the mice to learn to wait 
for the cue, whereas the later sessions provide a more pure index of inhibitory control and fo-
cused attention. Thus, this task taps learning, inhibitory control, focused attention.  
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Tissue preparation 
Upon completion of behavioral testing, mice were deeply anesthetized with ketamine (85 
mg/kg)/xylazine (13 mg/kg) via intraperitoneal injection, perfused transcardially with 0.9% sa-
line (50 ml), followed by 4% paraformaldehyde (50 ml) in phosphate buffer (PB; 0.1M; pH = 
7.4). Ages at sacrifice averaged 7.6 months for the young mice and 16.4 for older mice.  Brains 
were extracted from the calvaria, post-fixed for 24 h in the same fixative, and placed in a 30% 
sucrose PB solution at 4 °C until sectioning.  Each brain was cut in the coronal plane at 40 µm 
thickness, on a sliding freezing microtome into six adjacent series and stored at 4 °C in a cryo-
protectant solution (30 % ethylene glycol, 30 % glycerol, in 0.1 M PB) prior to immunohisto-
chemical staining (Ash et al., 2011; Kelley et al., 2014a, 2014b; Velazquez et al., 2013).  
  
Immunohistochemistry 
  Immunohistochemistry was performed as previously described (Kelley et al., 2014a, 
2014b). Tissue was immunostained using the primary antibody: a goat polyclonal antibody 
against choline acetyltransferase (ChAT, 1:1000; Millipore, Billerica, MA). A 1/6 series of sec-
tions was singly immunolabeled for ChAT. Briefly, sections were washed in 0.1 M phosphate 
buffer (PB; pH 7.4) to remove cryoprotectant, rinsed in Tris-buffered saline (TBS), and incubat-
ed in sodium (meta)periodate (2.139 g per 100 ml TBS) to inhibit endogenous peroxidase activi-
ty. To improve primary antibody penetrance throughout the full depth of the tissue, sections was 
washed in TBS with 0.25 % Triton X-100, followed by rinses in a blocking solution to prevent 
nonspecific binding consisting of 3 % serum (raised against host organism of secondary antibody: 
ChAT, horse serum) in TBS/Triton X-100. Tissue was then incubated overnight at room temper-
ature with the primary antibody in TBS/Triton X-100 with 1 % serum and then washed in TBS 
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and incubated for 1 h with a biotinylated IgG secondary antibody raised against the host of the 
primary antibody, ChAT anti-goat (Vector Laboratories, Burlingame, CA). Tissue was washed in 
TBS and incubated with an avidin-biotin complex  (ABC) solution (Elite Kit, Vector Laborato-
ries) for 1 h to amplify the immunochemical reaction. Immunolabeling was visualized using an 
acetate-imidazole buffer containing 0.05 % 3,3′-diaminobenzidine tetrahydrochloride (DAB; 
Sigma-Aldrich, St. Louis, MO) and 0.0015 % freshly prepared H2O2. Sections were washed in 
acetate-imidazole buffer to terminate the immunochemical reaction, mounted onto 
chrome-alum-subbed slides, air dried for 24 h, dehydrated through a series of graded alcohols 
(70%, 95%, and 100 %), cleared in xylenes, and cover-slipped with distyrene/dibutylphthalate 
(plasticizer)/xylene (DPX) mounting medium (Kelley et al., 2014a, 2014b; Velazquez et al., 
2013).  
 
Stereology  
ChAT -immunoreactive neuron counts were determined in the NBM/SI using the optical 
fractionator, a stereological model that pairs the optical disector probe (a three-dimensional 
counting space) with a two-dimensional grid that provides an unbiased random-start and system-
atic interval sampling of the region of interest. All analyses were conducted using Stereo Inves-
tigator software (version 9.14.5 32-bit, MicroBrightField, Inc., Williston, VT, USA) coupled to a 
Nikon Optiphot-2 microscope. Values are presented as estimate per brain derived from a sam-
pling of the region of interest bilaterally across a 1/6 series for each marker (X60, n.a. 1.40, 50 x 
50 µm counting frame, 151 x 151 µm grid size, 10 µm disector height).  Tissue thickness was 
measured at every site that contained cells and the reciprocal for (disector height) / (mean meas-
ured thickness) was used for reported numbers and statistical analyses. The large sampling frac-
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tion allowed for a CEm = 1 of ≤ 0.10 (Gundersen, 1999).  Cell density is presented as cells per 
1,000,000 µm3 (Kelley et al., 2014a, 2014b). Calculation was performed for each animal, prior to 
group averages. Photomicrographs were taken on a Nikon Optiphot-2 microscope (Tokyo, Japan) 
connected to Stereo Investigator software (MicroBrightField, Inc.) Background correction was 
used at the time of image capture to establish evenness of illumination across the field, and scale 
bars were added within the Stereo Investigator software. Panels were compiled in PowerPoint 
(version 14.0.6129.5000, 32-bit, Microsoft, Redmond, WA, USA) and each micrograph was 
equally corrected for brightness and contrast. No retouching or further manipulations were per-
formed. 
  
Neuron size   
BFCN size was measured using a 5-ray nucleator probe for an average of 60 cells per 
stain, per region, per animal (X60 oil-immersion lens n.a. 1.40) using random sampling across 
rostrocaudal and dorsoventral axes derived with the optical fractionator. The nucleator involves 
taking five measurements from an approximate center of the cell to the perimeter of the cell in 
one plane (< 1.0 µm z-axis) of section (Gundersen, 1988). The probe derives an average radius 
for each cell and volume was calculated from this value using a weighted geometric formulae 
(shape assumption spheroid).  
  
Antibody tissue penetration 
 A major criterion for the use of the optical disector is antibody penetration through the 
full depth of the stained section. The depth of ChAT antibody penetration through a tissue sec-
tion in the z-axis was determined using the same optical disector system and software used to 
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count labeled neurons in this study (see above). ChAT antibodies penetrated the full depth of the 
section allowing for the equal probability of counting all objects, a prerequisite for stereology 
(Mufson et al., 2000; Kelley et al., 2014a, 2014b; Velazquez et al., 2013).  
  
Statistical Analyses   
 Statistical analyses were performed using the Statistical Analysis System (Version 9.1; 
SAS Institute, Cary, NC). Performance measures were analyzed using PROC GLIMMIX pro-
gram, a generalized linear mixed model procedure for conducting repeated measures analyses of 
both normal and non-normal data by specifying an appropriate link function and error distribu-
tion (Wolfinger et al., 1993). The dependent measures included: percent correct, percent omis-
sions errors, percent inaccurate responses and percent premature responses.  If a violation of 
homogeneity of variance was present [determined by the Levene test of homogeneity (Levene, 
1960)], a non-parametric analysis (i.e., Kruskall-Wallis test) was utilized.  
 The primary dependent measures for the morphological data were the (1) number, (2) 
density, and (3) volume of ChAT-immunoreative cells within the NBM/SI. These analsyes were 
conducted using 2X2 ANOVAs. 
  Lastly, Spearman's rank correlation coefficients were used to assess the relationships 
between percent correct in attention task 2 and number, density and volume of ChAT-positive 
cells within the NBM/SI.  Attention task 2 was selected for these correlation analyses as it re-
vealed progressive attentional dysfunction in the trisomic mice as a function of age, providing an 
opportunity to investigate the underlying neural basis of this effect.  
 The alpha level was set at 5% for primary analyses of both behavioral and morphological 
endpoints.  However, a Bonferroni-Holm step down procedure was used to control for multiple 
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comparisons, as four a-priori contrasts were conducted regardless of whether or not the interac-
tion of genotype and age was significant, because they are central to the goals of the study; these 
four comparisons were: (1) disomic mice who started testing at 3 months of age (2N-Y) vs. tri-
somic mice who started testing at 3 months of age (Ts56Dn-Y), (2) Ts65Dn-Y vs. Ts65Dn-O 
(trisomic mice who started testing at 12 months of age), (3) 2N-Y vs. 2N-O (disomic mice who 
started testing at 12 months of age) and (4) 2N-O vs. Ts65Dn-O.  Using the Bonferroni-Holm 
step down procedure, the criteria for significance for these tests were:  0.05/4 (P = 0.0125) for 
comparison 1, 0.05/3 (P = 0.0167 for comparison 2, 0.05/2 (P = 0.025) for comparison 3, and 
0.05/1 (P = 0.05) for comparison 4.  
 
RESULTS 
Final sample size  
The final sample size for all behavioral and morphometric measures is presented in the 
figures for each task.  Differences in sample size between the various tasks and the morphologi-
cal endpoints resulted from several factors, including deletion of data due to apparatus malfunc-
tion, experimenter error, and tissue labeling variability.  
 
Body Weight  
Analysis of body weight at the completion of behavioral testing revealed significant ef-
fects of genotype (F (1, 34) = 16.12, P = 0.0003) and age (F (1, 34) = 18.31, P = 0.0001); the interac-
tion failed to achieve statistical significance (F (1, 34) = 3.52, P = 0.07).  Ts65Dn mice (mean = 
21.03 g; S.E.M. = 0.63) weighed significantly less than 2N mice (mean = 23.6 g; S.E.M. = 0.63).  
Furthermore, younger mice (mean = 20.95 g; S.E.M. = 0.59) weighed less than older mice (mean 
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= 23.6 g; S.E.M. = 0.66). This effect of the trisomy on body weight is consistent with prior re-
ports (Ash et al., 2011; Bianchi et al., 2010a; Fuchs et al., 2012; Roper et al, 2012; Velazquez et 
al., 2013).   
 
Five-choice visual discrimination task (no pre-cue delay, cue duration: 32s) 
The dependent measure for learning rate in the initial visual discrimination task – ses-
sions to criterion – was analyzed using the nonparametric Kruskal-Wallis test, because the data 
violated the assumption of homogeneity of variance.   This test revealed a significant effect of 
group (H (3) = 9.857, P = 0.0198; Fig. 1A). Subsequent post-hoc tests revealed a significant effect 
of aging for the 2N mice; i.e., 2N-O mice reached criterion significantly more slowly than the 
2N-Y group (P = 0.0027).  In addition, the trisomy tended to impair performance of the younger 
animals (P = 0.0416), although this comparison did not meet significance for the Bonferon-
ni-holm correction.   In contrast, for the older animals, learning rate was not affected by the tri-
somy.  
 
Attention Task 1 (no pre-cue delay, cue duration: 2s, 8 sessions)  
The analysis of percentage correct revealed a significant main effect of genotype (F (1, 34) = 
15.79, P = 0.0003; Fig. 1B): Ts65Dn mice performed significantly more poorly than their 2N 
counterparts. There was also a main effect of age (F (1, 34) = 10.50, P = 0.003) reflecting the fact 
that the older mice performed significantly worse than younger animals. There was no significant 
genotype x age interaction (F (1, 34) = 1.33, P = 0.257) suggesting that the magnitude of the im-
pairment of the trisomic mice (relative to 2N) was comparable at the two ages.  Planned contrasts 
revealed that the Ts65Dn-Y mice were significantly impaired relative to the 2N-Y mice (P = 
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0.0005).  2N-O animals were also impaired relative to the 2N-Y mice (P = 0.0040).  No other 
significant comparisons were found.   
 Percent omission errors were analyzed using the nonparametric Kruskal-Wallis test be-
cause the data violated the assumption of homogeneity of variance.   This test revealed a signifi-
cant effect of group (H (3) = 8.54, P = 0.031). Subsequent post-hoc tests revealed a borderline 
significant effect of aging for the 2N mice; i.e., 2N-Y mice committed a lower percentage of 
omission errors then the 2N-O group (P = 0.053, Fig. 1C), however this comparisons did not 
meet significance for the Bonferonni-holm correction.  There were no other significant compari-
sons.  
The analysis of percent inaccurate responses revealed a significant effect of age (F (1,34) = 
4.58, P = 0.04), reflecting the fact that the older mice committed a significantly higher percent-
age of inaccurate responses than the younger animals.  Neither the main effect of genotype (F (1, 
34) = 3.28, P = 0.08) nor the interaction of genotype x age (F (1, 34) = 2.48, P = 0.124) achieved 
statistical significance.  Planned comparisons revealed that within the young mice, a genotype 
effect was seen, with the trisomics committing a higher percentage of inaccurate responses than 
their 2N counterparts (P = 0.0161, Fig. 1D).  The old 2N mice had a significantly higher per-
centage of inaccurate responses than their younger counterparts (P = 0.0133).   No other con-
trasts were significant.   
 
   
Attention Task 2 (no pre-cue delay, cue duration: 1s, 15 sessions)  
The analysis of percentage correct revealed significant main effects of genotype (F 
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Figure. 1 Performance in the visual discrimination task (panel A) and Attention Task 1 (Panels 
B-D). (A) Mean (±SEM) sessions to criterion in the initial visual discrimination task. 2N-Y mice 
reached criterion significantly faster then the 2N-O group (p = .0027). (B) Mean (±SEM) percent correct 
in attention task 1. A significant main effect of genotype confirmed a performance deficit in Ts65Dn mice 
(p = .0003). A significant main effect of age indicated better performance in young mice (p = .003). 
Planned contrasts revealed significant impairment in Ts65Dn-Y mice compared to young 2N (p = .0005), 
and a detrimental effect of aging in the 2N mice (p = .0040). (C) Mean (±SEM) omission errors during 
attention task 1.  A borderline significant contrast reveals that 2N-Y mice tended to commit a lower per-
centage of omission errors than the 2N-O group (p = .053).   (D) Mean (±SEM) percentage of inaccurate 
responses during attention task 1.  A significant main effect of age indicated a higher percentage of 
inaccurate response for the older mice (p = .003). Planned contrasts revealed an effect of genotype in the 
young mice (p = .0161) and an effect of aging for the 2N mice (p = .0133)* p ≤ 0.05, ** p ≤ 0.01. 
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(1,37.29) = 12.68, P = 0.001) and age (F (1,37.29) = 9.48, P = 0.004; Fig. 2A), as well as a significant  
interaction of these two variables  (F (1,37.29) = 4.09, P = 0.05).  Post-hoc analyses revealed that 
whereas there was no effect of age in the 2N mice, the old Ts65Dn mice performed significantly 
less well than their younger counterparts (P = 0.0008).   In addition, although the younger triso-
mic mice did not perform more poorly than their 2N counterparts, the old trisomic mice were 
significantly impaired relative to the old 2N (P = 0.005).  
The analysis of percentage omission errors revealed a significant main effect of genotype 
(F (1,32) = 33.69, P < 0.0001) as well as a significant genotype x age interaction (F (1,32) = 6.01, P = 
0.02; Fig. 2B).  Post-hoc analyses revealed a significant effect of age for this measure in the tri-
somic mice (P = 0.0075), but not the 2N.   In addition, the trisomy increased the percentage of 
omission errors in the older mice (P < 0.0001), but not in the younger mice.  The effect of age 
was not significant (F (1,32) = 2.51, P = 0.126).   
The analysis of percentage inaccurate responses did not reveal significant effects of age, 
genotype, nor the interaction of these two variables. 
  
Attention Task 3 (Variable pre cue delay: 0, 2, 4 s; constant 1 s cue duration; 18 sessions)  
The analysis of percentage correct revealed a significant effect of pre-cue delay (F (2, 
302.7) = 605.07, P < 0.0001), reflecting the fact that performance declined as pre-cue delay in-
creased.  Session-block (6 blocks of 3 sessions each) was also significant (F (5, 208.8) = 154.73, P < 
0.0001), indicating the pronounced improvement in performance with continued training. A main 
effect of genotype was seen (F (1, 40.21) = 5.30, P = 0.03) as well as a significant genotype x delay x 
session block interaction (F (10, 300.7) = 3.71, P = 0.0001, Fig. 3).  Contrasts revealed that for trials  
 
114 
 
 
 
 
 
 
 
 
 
 
 
 
                           B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Performance in Attention Task 2. (A) Mean (±SEM) percent correct. A genotype x age in-
teraction revealed that for the older mice, the Ts65Dn mice performed more poorly than their 2N coun-
terparts (p = .005), whereas no genotype effect was seen for the young mice.  Contrasts also revealed a 
significant effect of aging in the Ts65Dn mice (p = .0008) but not the 2N. (B) Mean (±SEM) percent 
omission errors. Similarly, a significant genotype x age interaction revealed a significant effect of the 
trisomy for the old mice (p <. 0001) but not the young mice, and a significant effect of aging for the Ts65Dn 
mice (p = .0075), but not the 2N. * p ≤ 0.05, ** p ≤ 0.01.  
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with a 0 sec pre-cue delay, a significant geno type effect was seen during block 1, reflecting in-
ferior performance of the Ts65Dn mice (P = 0.003, Fig. 3A).  For trials with a 2sec pre-cue delay, 
Ts65Dn mice performed worse than 2N mice during blocks 3 (P = 0.0186, Fig. 3C), 4 (P = 0.003, 
Fig. 3B), and 5 (P = 0.0661), although only the session-block 4 contrast was significant after the 
Bonferroni-Holm correction. Lastly, for trials with a 4sec pre-cue delay, Ts65Dn mice performed  
significantly better than 2N mice during block 1 (P = 0.0124), but worse than the 2N during 
blocks 4 (P = 0.0037) and 5 (P < 0.0001).   
A three -way interaction of genotype, age, and pre-cue delay also found (F (2, 302.7) = 3.42, 
P = 0.034).  This three way interaction was driven by that fact that whereas the pattern of effects 
for the two young groups was constant across delay (inferior performance of the old animals), 
the pattern for the older animals tended to vary across delay.  However, because the two old 
groups did not differ significantly at any delay, coupled with the clear importance of ses-
sion-block (described above) in describing the influence of genotype and delay, it was deemed 
preferable to discuss the three way interaction of genotype, delay and session-block.  
The analysis of percentage premature responses revealed a highly significant effect of 
pre-cue delay (F (1, 223.6) = 457.64, P < 0.0001), reflecting the fact that the percentage of premature 
responses increased as the interval prior to cue presentation increased.  Session-block (6 blocks 
of 3 sessions each) was also highly significant (F (5, 121.5) = 82.96, P < 0.0001), indicating a de-
crease in the percentage of premature responses with continued training, as the animals learned 
to wait for the cue.  There was also a genotype x session-block interaction (F (5, 121.5) = 4.23, P = 
0.001) revealing that 2N mice committed a higher percentage of premature responses than 
Ts65Dn mice during the first block only (P = .0019, Fig. 4A).  The genotypes did not differ in 
the percentage of premature responses throughout the remaining sessions blocks.  
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Figure 3. Mean percentage correct (±SEM) in Attention task 3, for each of the three pre-cue delays. 
(A) For trials with a 0sec pre-cue delay, no effect of genotype was seen except for block 1 (p =. 003). (B) 
For trials with a 2sec pre-cue delay, Ts65Dn mice performed significantly worse than 2N mice in block 4 
only (p =. 003).  (C) For trials with a 4sec pre-cue delay, the trisomics performed worse than the 2N during 
blocks 4 (p = .0037) and 5 (< .0001), whereas the opposite pattern was seen for block 1 (p = .0124). p ≤ 
0.05, ** p ≤ 0.01. 
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The analysis of percentage omission errors revealed a significant effect of pre-cue delay 
(F (2, 86.24) = 7.91, P = 0.0007), reflecting the fact that the percentage of omission responses  
increased as the interval prior to cue presentation increased.  A highly significant effect of geno-
type was seen  (F (1, 19.49) = 18.98, P = 0.0003, Fig. 4B), reflecting that the trisomics committed a 
significantly higher percentage of omission errors than the 2N mice in this task. There was no 
significant main effect of age for percent omission errors (F (1, 19.49 = 0.02, P = 0.8887) nor signif-
icant interactions involving age.  
Lastly, the analysis of percentage inaccurate responses revealed a main effect of age (F (1, 
32.07) = 4.54, P = 0.0408) as well as a genotype x age interaction (F (1, 32.07) = 4.06 P = 0.05, Fig. 
4C).  Post-hoc analyzes revealed a significant effect of age for this measure in the 2N mice but 
not for the trisomics; 2N-O had a higher percentage of inaccurate responses than the 2N-Y  (P = 
0.0052).  
 
Morphology of ChAT-immunoreactive cells in the NBM/SI  
ChAT-immunoreactive cell number  
 The analysis of ChAT-immunoreactive cell count in the NBM/SI did not reveal a main 
effect of genotype (F (1, 55) = 0.80, P = 0.3762, Fig. 5A) nor a genotype x age interaction (F (1, 55) 
= 1.44, P = 0.2356).  There was a significant main effect of age (F (1, 55) = 6.53, P = 0.0134), re-
vealing a 16.6% decrease in in ChAT-immunoreactive cell number in older animals compared to 
their younger counterparts.  Planned contrasts revealed a significant reduction in 
ChAT-immunoreactive cell number in the 2N-O mice relative to their younger counterparts (P = 
0.0086, Fig. 5A). The remaining contrasts failed to reach significance.   
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Figure 4. Performance on Attention Task 3. (A) Mean (±SEM) premature responses, as a function 
of session-block. A significant genotype x session-block interaction revealed that genotype differences 
were seen only during block 1, where the 2N mice committed a higher percentage of premature responses 
than Ts65Dn mice (p = .0019). (B) Mean (±SEM) omission errors. Ts65Dn mice committed a higher 
percentage of omission errors than the 2N mice (P = 0.0003). (C) Mean (±SEM) percentage of inaccu-
rate responses   A significant genotype x age interaction revealed that aging increased the percentage of 
inaccurate responses for 2N mice (p = .0052) but not trisomics.  p ≤ 0.05, ** p ≤ 0.01. 
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ChAT-immunoreactive cell density   
 Genotype significantly altered ChAT-immunoreactive neuron density within the NBM/SI 
(F (1, 55) = 3.99, P = 0.05, Fig. 5B): Ts65Dn mice showed a 9.72% reduction relative to the 2N 
group. The effect of age was not significant (F (1, 55) = 1.31, P = 0.2568,) nor was the interaction 
of genotype and age (F (1, 55) = 0.36, P = 0.5523). Planned contrasts revealed a borderline signifi-
cant reduction in density for the Ts65Dn-Y animals relative to the 2N-Y (P = 0.0697), however 
this comparison did not meet significance for the Bonferonni-holm correction.  All other com-
parisons failed to reach significance.  
 
ChAT-immunoreactive cell size  
 The analysis of ChAT-immunoreactive neuron size within the NBM/SI revealed a signif-
icant main effect of genotype (F (1, 55) = 4.48, P = 0.0321) and a borderline effect of age (F (1, 55) = 
3.99, P = 0.0508). There was also a significant genotype x age interaction (F (1, 55) = 4.87, P = 
0.0316, Fig. 5C).  Contrasts revealed that for the 2N mice, advancing age resulted in atrophy of 
ChAT-immunoreactive neurons (P = 0.0035), whereas no effect of age was seen for the Ts65Dn 
mice.  Accordingly, a significant genotype effect was seen for the older mice, whereby, the older 
2N mice exhibited significantly smaller ChAT-immunoreactive cells than the older trisomic mice 
(P = 0.0031). 
 
Correlations between percent correct in Task 2 and morphology of ChAT immunoreactive 
cells in the NBM/SI  
Some measures of NBM/SI BFCN morphology significantly predicted percentage correct 
in Task 2.  For the older mice, a significant negative correlation was seen between percent   
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Figure 5. Morphology of ChAT immunoreactive neurons in the NB/SI (A) Mean (±SEM) cell count.  
A main effect of age indicated that older mice exhibited fewer cells than younger mice (p =. 0134). (B) 
Mean (±SEM) cell density. A significant main effect of genotype indicated reduced density in the tri-
somics (p = .05). (C) Mean (±SEM) cell size. A significant interaction of genotype x age reflected the fact 
that age decreased neuron size for the 2N (p = .0035) but not the trisomic mice. Accordingly, the older 2N 
mice had smaller ChAT-immunoreactive cells than the older trisomic mice (P = 0.0031). *p ≤ 0.05, ** p ≤ 
0.01. 
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correct and ChAT-immunoreactive cell size in the NBM/SI (rs = -.5412, P = 0.046 Fig. 6A), re-
flecting a decrease in performance with increasing neuron size.  In addition, for the 2N mice, a 
borderline significant positive association was seen between percent correct and 
ChAT-immuno-reactive cell number within the NBM/SI (rs = .4823, P = 0.058 Fig. 6B); i.e., as 
neuron number increased, performance improved.  
 
DISCUSSION 
 The results of the current study demonstrated impairments in learning and attention in the 
trisomic mice, recapitulating hallmark areas of dysfunction in children and adults with DS 
(Brown et al., 2003; Cornish et al., 2007; Clark and Wilson, 2003; Krinsky-McHale et al., 2008; 
Wilding and Cornish, 2004).   Importantly, this study is the first to characterize the effects of 
aging on either attentional function or morphology of NBM/SI neurons in Ts65Dn mice.  The 
assessment of both endpoints within the same animals provided a unique opportunity to assess 
functional relationships.  
 
Comparison of the young 2N and trisomic mice  
 The young trisomic mice tended to learn the initial visual discrimination task more slow-
ly than their 2N counterparts (see Fig. 1A).  The fact that the young Ts65Dn mice eventually 
reached a high level of performance on this task indicates that their slower learning in this task 
was not due to deficits in visual acuity, motor function, or motivation but rather appears to reflect 
impaired associative learning, as reported for children and adults with DS (Ohlrich and Ross, 
1968; Woodruff-Pak et al. 1996).  
 This series of tasks also provided new evidence of attentional dysfunction in young  
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Figure 6. Correlations between performance in Attention Task 2 and morphological characteristics 
of ChAT-immunoreactive neurons in the NB/SI. (A) For the old mice (both genotypes combined), a 
significant negative correlation was seen between percent correct and ChAT-immunoreactive cell size (rs = 
-.5412, P = 0.046); i.e. as ChAT-immunoreactive cell size increased, percent correct decreased. (B) 2N 
mice (old and young combined) showed a borderline significant positive correlation between percent cor-
rect and ChAT-immunoreactive cell number within the NBM/SI (rs = .4823, P = 0.058); i.e., as neuron 
number increased, performance improved.  
  
A 
123 
 
Ts65Dn mice. They committed a significantly higher percentage of inaccurate responses in at-
tention task 1, the first task in which cue duration was relatively brief, thereby increasing atten-
tional demands.  Since the rules of the task had already been mastered prior to this task, the most 
ikely explanation for the increased incidence of inaccurate responses by the young trisomic mice 
(v 2N-Y) is attentional dysfunction; i.e., missing the cue due to lapses in attention and then 
guessing between two ports in the general vicinity of the illuminated port which is consistent 
with prior reports (Driscoll et al., 2004).  This inference is supported by the types of errors com-
mitted in attention Task 3, the first task that included variable delays before cue presentation. In 
this latter task, the Ts65Dn-Y mice performed more poorly than the young 2N mice, and im-
portantly, the magnitude of the impairment appeared to become progressively more pronounced 
as the delay before cue onset increased (Fig 3A-C).  Analysis of the various types of errors re-
vealed that this impairment in performance (percentage correct) was driven primarily by an in-
creased incidence of omission errors by the trisomics (Fig. 4B), indicative of missing the cue.  
Ts65Dn mice did not commit a higher percentage of premature responses than the 2N animals, 
indicating that their impairment for trials with longer pre-cue delays was not due to impaired 
inhibitory control but rather an impaired ability to maintain attentional focus until cue presenta-
tion. In sum, these finding suggest that young TS65Dn mice are impaired relative to young 2N 
mice in tasks where they must wait for a cue and maintain focused attention during the delay. 
These findings are consistent with the human literature showing that children and young adults 
with DS are impaired in sustained attention (Brown et al., 2003; Cornish et al., 2007; Tompor-
owski et al., 1990; Wilding et al., 2002).  
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Attention in aged Ts65Dn mice (vs. aged 2N mice) 
Old Ts65Dn mice did not differ from their 2N counterparts in rate of learning the initial 
visual discrimination task, consistent with previous findings (Driscoll et al., 2004, Moon et al., 
2010; Powers et al., in preparation).  When the visual cue duration was shortened to 2sec in at-
tention task 1, there were no detectable differences between old trisomics and 2N mice.  Howev-
er, when the cue duration was made even briefer in attention task 2 (1 sec), Ts65Dn-O animals 
performed significantly worse than their 2N counterparts (Fig. 2A), consistent with our prior 
findings (Driscoll et al., 2004; Moon et al., 2010; Powers et al., in preparation).  This impairment 
was driven by an increased percentage of omission errors (Fig. 2B), suggesting an inability of the 
trisomics to maintain attentional focus. When further challenging the mice with a variable 
pre-cue delay in attention task 3, the trisomics, regardless of age, were impaired relative to the 
2N mice (Fig. 3B, C), with the magnitude of the impairment appearing to get larger with in-
creasing pre-cue delay.  This impairment in percent correct was driven by an increased incidence 
of omissions by the trisomic mice (Fig. 4B), further indicating that this deficit was due to im-
paired attention, not impaired inhibitory control, consistent with prior reports (Driscoll et al., 
2004, Moon et al., 2010; Powers et al., in preparation).  This inference is further supported by the 
results of videotape analyses presented in a prior report from our laboratory.  These analyses 
revealed that the aged trisomics were frequently off-task, exploring in the side of the chamber 
opposite to the ports.  This behavior may indicate dementia due to AD-like pathology, in addi-
tion to impaired sustained attention (Driscoll et al., 2004). In sum, these finding suggest that 
aged TS65Dn mice are impaired relative to age-matched 2N mice in tasks which require focused 
attention. 
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Comparison of the young and old Ts65Dn mice 
It was hypothesized that attentional dysfunction of the trisomic mice would become more 
pronounced with aging due to atrophy of BFCNs, particularly those of the NBM/SI.  This proved 
to be the case in some, but not all tasks. The old Ts65Dn mice did not differ from their young 
trisomics mice in performance of attention task 1, the first task in which a relatively brief cue 
was used. However, when cue duration was further decreased to 1s duration, placing even great-
er demands on attention, the older trisomics did, in fact, perform significantly more poorly than 
the young trisomics.  This decreased percent correct seen in older trisomics (relative to their 
younger counterparts) was driven by an increased percentage of omission errors (Fig. 2B), sug-
gesting impaired focused attention in the older trisomic mice, or a greater incidence of being off 
task, as discussed above (Driscoll et al., 2004).  In attention task 3, as discussed previously, both 
young and old trisomics were impaired when compared to 2N animals, driven primarily by an 
increased incidence of omission errors. However, in this task the two trisomic groups did not 
differ from each other. In sum, these finding suggest that older TS65Dn mice are impaired rela-
tive to younger trisomics in tasks which require focused attention but predictable cue onset, 
whereas these groups are both impaired, but to a similar degree, in tasks requiring sustaining 
attention over a variable delay.   
 
Effects of aging in the 2N mice  
 A growing body of evidence suggests that normal aging results in loss of attentional 
function in humans (Parasuraman and Giambra 1991; Greenwood et al., 1997; Berardi et al., 
2001) and in laboratory rodents (Jones et al. 1995; McGaughy and Sarter 1995; Muir et al.1999). 
The present study revealed impairments in both learning and attention in the normal 2N mice as 
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a function of age. First, a clear effect of aging was seen in the rate at which the 2N mice learned 
the initial visual discrimination task. Younger 2N mice reached criterion significantly fasten then 
the older 2N counterparts (Fig. 1A).   This finding is consistent with a prior report, which found 
that 3month old rats are faster at learning the initial rules of the 5-choice serial reaction task of 
attention than 15month old animals (5-CSRT; Jones et al., 1995).   
A detrimental effect of aging was also seen for the 2N mice in attention task 1, when the 
cue duration was made relatively brief (2 s) but still with a predictable onset time (Fig. 1B).  This 
performance deficit was driven by increased percentage of omission errors by the older 2N mice, 
indicative of missing the cue.  In addition, in Attention Task 3, the older 2N mice committed a 
significantly higher percentage of inaccurate responses also indicative of a deficit in maintaining 
attentional focus.  This pattern of findings indicates that aging produces impairments in both 
learning and attention in normal disomic mice, as seen in humans (Parasuraman and Giambra 
1991; Greenwood et al., 1997; Berardi et al., 2001).  
  
Assessment of BFCNs and their relationship to cognitive function 
                 We utilized quantitative stereology to obtain unbiased measures of 
ChAT-immunolabled BFCNs in the NBM/SI. BFCNs in the NBM/SI project to neocortex and 
are important in modulating attention (Hasselmo and Sarter, 2011; Mesulam et al., 1983; Rye et 
al., 1984). Although there has been work investigating BFCNs in Ts65Dn, most prior research 
has focused on the BFCNs in the MS in older animals.  This study is the first to examine BFCN 
morphology in the NBM/SI of behaviorally tested animals at young and old ages.  
                 A main effect of age revealed a 16.6% reduction in the number of 
ChAT-immunolabeled neurons within the NBM/SI (Fig. 5A) of older mice.  Planned contrasts 
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revealed that this effect of age was more pronounced for the 2N mice than the trisomics. For 
density of these neurons within the NBM/SI, a genotype effect revealed a 9.72% decrease within 
the NBM/SI for trisomics relative to 2N mice, with a comparable effect for the two age groups.  
The reduced density of these neurons may contribute to the attentional dysfunction seen in 
Ts65Dn mice; however, because the magnitude of this effect was comparable for the two age 
groups, it seems likely that other neural changes may underlie the progressive decline in atten-
tional function with aging in these mice. A very interesting pattern of effects was seen for size of 
these neurons in the NBM/SI. For the 2N mice, there was a significant reduction in ChAT- im-
munoreactive cell size as a function of aging, but not for the trisomic mice. The young trisomics 
and young 2N mice did not differ in neuron size, but for the older animals, the size of NBM/SI 
BFCNs was significantly larger for the old trisomics than for their 2N counterparts. Although it 
is not clear why NBM/SI ChAT- immunoreactive neurons do not atrophy with age in trisomics 
as they do in 2N mice (Fig 5C), one possibility is that this may be due to some sort of compen-
satory mechanism to increase cholinergic activity to target regions.  
 These effects of the trisomy on NBM/SI neurons are consistent with two previous studies 
by our group. In one study, trisomic and 2N mice were examined at 6 months of age, with no 
genotype effect seen for number, density or size of ChAT- immunolabeled cells in the NBM/SI 
(Kelley et al., 2014a, b). A second study from our group assessed attention and morphology of 
NBM/SI neurons in aged Ts65Dn and control mice. Similar to the pattern of effects in the pre-
sent study, this study reported increased count and size of BFCNs in the NBM/SI in the (aged) 
trisomic mice (Powers et al., in preparation).  The present findings provide pivotal new infor-
mation to aid in the interpretation of these findings in the older trisomics: They reveal that the 
genotype effect seen in the old animals in this prior study (Powers et al., 2011) for both BFCN 
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count and size in the NBM/SI (with increased size and count in the trisomics) is not due to an 
age-related increase in the trisomics, but rather due to an age-related decline in the 2N mice, but 
not the trisomics.    
The correlational analyses revealed some interesting relationships between the behavioral 
and neural measures, providing support for functional links.  A borderline significant positive 
association was seen between ChAT-immunoreactive cell number in the NBM/SI and perfor-
mance in attention task 2 for the 2N mice (old and young combined); i.e., as cell number in-
creased, performance increased (Fig. 6B).  This finding supports the importance of NBM/SI 
neurons for attentional function and suggests that the aging related decline in attention in the 2N 
mice may reflect the corresponding loss of NBM/SI neurons.  
Our analyses also revealed that for the older animals (genotypes combined), increased 
BFCN cell size was associated with poorer performance in attention task 2 (Fig. 6A), consistent 
with one other report from our lab (Powers et al., in preparation). It is not clear whether this cor-
relation merely reflects the fact that the older trisomics both perform more poorly and have larg-
er cells than their 2N counterparts; i.e., that the correlation is an epiphenomenon, or alternatively 
whether these larger cells are functioning less well, resulting in poor attention.   Future studies 
are needed to make this determination.    
 
Conclusions  
        The impairment in focused or sustained attention observed in young Ts65Dn mice parallels 
the attentional dysfunction reported for young individuals with DS (Brown et al., 2003; Cornish 
et al., 2007; Clark and Wilson, 2003; Wilding and Cornish, 2004), providing further support for 
the validity of the Ts65Dn mouse as a model for DS.  The findings in the aged trisomics are con-
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sistent with previous reports that Ts65Dn mice exhibit attentional dysfunction relative to aged 
2N mice (Driscoll et al., 2004; Moon et al., 2010) and are consistent with findings in DS humans 
after the onset of AD-like neuropathology (Della Sala et al., 1992; Foster, 2001; Krin-
sky-McHale et al., 2008; Levinoff et al., 2004; Pignatti et al., 2005). One main goal of this study 
was to determine whether attentional dysfunction becomes more pronounced with age in Ts65Dn 
mice or manifests differently.  This study revealed that in tasks requiring focused attention but 
with a predictable cue onset time, older trisomics were more impaired than young trisomic mice, 
but that in tasks requiring attention over a variable pre-cue delay, the two age-groups were im-
paired to a similar degree.  
This study also provided the first examination of aging effects on morphology of 
NBM/SI BFCNs of the Ts65Dn mouse model of DS, and assessed their relationship with the 
attentional deficits in these animals.   It has been hypothesized that the attentional dysfunction 
seen in Ts65Dn mice may be due to a reduced number of cholinergic neurons in the NBM/SI 
neurons.  However, the present study did not reveal a loss of neurons in the NBM/SI in the tri-
somic mice (relative to 2N) at either age. For both age-groups, however, the density of these 
neurons was lower in the trisomic mice than the 2N, which may contribute to the attentional 
dysfunction seen in both groups.  However, the fact that this decreased density did not become 
more pronounced with aging suggests that the progressive decline in attention seen in the older 
trisomics must be caused by some other neurological change associated with AD onset.  It is also 
notable that the trisomic mice did not exhibit the normal age-related decline in number and vol-
ume of these neurons, as seen in the 2N mice.  It’s possible that the absence of this age-related 
atrophy reflects a compensation for dysfunction in the cholinergic system or some other system. 
Future studies are needed to investigate this.  But it is a contribution of this paper to demonstrate 
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that the attentional dysfunction seen in either young or old trisomics is not due simply to a reduc-
tion of cholinergic neurons in the NBM/SI, as many have hypothesized based on early findings 
in humans with DS (Casanova et al., 1985).      
 Lastly, our studies shed light on the age-related cognitive deficits seen in normal rodents.  
Previous studies have shown that with age, attentional function does decline which may be due 
to decreased cholinergic function (Jones et al. 1995; McGaughy and Sarter 1995; Muir et 
al.1999). The present study corroborated aging-related attentional dysfunction in normal 2N 
mice and detected important correlations between attentional performance in the 2N mice and 
morphology of cholinergic neurons in the NBM/SI.  Specifically, we found that both number and 
size of these neurons decline with aging in the 2N and furthermore that neuron count in the 
NBM/SI correlated significantly with the attentional ability of these mice.  This correlation sup-
ports the notion that the loss of these neurons with aging in the 2N mice may underlie their atten-
tional dysfunction.   
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APPENDIX 
 
 
 
 
Figure A.1. Photomicrographs of ChAT cells in the NBM/SI: Photomicrographs show the distribution 
of ChAT- (A – D) immunoreactivity within the NBM/SI for the four groups of mice.  
 
  
132 
 
GENERAL DISCUSION 
The studies presented here have provided further evidence that MCS produces lasting 
benefits to Ts65Dn mice.  Furthermore, we have found that cholinergic neurons within the 
NBM/SI do not atrophy similarly to that seen in the MS (Cooper et al., 2001; Granholm et al., 
2002; Holtzman et al., 1996).   Collectively, these findings further contribute to the understand-
ing of changes within the basal forebrain with the onset of AD that arise in DS and furthermore 
provide support that additional MCS may lessen cognitive function in the case of DS offspring. 
 
Contributions and implications  
The study presented in Chapter 3 revealed that Ts65Dn mice exhibit attentional dysfunc-
tion as early as 3 months of age, which becomes more pronounced with aging as evident by an 
increased percentage of omission errors and inaccurate responses in Ts65Dn mice tested from 
12-14 months of age, relative to those tested from 3-5 months of age.   These findings further 
validate the Ts65Dn mouse as a suitable model of DS as attentional dysfunction has been re-
vealed in children and adolescents with DS (Brown et al., 2003; Clark and Wilson, 2003; Cor-
nish et al., 2007; Tomporowski et al., 1990; Wilding et al., 2012). A further contribution of this 
study was to reveal that the Ts65Dn mouse model of DS does not exhibit loss or atrophy of cho-
linergic neurons within the NBM/SI with the onset of AD-like neuropathology, contrary to 
BFCNs in the MS.  Past research has been interpreted to suggest that the basal forebrain cholin-
ergic system in its entirety atrophies in these mice starting at 6 months of age; however this in-
ference has been reached by solely examining BFCNs within the MS (Cooper et al., 2001; 
Granholm et al., 2002; Holtzman et al., 1996).  This study is the first to examine morphology of 
cholinergic neurons within the NBM/SI of Ts65Dn mice as a function of age.  This finding is 
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consistent with other reports from our laboratory concerning young (Kelley et al., 2014a, b) and 
old (Powers et al., in preparation) Ts65Dn mice. Ts65Dn mice did show a reduced density of 
NBM/SI cholinergic neurons that could contribute to the attentional dysfunction seen at both 
ages, but the decline in attention across the lifespan in these mice appears to be due to some oth-
er neuropathological change. Future work should consider examining other neuropathologies that 
may contribute to the impairments in DS with age.   
Our subsequent studies supplementing the maternal diet with additional choline during 
pregnancy and lactation revealed substantial improvements of spatial cognition in Ts65Dn off-
spring that were tested long after this early developmental nutritional manipulation (mean = 15.4 
months).   These are the first reports of improved spatial cognition with MCS in the Ts65Dn 
mouse model of DS and further add to the pool of research findings that show benefits of MCS 
in this mouse model (Moon et al., 2010) as well as normal rodents (Cheng et al., 2008; Glenn et 
al., 2007, McCann et al., 2006, Meck et al., 1988; Meck et al., 1999; Meck and Williams, 2003; 
Mohler et al., 2001; Wong-Goodrich et al., 2008; Zeisel, 2000) and models of other neural in-
sults (Blusztajn, 1998; Guo-Ross et al., 2002; Moon et al., 2010; Powers et al., 2011; Meck and 
Williams, 1997b; Meck and Williams, 2003; Yang et al., 2000; Thomas et al., 2000).  Further-
more, our studies demonstrate that MCS increased adult hippocampal neurogenesis of the triso-
mic offspring and offered protection to BFCNs in the MS, both of which were correlated with 
improved spatial cognition. These results provide exciting new evidence that supplementing the 
maternal diet with additional choline may represent a safe and effective treatment approach for 
expectant mothers carrying a DS fetus, as well as a possible means of BFCN neuroprotection 
during aging for the population at large.  
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Limitations in our studies  
Although the Ts65Dn mouse does mimic pathologies seen in the human disorder, it does 
not have all the features of DS patients.  For example, Ts65Dn mice do not develop Aβ plaques 
or neurofibrillary tangles like adult humans with DS (Davisson et al., 2005).  Aβ plaques and 
neurofibrillary tangles are neurotoxic, further compromising cognitive functions (Mufson et al., 
2003; Isacson et al., 2002; Sendera et al., 2000; Whitehouse et al., 1982). The lack of expression 
of these pathologies in Ts65Dn mice may reflect the fact that these mice are not trisomic for all 
of the genes on HSA21, and are trisomic for some genes that are not trisomic in humans with DS 
(reviewed in Davisson, 2005). Nonetheless, the Ts65Dn mouse model is the most robust and 
genetically sound to study behavioral and mental deficits associated with DS (reviewed in Da-
visson, 2005).  It has contributed to the further understanding of deficits that arise in the disease 
as well as treatments that may helpful or harmful for humans with DS. One example includes the 
test of the drug Piracetam, which was being considered for use in patients with DS after 
pre-clinical trials; however, after being tested in the Ts65Dn mouse, was removed as a potential 
therapy because it caused further impairments in learning and memory (Moran et al., 2002).   
   
Future Directions  
There is still much to be learned about the degeneration of BFCNs in this mouse model 
and the relation to cognitive functions. In particular, a few questions arose from the data in 
chapter 3 that may require further elucidation.  One question was why was there a decrease in 
cell size and number of cholinergic neurons within the NBM/SI for 2N animals that was not ob-
served in the trisomics and furthermore, what could account for the more pronounced attentional 
dysfunction seen with aging in the trisomic mice.  One possibility is that other structures that are 
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important in attentional functions, such as the frontal cortex (reviewed in Meck and Williams, 
2003; McCann et al., 2006), may show damage with age that may lead to further impairments. 
Another possibility is that may be changes within the NBM/SI that were not detectable with the 
markers that we utilized.  For example, it may be possible that delivery of acetylcholine from the 
NBM/SI or the bindings of receptors at the target sites are faulty.  Future work should examine 
other possible neuropathologies that may lead to attentional dysfunction and use different 
measures to detect changes within the NBM/SI.      
 A few questions remain from our MCS studies.  Since we did show that MCS corrected 
deficiencies in adult hippocampal neurogenesis, the question remains whether we may have cor-
rected ontogenetic neurogenesis and reduced hypocellularity reported at birth in the Ts65Dn 
mice (Bianchi et al., 2010a; Guidi et al., 2014). Researchers have speculated that adult neuro-
genesis is an extension of ontogenetic neurogenesis that relies on similar molecular machinery 
(reviewed in Kuhn and Blomgren, 2011).  If this is true, the hypothesis that developmental neu-
rogenesis is corrected with MCS should hold true. Another future direction, based on previous 
findings from MCS studies in our laboratory (Moon et al., 2010), is to identify what underlies the 
improved performance in attentional function seen in MCS T65Dn and 2N mice. 
Converging evidence continues to suggest that additional CH during gestation and lacta-
tion produces lasting improvements in cognitive and affective functioning in normal offspring 
(Lamoureux et al., 2008; Meck and Williams, 1997a) as well as provides a powerful intervention 
to help reduce cognitive dysfunction and neurodegeneration in DS and AD (Ash et al., 2011; 
Moon et al., 2010; Powers et al., 2011; Velazquez et al., 2013). However, prior to recommending 
that pregnant women increase their choline intake, it is necessary to further elucidate the mecha-
nism(s) underlying these lasting beneficial effects. One future direction, which is currently in its 
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beginning phases in our laboratory, is to identify the epigenetic changes that underlie the im-
proved cognitive functioning.  A start point for this future direction is to look at whether there 
are differential alterations of DNA methylation in animals whose mothers received additional 
choline during pregnancy and lactation.  DNA methylation is an epigenetic mechanism that alters 
the expression of genes and is mediated in part by increased maternal CH intake (review in Jiang 
et al., 2014). Animals that previously participated in behavioral testing provided tissue that will 
be utilized in this future study to detect change in DNA methylation and gene expression, 
providing the optimal circumstances to establish functional relationships.  This will allow for a 
determination of what genes are being affected by early CH supplementation and whether these 
genes are (1) the reason why we see increases in neurogenesis and protection of BFCNS; and (2) 
whether they are behind the increased performance in spatial memory and (3) whether they are 
behind the increased performance in attentional function (see in Moon et al., 2010).  This study 
will also fill in the gap of what potential genes are being altered with CH and perhaps aid in de-
termining whether such genes can be targets for other therapeutics during adulthood. 
The translation of this work to humans is another future direction.  As mentioned in the 
introduction, one study found benefits in sensory gating in offspring of CH supplemented moth-
ers (Ross et al., 2013).   As a starting point, future studies should impose a longitudinal approach 
and test a variety of cognitive abilities in the adult offspring of CH supplemented mothers.   The 
preliminary stages of additional CH in pregnant mothers has begun in the laboratory of Dr. Bar-
bara J. Strupp and Dr. Marie Caudill at Cornell University. In addition, MCS studies should as-
sess whether DS offspring of pregnant mothers benefit from this intervention in childhood and 
throughout life.  In conclusion, CH recommendations should be reconsidered in order to meet the 
high demands for optimal fetal development and thus produce favorable health outcomes for 
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offspring with DS and for the general population.  
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